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Summary 
Introduction: Phenylketonuria (PKU) is an autosomal, recessive inborn error of metabolism caused 
by a deficiency of the enzyme Phenylalanine Hydroxylase (PAH). Reduced activity or absence of 
PAH results in increased concentrations of phenylalanine in plasma and brain, which if not addressed 
will result in severe disability and reduced quality of life.  
 The accepted management of PKU is to restrict intake of dietary phenylalanine and to adhere 
to a semi-artificial diet which consists of: a phenylalanine free protein substitute; measured amounts 
of phenylalanine containing foods; specially manufactured low protein staple foods (LPSF) and vir-
tually unrestricted use of phenylalanine free natural foods. Dietary restriction of phenylalanine was 
first reported in the early 1950’s and although the use, format and efficacy of the protein substitute 
has been well researched, evidence for the use of the LPSF is scarce.  
 Anecdotally the LPSF are believed to play a substantial role in PKU management and con-
tribute to the nutritional requirements of patients. However, how patients and their carers perceive 
their usefulness and the role they play in the overall management of the disease has not been evaluat-
ed.  Recommendations exist for the amount of LPSF required by patients has been produced by the 
NSPKU society, but are not evidence based. 
 
Aim: To evaluate the contribution LPSF make to the typical diet of children with PKU. To explore 
any association between LPSF and nutritional status, quality of life, diet variety and any issues pa-
tients and carers may face when obtaining supplies. 
 
Method: The use of LPSF in PKU management was evaluated in two ways: a) by a survey of adult 
patients and carers of children from metabolic centres throughout Scotland, to explore perception of 
the need for LPSF and any issues faced when obtaining supplies, b) a cross-sectional study using pa-
tients from one of the metabolic centres to determine the contribution these foods make to the nutri-
tional status and quality of life. This was achieved by allocating patients into user groups dependent 
on daily use of LPSF using food diaries and and Food Frequency Questionnaire (FFQ). 
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Results:  
Study 1: 178 questionnaires were sent to patients with PKU in Scotland returning a response rate of 
46%.  97% of patients and carers who responded understood the need for LPSF in managing their 
condition, with 96% using the LPSF to control phenylalanine levels; 80% used the foods to provide 
diet variety and satisfy appetite. The most common foods requested were core LPSF of pasta and 
pasta products (77% of monthly prescriptions); flour mix (61%). Greater than 40% of respondents 
reported that the sensory properties of LPSF were good. However, 49% of respondents experienced 
comments from primary health care providers when requesting prescriptions, with 59% of these hav-
ing a comment of a negative nature which affected the number of prescription requests made. Of the 
respondents 50% ordered less than the amount of LPSF recommended by the NSPKU society. When 
questioned about use of a home delivery service, 51% used this service for ordering LPSF and 68% 
had attended cookery workshops arranged by their dietitian. No information regarding disease severi-
ty was requested for this survey.  
 
Study 2: 40 patients (children aged between 2-17 years: 56% (n=23) male) were recruited of whom 
30 (75%) completed the seven-day food diary and FFQ. 67% (n=27) had classical PKU; 7.5% mod-
erate (n=3) and 25% (n=10) having mild PKU (exchanges / day: 2-6; 7-8; 9-13). Of the children, 
67% (n=27) had a SDS BMI within the normal range; 22% (n=9) were overweight; 7% (n=3) obese. 
Those of secondary school age (27%; n=11) took significantly less energy (%EAR) from the protein 
substitute than the younger children (p=0.007). When the subjects were allocated into LPSF user 
groups, no difference between SIMD score, quality of life domains, metabolic control or height was 
observed between the groups. However, the low users of the LPSF had a significantly higher SDS weight 
(p=0.047) and SDS BMI ((p=0.036). Children from the mildest disease category recorded the lowest 
amount of energy from the LPSF (p=0.012), and ingested significantly more energy from snack 
foods (which included both LPSF and regular snack foods) [high vs. medium vs. low: median (IQR): 
12% (11); 14% (13); 36% (26) (p=0.010)]. All patients from the three LPSF user groups took less 
than 50% of non-protein energy (%EAR) from LPSF (0-49%). Low users in particular only took be-
tween 0-17% of the recommended number of units suggested by the NSPKU society. The use of 
food from groups as outlined in the NDNS survey was similar for children with PKU as with the 
general population however intake of all food groups was lower, especially in the potatoes and cereal 
(including LPSF) groups. 
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Conclusion: Patients and their carers have a positive attitude and perception on the use and need for 
LPSF in the management of their diet for PKU, but have issues in obtaining supplies. Low users of 
LPSF were in the milder disease category and had a greater intake of energy from snack foods, also a 
higher SDS weight and SDS BMI.   
 Low users of LPSF who have milder mutations of PKU should be encouraged by their meta-
bolic specialists in the use of use some protein dense foods to provide their phenylalanine require-
ments. This would allow the use of a greater amount of LPSF to ensure that energy needs are met by 
the staple LPSF rather than regular high energy snack type foods. Support by specialists in the meta-
bolic centres to aid parents and carers obtain sufficient supplies of LPSF in a timely manner is essen-
tial to promote use of product.  
Further studies are needed to determine the perception of the usefulness of LPSF in the man-
agement of PKU by patients with mild disease and by low users of LPSF. In addition there is a need 
to explore whether it is low LPSF users who find it most difficult to obtain supplies. Studies with the 
adult PKU population exploring any association between obesity and use of LPSF are also necessary 
given the lack of information in this group of patients.  
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Introduction 
Phenylketonuria 
 Phenylketonuria (PKU) is an autosomal recessive inborn error of metabolism caused by defi-
ciency of the enzyme Phenylalanine Hydroxylase (PAH). PAH is essential for the conversion of the 
amino acid phenylalanine to tyrosine along with the co-factor Tetrahydrobiopterin (BH4). Reduced 
activity or absence of PAH results in increased concentrations of phenylalanine and reduced levels of 
tyrosine in plasma. PKU has an incidence of 1:10,000 per year in the UK (MRC Steering committee, 
1981) and the prevalence is similar in European populations (Mitchell, Trakadis & Scriver 2011) alt-
hough variations amongst ethnic groups are noted (Hardelid et al. 2008). Since 1969 PKU has been 
diagnosed through the U.K National Newborn Screening programme. 
Historical overview 
 PKU was first described in 1934 by AsbjØn FØlling  (Følling 1994)  a professor of nutritional 
medicine, physiology and biochemistry, who suggested that the presence of phenylketones in the 
urine as being the underlying cause of neurological deficits in two siblings Liv and Dag Egeland 
from Oslo. Their parents’ persistence in wanting to find the cause of their children’s mental retarda-
tion persuaded FØlling to examine the children. The parents also noted that the urine of both children 
had an unusual odour. During the examination of the children, a routine urine check detected phe-
nylpyruvic acid. 
 FØlling speculated that the presence of the ketoacids in the urine was the result of an inability 
to metabolise the amino acid; phenylalanine. He then went on to test urine of other children with 
mental retardation and discovered another 8 children with urinary phenylpyruvate. All 8 children had 
similar characteristics notably: eczema, fair skin, a spastic gait and severe intellectual impairment. 
FØlling described this condition as “imbecillitas phenylpyrouvica”.  
 Following this discovery, Jervis (USA) and Penrose (UK) tested similarly affected individu-
als in their respective countries. In 1937, Jervis identified a deficiency of the enzyme PAH as the 
cause for the phenylketones present in the urine (Williams, Mamotte & Burnett 2008). The condition 
became known as “phenylketonuria”, and is still commonly referred to as this, although hyper-
phenylalaninaemia more accurately identifies the range of conditions treated today. In 1950, Horst 
Bickel introduced a low phenylalanine diet which was found to be effective in lowering phenylala-
nine levels. Woolf (Woolf, Vulliamy 1951) suggested that the neurological damage characteristic in 
PKU was caused by an intoxication of phenylalanine and that the low phenylalanine diet would re-
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lieve the symptoms of mental deficiency. Armstrong reported the first use of a synthetic diet using an 
amino acid mixture and low phenylalanine foods in 5 children with phenylketonuria (Armstrong, Ty-
ler 1955a). The children who were aged between 7 months and 4 ½ years all showed improvement in 
behaviour, development and a lowering of seizure activity.  
 The detection, treatment and effect on intelligence of PKU were all described in the early 
1950’s by several authors (Woolf et al. 1958; Blainey, Gulliford 1956; Woolf, Griffiths & Moncrieff 
1955;  Gibbs, Woolf 1959).  
 A report in the British Medical Journal of 1958 suggested that by the time the condition was 
diagnosed and diet established, the mental rating was only able to be raised from “idiot to imbecile 
level” and noted that the effect of treatment varied with the age dietary restriction was started. 
Moncrieff suggested that early diagnosis from the age of 3 weeks and use of a low phenylalanine di-
et, intelligence could be improved (Moncrieff, Wilkinson 1961). Parents of these treated children al-
so commented that their affected children were more manageable, less restless, fits ceased and their 
eczema cleared up when on diet. 
Introduction of screening for PKU 
 In 1960, Allen described a method of screening patients identified with neurological defects 
who attended his paediatric clinic (Allen 1960). The test consisted of strips impregnated with ferric 
chloride which detected urine phenylpyruvic acid. The strips were given to the parents to test the 
urine in nappies and then return to him in the post. Robert Guthrie, a cancer researcher, whose niece 
had intellectual delay caused by PKU, developed the microbial inhibition technique (Guthrie, Susi 
1963) used for mass screening of new-born’s from the late 1960’s.  
 In 1963, the report to the Medical Research Council (MRC) of the conference on Phenylke-
tonuria gave recommendations on screening, diagnosis and treatment of Phenylketonuria (Anony-
mous 1963). This committee recommended that screening of infants be carried out in the fourth week 
of life by a urine test to detect phenylpyruvate acid. As a result of this conference, 131 local health 
authorities in England and Wales introduced routine urine testing, 5 planned to do so and 9 had no 
plans. In 1967, South Eastern Scotland introduced the first routine blood testing by the heel prick test 
using the Guthrie method at day 6. The tests were analysed by the bacteriology department at 
Stobhill Hospital and the laboratory subsequently became the National Screening Laboratory for 
Scotland. This test, commonly referred to as the Guthrie test, and the more modern tests using tan-
dem mass spectrometry, now form the basis of neonatal screening for PKU in many countries around 
the world.  
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 Newborn screening has been credited by Kyriakie Sarafoglou MD, Minnesota, as being “one 
the most important public health advances of the 20
th
 century, allowing children with rare disorders 
to live a better life” (Kuchn 2013). 
Current newborn screening 
 The newborn screening programme today uses a heel prick blood sample taken between day 
5-8 (UK) from all newborn infants (99.9% uptake; www.newbornbloodspot.screening.nhs.uk) and 
now tests for a range of treatable conditions including: PKU, MCADD (Medium-chain-acyl-co-a-
dehydrogenase-deficiency), Cystic Fibrosis (CF), Sickle Cell Disease, and Congenital Hypothyroid-
ism (in Scotland). Tests for additional Inborn Errors of Metabolism were introduced as a pilot 
scheme in England and Wales (http://newbornbloodspot.screening.nhs.uk/expandedscreeningstudy) 
and will be incorporated into the screening programme from this year.  
 The test for PKU will identify abnormal phenylalanine and tyrosine levels. Normal phenylal-
anine levels are between 60-90 umol/l and the threshold for reporting abnormal samples is 
>240umol/l for phenylalanine and <240 umol/l for tyrosine for a diagnosis of PKU. Tyrosine levels ≥ 
240 umol/l are reported as needing further investigation for conditions affecting tyrosine metabolism 
or liver dysfunction such as Galactosaemia. Screening and the prompt introduction of a phenylala-
nine restricted diet has enabled affected individuals to be identified and escape the severe neurologi-
cal effects of untreated hyperphenylalaninaemia. Nowadays with early diagnosis and effective die-
tary control of the phenylalanine levels, individuals with PKU are expected to have the same ability 
and life chances as unaffected people (Spronsen et al. 1997; Weglage et al. 1996). 
Classification of PKU 
 Severity of hyperphenylalaninaemia is a result of a mutation in the phenylhydroxylase (PAH) 
gene of which there are around 564 different mutations (Yu 1970a; Blau et al. 2011). Yu (Yu 1970a) 
in his review of phenylketonuria described 5 groups of hyperphenylalaninaemia severity based on the 
Guthrie screening test (Table 1). Classical phenylketonuria was defined as the fasting phenylalanine 
level being above 1,200 umol/l, after 6-10 days of age with phenylketones present in the urine, re-
sulting from very low or absent PAH activity. 
 Atypical phenylketonuria was classed as having phenylalanine levels of 240-1200 umol/l 
with partial absence of the enzyme. Other groups included: maternal PKU, phenylalanine transami-
nase defects, and transient neonatal hyperphenylalaninaemia. Blau (Blau, van Spronsen & Levy 
2010) classified severity of hyperphenylalaninaemia by the phenylalanine level based on newborn 
screening results before treatment has started. Those with blood phenylalanine concentrations of 120-
19 
 
600 umol/l are described as having mild hyperphenylalaninaemia; concentrations between 600-1,200 
umol/l as moderate hyperphenylalaninaemia and classical phenylketonuria is where the phenylala-
nine levels are above 1200 umol/l. Current UK classification as denoted by the UK Newborn Screen-
ing guidelines is noted in Table 1. 
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Table 1: Classification of PKU 
Author Number of catego-
ries of disease 
Method of de-
termination 
Classification Phenylalanine concentration  
umol/l 
 
Yu 1970 
 
5 groups 
 
Based on  
screening result 
 
Atypical 
Maternal 
Phe transaminase defects 
Transient neonatal 
Hyperphenylalaninaemia 
 
 
240 – 1200 
 
Blau 2010 
 
3 groups 
 
Based on  
screening result  
Not reported 
Monitored – no treatment 
Mild Hyperphenylalaninaemia 
Moderate Hyperphenylalaninaemia 
Classical PKU 
 
<240 
240 -  400 
400-600 
600-1200 
>1200 
 
Guldberg 1998 
MRC working party 
 
3 groups 
 
Based on phenyl-
alanine tolerance 
 
Severe 
Moderate 
Mild 
 
250 -  350mg Phe/day 
350 -  400mg Phe /day 
400-600mg Phe / day 
 
 
Current Newborn 
screening 
classification 
 
4 groups 
 
Based on screen-
ing result 
 
Hyperphenylalaninaemia or Non-PKU 
Hyperphenylalaninaemia 
Mild PKU 
Moderate PKU 
Classical PKU 
 
<600 
 
600-900 
900-1200 
>1200 
             
 PKU register 
 In 1963 the MRC/DHSS Phenylketonuria Register was set up under the supervision of 
the MRC Committee for Phenylketonuria and later Dr Isabel Smith (Institute Child Health, 
London) to monitor the effectiveness of the dietary management of PKU. Patients, whose 
phenylalanine levels remained below 480 umol/l, and were on free diet, were excluded from 
the register. The register kept details of diagnosis, dietary management and intellectual ability 
of all patients diagnosed with PKU in the UK from 1964. This register allowed information to 
be gathered and analysed regarding the incidence and effectiveness of the low phenylalanine 
diet to aid the formation of treatment guidelines. The register was kept until 1998 and finally 
discontinued due to lack of funding. 
Early dietary management 
 The early low phenylalanine diet was based on a low phenylalanine casein acid hy-
drolysate powder mixed with oil and sugar, with the phenylalanine being removed by char-
coal treatment (Woolf, Griffiths & Moncrieff 1955). These protein substitutes included: Min-
afen (Truefood Ltd) and Lofenalac (Mead Johnston Ltd) used for infants and Cymogran (Al-
len & Hanbury Ltd) and Albumaid XP (Scientific Hospital Supplies) for older children. The 
remainder of the diet was based on: tinned fruit, some vegetables, vegetable margarine and 
specially prepared bread and biscuits made from wheat starch. Later, low phenylalanine prep-
arations based on amino acids (Aminogran Food Supplement, UCB Pharma) were developed 
and had a more acceptable taste (Smith et al. 1975). The protein substitute was lower in fat 
and carbohydrate than previous substitutes, thereby allowing for the addition of a greater 
range of “normal” foods such as fruit and some vegetables into the diet. All the preparations 
required supplementation of vitamins and minerals to varying degrees.  
 The diet was considered complicated and children were accepted for treatment only if 
the parents were considered able to manage the diet at home following a long period in hospi-
tal stabilising phenylalanine levels (Woolf, Griffiths & Moncrieff 1955). Several reports 
mention the competency and intelligence needed by the parents in managing this complicated 
diet (Moncrieff, Wilkinson 1961; Woolf, Griffiths & Moncrieff 1955; Yu 1970b; Brim-
blecombe et al. 1961b). 
 Centerwall (Centerwall et al. 1961) described treatment and the dietary restrictions 
used in 10 cases of children aged 8 months to 3 years. He reported that the diet was well re-
ceived and the children demonstrated an improvement in their development. All children  
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received daily vitamin and iron supplements and had weight in proportion to their height, but 
their height was below average. 
 The dangers of a low phenylalanine diet were reported by (Moncrieff, Wilkinson 
1961) and included growth failure, weight loss, severe rash, skin lesions and anorexia in three 
treated infants. The affected infants, who were all fed different low phenylalanine prepara-
tions, responded to cow’s milk being added to the diet. They consequently made a dramatic 
recovery and their blood when tested for phenylalanine concentrations showed that the in-
fants were suffering from severe phenylalanine deficiency.  
Early dietary management guidelines 
 In 1963, the report to the MRC (Anonymous 1963) of the conference on Phenylke-
tonuria, gathered information from several countries on complications with the dietary man-
agement of PKU. It gave recommendations on screening, diagnosis and treatment of Phenyl-
ketonuria. The report from this conference concluded that infants should be given 25mg/kg 
phenylalanine from milk or cream and this adjusted as necessary to keep the blood phenylal-
anine levels just above the normal range for unaffected individuals. 
 The MRC also advised that 50% of the calories should come from carbohydrate and 
35% from fat. The carbohydrate intake could be supplemented by the use of gluten free wheat 
starch and sugar. Recipes were developed to enable the wheat starch to be made into cakes 
and biscuits “to make the diet interesting”. Yu (Yu 1970b) in a review of phenylketonuria 
reported the diet as being “one of the most difficult and socially limiting of therapeutic diets”. 
 Included in the report were tables of natural foods which had their phenylalanine con-
tent estimated which allowed them to be incorporated into the diet. The estimated phenylala-
nine content was based on the assumption that animal and vegetable proteins contain between 
4 -6% phenylalanine. Thereby these lists of foods could be used to aid variety in the diet and 
have formed the basis of the phenylalanine exchange system (50mg / 100g food) still in use 
today. 
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Consequences of PKU  
Neurological consequences of PKU 
 As early as 1951 the mechanism of the damage to brain development caused by raised 
phenylalanine levels had been described (Woolf, Vulliamy 1951). The deficiency or reduced 
activity of PAH which results in high phenylalanine levels and consequently reduced tyro-
sine, leads to a shortage of dopamine, noradrenaline, and tryptophan, the precursor of seroto-
nin. The raised phenylalanine levels restrict the transport of large neutral amino acids such as 
tryptophan and tyrosine, by competitive inhibition, across the blood–brain barrier interfering 
with the normal transport of neurotransmitter precursors. In addition, this insufficiency of 
large neutral amino acids may be linked to the mental impairment observed in phenylketonu-
ria. A shortage of tyrosine is implicated in the cognitive and behavioural difficulties reported 
in early treated children who had higher than recommended phenylalanine levels (Van Spron-
sen, Ahring & Gizewska 2009).  
 With the introduction of newborn screening and prompt dietary therapy, the risk of 
severe neurological damage was eradicated. The focus then moved to determining: what de-
gree of phenylalanine levels above normal (60-90 umol/l) require treatment; what are “safe” 
phenylalanine levels; how long the diet should be continued and whether or not the deter-
mined safe range is suitable for all ages (Waisbren et al. 2007; Pollitt 2012). 
 Griffiths (Griffiths, Campbell & Robinson 1998) compared executive function in 
eleven early treated primary school children with age matched controls and found no differ-
ence in the ability to maintain attention or make decisions when phenylalanine levels were 
kept under 300 umol/l. However, (Leuzzi et al. 2004) compared 14 early treated children (ag-
es 8-13) and demonstrated impairment of executive function with similar phenylalanine lev-
els (<400umol/l).  
 A review by Waisbren (Waisbren et al. 2007) discussed the reliability of using phe-
nylalanine levels to predict outcomes in intelligence and the wide variation in accepted rang-
es of phenylalanine levels worldwide. The review noted that during childhood, for every rise 
of 100umol/l of phenylalanine there was a loss of between 1.3 and 3.1 IQ points. It concluded 
that levels ≤360 umol/l were optimal in preventing loss of IQ and that using of phenylalanine 
levels were a good indicator of future IQ. Gentile (Gentile, Ten Hoedt & Bosch 2010) high-
lighted the “hidden disability” experienced by well controlled patients with PKU and de-
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scribed the emotional and social difficulties experienced by treated individuals which led to 
impact on quality of life. 
Effect on growth 
 During the early days of dietary treatment, restricted growth was attributed in part to 
excessive protein restriction to limit phenylalanine intake (Fisch, Walker & Anderson 1966). 
This may not be the case at the present time as treatment has substantially improved (Spron-
sen et al. 1997). The increase in recommended protein intake from the protein substitutes 
(MRC 1993) has contributed to growth not being an issue with the majority of patients at the 
present time (Huemer et al. 2007). 
Quality of life 
 Quality of life is a concept comprising many facets: mental, social, functional and 
psychological well-being. The complex nature of the dietary management for PKU such as: 
keeping track of natural protein intake; children requiring encouragement to take the protein 
substitute; regular blood tests and the clinic visits that are required by the clinicians managing 
the child, have been implicated in poor quality of life. The day to day management of PKU 
places a burden on parents and patients, especially the younger children (Vegni et al. 2010; 
Fidika, Salewski & Goldbeck 2013). Parental acceptance of the diagnosis has been shown to 
affect their levels of stress and coping abilities (Lord, Ungerer & Wastell 2008), although this 
did not seem to contribute towards any behaviour problems in the child with PKU. 
Obesity 
 The trend towards obesity has been shown in particular with the older, female patients 
who have classical PKU (Burrage et al. 2012; Robertson et al. 2013). They also found that 
adults with PKU had a similar rate of obesity and overweight to the general population in the 
UK and demonstrated there was a correlation between high phenylalanine concentrations and 
rate of obesity. The aetiology behind this remains unclear, but may be related to lack of exer-
cise, poor compliance with the diet or poor dietary choices. Physical activity and poorly con-
trolled PKU is an area where there is little information and with the lack of knowledge of the 
general health of an aging PKU population is an area that is of interest for future study.  
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Micronutrient deficiencies 
 Although present in sufficient amounts in the protein substitute, Vitamin B12 is the 
most frequently reported vitamin deficiency (Walter 2011; Vugteveen et al. 2011; Lee et al. 
1999; Hanley et al. 1996). Patients who are at most risk are those who are non-compliant with 
their protein substitute (Lee et al. 1999) or have discontinued their diet and have not com-
pletely normalised their dietary intake by using high protein foods such as meat, fish, eggs 
and dairy products (Robinson et al. 2000a).     
          Selenium is found mainly in foods that are restricted in the PKU diet, including: cere-
als, eggs, fish and Brazil nuts and was not routinely added to the protein substitute until the 
1990s. Fruit and vegetables which are low in selenium because the soils of Europe generally 
tend to be depleted in selenium, make it essential that there is the addition of selenium to the 
protein substitute to provide requirements. A review of literature by Robert (Robert et al. 
2013) suggests that while low serum selenium is common, reports of symptomatic selenium 
deficiency are rare in treated PKU (Greeves et al. 1990). Selenium deficiency has been linked 
to poorer performance in neuropsychology tests and altered antioxidant status (Gassió et al. 
2008; van Bakel et al. 2000).  
        Early studies linked Zinc deficiency with poor growth (Acosta et al. 1982), but although 
nowadays low plasma zinc is frequently described (Fisberg et al. 1999b; Rohr, Munier & 
Levy 2001a; MacDonald et al. 2008), poor growth does not appear to be an issue. 
       Bone health and PKU is an issue currently attracting more attention with reduced bone 
mineral density and increased risk of fractures reported (Greeves, Thomas & Carson 1995; 
Greeves et al 1997), however, Mirás  linked the development of bone disease with the re-
duced natural protein intake in well controlled, classical PKU (Mirás et al. 2013). 
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Use of Protein substitutes in PKU 
Early protein substitutes 
 Low phenylalanine protein substitutes were commercially developed in the early 
1950’s. They were based on a protein hydrolysate rendered free from phenylalanine by pass-
ing it through a column of charcoal which removed phenylalanine along with tyrosine and 
tryptophan (Woolf, Griffiths & Moncrieff 1955). 
 This powder was made into a “soup” along with wheat starch, kosher margarine, glu-
cose and water and given 4 or 5 times over the day. Additional vitamins, minerals and arachis 
oil were also added. As phenylalanine could not be converted to tyrosine, tyrosine therefore 
became an essential amino acid and was a necessary addition to the casein hydrolysate along 
with tryptophan. The first synthetic amino acid mixture was described by Armstrong (Arm-
strong, Tyler 1955a) and provided free by several companies for use in his experiments. This 
mixture required the addition of salts, vitamins, carbohydrate as sucrose and olive oil, made 
into a slurry and fed to infants and given as a paste to the older children. All children had wa-
tery diarrhoea, intestinal cramps and retching with the diet initially which settled down after a 
week or so. 
 The early “complete” protein substitutes were found to be deficient in zinc and sele-
nium (Barretto et al. 2008; Fisberg et al. 1999a; Gokmen-Ozel et al. 2009), which prompted 
increased supplementation now contained in the substitutes used today. A report by Wilson 
and colleagues (Wilson, Clayton 1962) describes infants with PKU fed a low phenylalanine 
formula “Minafen” (Truefood Ltd) developing a severe skin rash and lack of weight gain due 
to micronutrient deficiencies. Such difficulties often led to the diet being stopped before the 
age of 8 or 10 years.  
 In 1970, Clayton and Frances trialled a new form of protein substitute as an amino 
acid formula (Aminogran, UCB Pharma) and demonstrated that this improved the palatability 
of the diet, improved acceptance and intake of early treated children with PKU. This new 
product required supplementation with vitamins and minerals, but a smaller amount of pow-
der was needed to provide the required protein allowance was and was often recommended to 
be mixed with sugary, fizzy drinks such as cola or lemonade to make it acceptable. 
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Current use of protein substitutes 
 Macdonald described problems associated with taking the protein substitute in young 
children such as refusal to take the substitute (MacDonald et al. 1994). Over the years there 
have been many studies associated with the presentation and palatability of the protein substi-
tute (MacDonald et al. 2004; MacDonald et al. 2006; Rohr, Munier & Levy 2001b). As the 
low phenylalanine diet is now recommended for life (NSPKU), protein substitutes have had 
to be adapted to become more acceptable to adults and consequently their lifestyle. This need 
has led to the development of tablets and “ready to drink” products in addition to changes in 
packaging which aim to aid convenience and reduce the medical appearance of the products 
and thereby improve adherence with the diet. 
 Another area of study has been on the amount of protein substitute and frequency it 
should be given. MacDonald (MacDonald et al. 2003; MacDonald et al. 2006) suggested that 
the more often the protein substitute is given over a 24 hour period, including overnight, the 
more stable the phenylalanine concentrations. However, the study acknowledged that this 
was generally impractical in reality.  
 The amount of energy supplied by the protein substitute has also been an area of in-
terest (Gokmen-Ozel et al. 2011) with the trend towards lowering the carbohydrate content 
and therefore the satiety effects of carbohydrate to try to improve appetite without an adverse 
effect on phenylalanine control. 
Design of the protein substitute and adherence to diet 
As recommendations for “diet for life” have become the norm, there was a need to 
develop protein substitutes that were acceptable to adolescents and adults. Over the years, 
studies on the protein substitutes were designed to produce products concentrating on im-
proving the taste, efficacy and acceptability using patients as their own controls (Bentovim et 
al. 1970; Macdonald et al. 2004; Yi, Singh 2008a). In addition, the focus also turned also to 
producing protein substitutes that were more convenient and easy to use (MacDonald et al. 
2003; MacDonald et al. 2004; MacDonald et al. 2006). These protein substitutes became 
available in a variety of forms such as: ready to drink liquids, tablets, fat coated granules and 
bars. 
Gokmen-Ozel in her study, reported on the modification of the protein substitute by 
the reduction of the carbohydrate content and the effect this had on phenylalanine control. 
Subjects again were their own controls and the ready to drink protein substitute was com-
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pared with the protein substitute they were taking before the investigation and no effect on 
phenylalanine control was found (Gokmen-Ozel et al. 2011). 
Specialist nutrition companies such as (Nutricia) SHS International Ltd, Vitaflo Inter-
national Ltd and Milupa Ltd have strived to develop products designed to be more acceptable 
to the growing child and adolescent through to the adult with PKU. The companies aim to 
help maintain dietary control and attempt to increase adherence amongst this age group. The 
increased range of products has led to improved compliance with the protein substitute 
(Gokmen-Ozel et al. 2009; MacDonald et al. 2006; Yi, Singh 2008b; Rohr, Munier & Levy 
2001b), however, the studies were short term and it is not known if the effect is sustained.  
 Compliance or adherence with treatment has been the subject of many reports (Alaei 
et al. 2011; MacDonald 2000; Bik-Multanowski et al. 2008). In a review of diet and compli-
ance with treatment, MacDonald (MacDonald 2000) concluded that the concept of compli-
ance was complex. Adherence was related to many factors, not only with taking the pre-
scribed amount of protein substitute, but found that motivation and a positive attitude towards 
the diet was essential and support from all health professionals involved in the care of fami-
lies and patients was paramount. 
Current management practice 
Biochemical Monitoring 
 Following the 1963 MRC report, Clayton and Francis published a very detailed, pre-
cise method for feeding and monitoring an infant with PKU and this formed the basis of the 
advice still used at the present time (Clayton, Francis & Moncrieff 1965).  An intake of 20-
45mg phenylalanine/kg (Centerwall, Centerwall 1969; Brimblecombe et al. 1961a) was sug-
gested for infants in order to maintain serum phenylalanine levels between 180-480 umol/l 
(3-8mg/100ml). Although levels less than 600-720 umol/l (10-12 mg/100ml) were widely 
used during the  1970’s (Yu 1970b), it was recognised that phenylalanine levels above 20mg / 
100ml (1200 umol/l) were regarded as an upper safe limit in relation to the prevention of neu-
rological impairment.  
 Safe limits for target phenylalanine levels advised for children as they grow into 
adulthood vary between countries (Table 2), as although the requirement for dietary man-
agement is undisputed, there is a lack of evidence as to the agreed goal of management. 
Table 2: Target phenylalanine concentrations by age groups* 
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 UK France Germany USA 
Birth – 6 years  120-360 120-300 40-240 120-360 
7-9years 120-480 120-300 40-240 120-360 
10-12 years 120-480 120-600 40-900 120-360 
13-15 120-700 120-900 40-900 120-600 
>16 120-700 120-1200 40-1200 120-900 
* adapted from Blau (2010) 
 
 New guidelines about to be published by the NSPKU (2014) will advise that all chil-
dren with PKU up to the age of 16 should keep their phenylalanine levels below 480 umol/l 
and adults are recommended to maintain levels below 700 umol/l. However, guidelines to be 
published in the USA will state that phenylalanine levels for all ages should be kept between 
12- 360 umol/l to maintain optimum health and wellbeing. 
Frequency of monitoring 
 In addition to the variation of safe phenylalanine concentrations between countries, 
there is also variation in the recommendations of frequency of monitoring phenylalanine lev-
els. Schweitzer-Krantz (Schweitzer-Krantz, Burgard 2000) reviewed practices in Europe and 
found that guidelines were very rarely updated and that the main variation between countries 
was the age at which less frequent blood spots were requested by the managing centres (Ta-
ble 3). 
 
Table 3: Variation in frequency of phenylalanine monitoring in Europe* 
 UK 
1993          
 
Hungary 
1998 
Czech  
Republic 
1998 
Slovakia 
1998 
France 
1996 
Germany 
1997 
Poland 
1996 
Weekly 0-4 yrs. 0-4 yrs. 0-1 yr. 0-1 yr. 0-2 yrs. 0-1 yr. 0-6 mths. 
Fortnightly 5-9 yrs. 5-9 yrs.   3-8 yrs. 1-9 yrs. 6-12 mths. 
Monthly 
 
> 9yrs > 9yrs 1-6 yrs. 1-6 yrs.  10-15 yrs. > 1 yr. 
3 monthly 
 
  > 6 yrs. > 6 yrs. 9-13yrs. >15 yrs.  
Yearly     > 13 yrs.   
* adapted from Schweitzer-Krantz & Burgard 2000 
 In addition to the monitoring of phenylalanine levels, monitoring of growth, amino 
acids and clinical review varied widely between ages of patients at across Europe (Van 
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Spronsen, Ahring & Gizewska 2009) with clinical review decreasing from around 9 times a 
year for the under 1 year olds to yearly for patients over 12 years of age. 
 Several authorities recommended that children with PKU should be managed by spe-
cialists where expertise and support was available (Clayton, Heeley & Heeley 1970; McBean, 
Stephenson 1968; NIH, 2000). Current guidelines recommend that the specialist team con-
sists of a consultant paediatrician in inherited metabolic disease, a paediatric dietitian with 
metabolic disease expertise, a metabolic nurse and suitable biochemical facilities.  
(.http://www.newbornbloodspot.screening.nhs.uk). 
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Current Dietary Practice 
Current UK Dietary Guidelines 
 The management of PKU today is based on the 1993 recommendations and include: 
1. The daily use of a phenylalanine free protein substitute containing all amino acids 
apart from phenylalanine, along with vitamins and minerals. This replaces protein 
containing foods such as meat, fish, nuts, soya, poultry, cereals and legumes, and 
these foods must be completely avoided. The protein substitute used should be tai-
lored to the age requirements of the infant, child or adult with PKU.  
2. The use of LPSF produced by specialist food companies which have negligible phe-
nylalanine content. These low protein foods which are available on General Practi-
tioner (G.P) prescription (UK), such as rice, bread and pasta, generally provide a main 
food ingredient around which a meal can be created and act as a substitute for “con-
ventional” foods. 
3. A daily phenylalanine intake provided by natural foods such as potatoes, breakfast ce-
reals and some vegetables. These foodstuffs contain a known, measured amount of 
Phenylalanine which is 50 mg per 1g of naturally occurring protein and are generally 
referred to as protein exchanges. 
4. Natural foods very low in phenylalanine e.g. most fruit and vegetables, fats, oils and 
sugars. These foods have had dietary analysis carried out by the National Society for 
Phenylketonuria (NSPKU) and are able to be given in moderate amounts without be-
ing counted in the phenylalanine allowance. These foods generally have a phenylala-
nine content of < 25mg phenylalanine / 100g. 
Low protein manufactured foods 
 LPSF are specially manufactured alternatives to natural basic foods such as bread, 
pasta, biscuits and milk. The earliest described LPSF was a biscuit made from wheat starch, 
sugar and fat (Armstrong, Tyler 1955a; Woolf, Griffiths & Moncrieff 1955). A little later, 
bread became available in tins, but in Glasgow, a special low phenylalanine loaf and also bis-
cuits were made by a local bakery and were reported as being a boon to patients (McBean, 
Stephenson 1968). These foods represent alternatives to foods eaten by the general popula-
tion and serve to improve convenience for patients on a restrictive diet.  
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 The LPSF have improved considerably in the variety, palatability and visual appeal 
over recent years. Nowadays, patients with PKU can be prescribed a wide range of products 
including: flour and cake mixes, vacuum-packed bread, rolls and pizza bases, along with 
burger mixes, several pasta shapes and dried ready meals which aim to improve variety and 
flexibility with the diet. 
 Recommendations from the medical advisory panel of the NSPKU (NSPKU-
http://www.nspku.org/publications/publication/prescription-guidelines) are available which 
provide some guidance on the amount of the LPSF that should be prescribed, based on 50% 
non-protein energy requirements (EAR) (Table 4). 
 
Table 4: Recommended maximum number of units of LPSF for each age group (NSPKU) 
              
Age of patient with PKU  Recommended maximum number of 
low protein items to prescribe each 
month*  
4 months -3 years  15 units  
4-6 years  25 units  
7-10 years  30 units  
1-18 years  50 units  
Adults  50 units  
Pre-pregnancy/Pregnancy  50 units  
*This excludes low protein milk replacements and protein substitutes  
 
 The guidance from the NSPKU allows the G.P to have some indication whether or not 
the individual with PKU is having sufficient LPSF when dispensing prescriptions. Many pa-
tients will order a variable amount each month and anecdotal reports from patients and their 
carers is that they have difficulty obtaining sufficient product on prescription because they do 
not need to order the same amount each month.  
 When comparing the calorie content of the LPSF against their regular equivalents it 
can be seen from Table 5 that they are very similar (figures for regular foods taken from the 
website of a popular supermarket). 
 
 
33 
 
Table 5: Comparison of calorie content with regular foods and LPSF equivalent  
Calories / 100g Regular foods LPSF equivalent 
Dried pasta 360 363 
Dried rice 355 366 
Crackers 440 448 
White bread 243 259 
Semi skimmed milk / 100ml 50 40 
Full cream milk / 100ml 65 66 
Cheerios breakfast cereal 382 385 
Access to dietary products 
 Although within Europe and the USA screening for PKU is offered to all new-borns, 
the treatment consisting of a low phenylalanine diet necessitating the use of LPSF and protein 
substitutes is not freely available to all (Camp, K et al. 2012).  The cost borne by state and 
patients varies considerably between countries. In the United States, costs for screening and 
diagnosis are paid for by the state, but not treatment. Some states cover the cost of the protein 
substitute, but not the cost of the LPSF. In other states, medical insurance companies are re-
quired to cover the cost and policies vary between the states with no consensus of who should 
pay. Within Europe, the state or insurance companies bear the cost of the protein substitutes, 
however access to LPSF varies. In Belgium, Norway and Denmark, patients receive an annu-
al allowance; in Poland patients are required to purchase LPSF over the internet, whereas in 
Germany, no allowance is made except for patients on state welfare (Bélanger-Quintana et al. 
2011) 
 In the UK, the dietary products used in the management of PKU are prescribed by the 
G. P. and the expense borne by the primary care budget. The amount contributed by the pa-
tient varies between regions, with Scotland and Wales providing free prescriptions for all ag-
es. Within the rest of the UK, patients over the age of 16 years pay a prescription charge, alt-
hough a prepaid prescription can be bought which allows free prescriptions for a year. Con-
sequently the cost of the protein substitute and LPSF foods adds a considerable amount to the 
budget of the UK primary health care service.  
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Cost of dietary management 
 Woolf (Woolf, Griffiths & Moncrieff 1955) considered the economic cost of dietary 
treatment of PKU, quoting a perceived incidence of 4:100,000 and suggested that the untreat-
ed patient in 1955 would require care in an institution which would entail a cost of £5 per 
week. He also calculated the cost of the dietary constituents as 7s 4d per day, which included 
the casein hydrolysate, tryptophan, vitamins, liver extract and choline and therefore treating 
by diet would cost more than institutional care. Woolf concluded that if the patients were 
treated, they would be able to attain a level of education at normal schools although still be 
classed as educationally subnormal, but the cost of institutional care would be saved. The pa-
tients may then go on to be productive members of society. Consequently the cost of the diet 
should not be allowed to have an influence on the decision taken on whether or not to treat an 
affected individual. 
 Today, an average 8 year old child with PKU could cost around £6,700 per year for 
the protein substitutes and a further of £2,200 for LPSF based on the information to G.P’s 
from the NSPKU. Guest and colleagues (Guest et al. 2013) calculated the expense of main-
taining an early treated adult on diet up to the age of 35 years in 2007-2008 as between 
£21,000 and £149,000 dependant on the amount of prescribable products they received.   
  The cost of the protein substitute should not fluctuate significantly as patients are 
generally prescribed a specific daily dose to ensure their protein requirements are met. How-
ever, the use of LPSF will vary considerably between patients and the amount used is deter-
mined by: a) an individual’s preference for the products, b) their compliance with the diet, c) 
the skills of the person managing the diet and d) the amount prescribed by the GP. Therefore, 
in times of increasing scrutiny of health service spending, the lack of evidence based guide-
lines may impact on the amount of LPSF a G.P may be willing to prescribe. 
Duration of dietary treatment 
 There has been much debate as to how long an individual with PKU should remain on 
restricted diet. The MRC report (1963) did not give any recommendations. Clayton (Clayton, 
Moncrieff & Roberts 1967) suggested that although raised phenylalanine levels in the mature 
brain will not cause damage, a change was seen on electroencephalogram with loading doses 
of phenylalanine, therefore the committee advised not to stop dietary treatment.  
 McBean (McBean, Stephenson 1968) monitored the progress of a group of 31 chil-
dren with PKU from Glasgow who were established on diet before the age of 7 years. Eight 
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of the children were commenced on diet before 3 months of age. Observations from the group 
included; the effect of stopping diet on intelligence and degree of dietary control required to 
improve intelligence. They used an upper limit of 4mg/100ml (240 microgram/l) as recom-
mended by the MRC 1963 (Anonymous 1963) and noticed that levels above 12mg/100ml 
(720 microgram / l) was associated with lower intelligence. Their conclusion was that infants 
treated before 3 months would have normal intelligence provided phenylalanine levels were 
controlled below 12mg/100ml (720 microgram / l) and that results of stopping the diet in old-
er children should be done with caution as intelligence may be affected. Due to the complexi-
ty of the diet and management of the children, they advised that infants detected by screen-
ing, should be managed in specialist centres. 
 Yu suggested that once brain growth was complete, then high phenylalanine levels 
would not cause damage and that stopping the diet in early treated children may be possible 
(Yu 1970a). However, the later diagnosed children who had problems with restlessness, irri-
tability and autistic type behaviours and who were helped by the diet, may not benefit from 
the diet being stopped.  
 Smith (Smith, Beasley & Ades 1990) published a study of 599 early treated (treatment 
starting before 4 months of age) children detailing intellectual progress from 4-14 years using 
information collected from the UK PKU register. Children were divided into 2 groups: chil-
dren born between 1964 and 1971 and the second group born between 1972 and 1978. Die-
tary control, IQ assessments using the Revised Standord-Binet Test for children under the age 
of 6.5 years or the Wechsler Intelligence Scale for Children (WISC) for older children (ages: 
4,8,10,12 and 14 years), severity of PKU and social class were compared. This study con-
cluded that optimal intelligence was achieved with phenylalanine levels maintained below 
400umol/l in early childhood and that maintaining good biochemical control was more diffi-
cult with classical PKU, but effect on intellectual deterioration diminished as the child grew. 
The PKU register also revealed that 0.4% of children on the register developed neurological 
complications later in life and had lesions on subcortical white matter seen on MRI. The au-
thor concluded that patients with PKU should be advised to continue restricted diet indefi-
nitely, but acknowledged the difficulties families faced in maintaining strict control.    
 The 1993 (Anonymous 1993) report from the MRC committee noted evidence of ab-
normal changes to myelin under MRI and the effect on the foetus of women on uncontrolled 
diet and advised promoting diet for life.  
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Maternal PKU syndrome 
Mabry and colleagues (Mabry, Denniston & Coldweu 1966) reported on 3 cases of women 
with PKU having children who were mentally retarded of which one of the offspring, alt-
hough severely retarded, subsequently went on to have a child of normal intelligence. This 
led them to postulate that it was high phenylalanine levels in the mother before conception 
that caused the defects rather than a genetic abnormality. A higher rate of miscarriage was 
also reported in women who had high phenylalanine levels at conception (Stevenson, Huntley 
1967; Mabry, Denniston & Coldweu 1966). Allan (Allan, Brown 1968) reported a case of a 
woman being placed on diet during pregnancy and the infant consequently not developing 
any of the defects previously reported. By the age of 9 months the infant was reported to have 
had normal development. Lenke (Lenke, Levy 1980) identified a distinct range of symptoms 
associated with high maternal phenylalanine levels which included: facial dysmorphism, mi-
crocephaly, developmental delay, learning difficulties, and congenital heart disease (CHD). 
This became referred to as the “Maternal PKU Syndrome”. 
 Smith (Smith, Beasley & Ades 1990) reported on data collected on 94 infants born to 
women with PKU from the UK PKU register. They found that the birth weight fell by 98g 
and head circumference decreased by 0.46cm with each 200 umol rise in phenylalanine con-
centration. The range of complications in offspring of these women with PKU who did not 
start diet before conception also included microcephaly, CHD and low birth weight. 
 Members of the MRC DHSS PKU register went on to set up a maternal PKU register 
and reported on data collected on 228 pregnancies of women with PKU between 1978 and 
1997 (Lee et al. 2005). Of these, 18 (8%) did not have any dietary phenylalanine restriction 
during pregnancy, 91 (42%) started diet at some point during pregnancy and 110 (48%) start-
ed a low phenylalanine diet before conception and 2 had no recorded dietary information. Of 
the pregnancies of mothers who started diet before conception, the incidence of CHD was 
2.4% and mean 4 year development quotient (DQ) was 108.9, whereas in women who started 
diet after conception, the incidence of CHD was 17% and DQ 96.8, both birth weight and 
head circumference were also significantly lower in women who did not start diet before con-
ception. 
 The recommendation for phenylalanine levels prior to conception and during preg-
nancy is to maintain them between 60-250 umol/l (Smith et al. 1993). It is the aim of all units 
who manage women with PKU of childbearing age to ensure that they are aware of the need 
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for strict metabolic control before conception to prevent the complications associated with 
Maternal PKU Syndrome.  
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Integrative Statement 
 To date, the majority of studies on the nutritional management of PKU have concen-
trated on the use of the phenylalanine free protein substitute and its association with nutri-
tional status of the patient. However, no studies have looked at the use of LPSF and their im-
portance to the management of patients with PKU, although anecdotally they are believed to 
play a substantial role and contribute to the nutritional requirements of patients with PKU. 
There are also no evidence based guidelines or rationales for the exact amount of the LPSF 
required by patients with PKU. 
 
  
Hypothesis 
 The use of LPSF is necessary to achieve energy requirements, optimal control of phe-
nylalanine levels and aid compliance with the low phenylalanine diet and add to diet variety 
for children and adults with PKU 
Aim of the study 
 
The aim of this MSc project is two-fold: 
 
1. First to determine the beliefs held by patients and their carers on the need for the 
LPSF in managing their condition and the issues they face with access and accepta-
bility of the products. 
2. Secondly, to assess the contribution the LPSF make to the dietary intake, nutritional 
status, diet variety, management of PKU, quality of life and compliance of PKU. 
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Study 1 
A questionnaire survey on the usage 
of low protein staple foods 
by people with phenylketonuria in 
Scotland. 
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Summary  
 The first study explored beliefs, acceptability and issues around the use of LPSF by 
people with PKU or their carers. This was achieved by posting a semi-anonymous question-
naire to 178 people with PKU in Scotland (104 children 2-17 years and 74 adults). Questions 
explored: type and amount of LPSF ordered; perceptions on use and usefulness of LPSF; ac-
ceptability of the LPSF sensory properties (i.e. taste, smell, texture, appearance); support for 
the supply and use of LPSF and comments from primary care health professionals regarding 
dispensing and prescription. 
 Eighty two subjects returned the questionnaire and the majority perceived that the 
LPSF were useful for management of their diet. In addition, more than 85% reported LPSF 
important for phenylalanine control, satisfying appetite, and diet variety. The most common 
LPSF ordered were pasta/rice/cous cous, flour, biscuits and bread. The sensory properties of 
LPSF were well perceived. Nearly half of all respondents had received a comment from pri-
mary health care staff regarding the prescription or dispensing of their LPSF. 
 This part of the study concluded that there is a positive attitude and perception on the 
use and usefulness of LPSF in the management of PKU. Issues in supply and provision of 
LPSF within primary health care may indicate poor communication between specialists and 
primary care professionals or a lack of scientific evidence demonstrating their clinical effec-
tiveness. 
Introduction 
 Treatment of PKU relies on limiting dietary phenylalanine to maintain plasma phe-
nylalanine concentrations within the recommended range as recommended by the MRC 1993 
(Smith et al. 1993). As phenylalanine occurs in all protein containing foods, the conventional 
management approach is to restrict the intake of dietary protein and adhere to a partially “ar-
tificial” diet. 
In UK, patients are generally managed in specialist metabolic centres under the care 
of a multidisciplinary management team encompassing a consultant in metabolic medicine, a 
specialist dietitian and nurse. To date, dietary management in PKU comprises: a) free con-
sumption of natural foods low in protein, such as fruit and vegetables; b) use of phenylala-
nine-free amino acid substitutes containing micronutrients: c) a measured amount of natural 
protein, which is dependent upon the degree of residual PAH activity and d) use of LPSF 
with negligible phenylalanine content.   
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The LPSF are specially manufactured versions of common basic foods such as pasta, 
bread, rice and biscuits. In the U.K, these LPSF are only available on prescription from the 
G.P. and dispensed by pharmacists, unlike other specially manufactured products, such as 
gluten free foods for the management of coeliac disease, which are widely available in retail 
outlets. Although the dietary management of people with PKU is provided by the specialist 
health care professionals, the prescription and dispensing of the LPSF remain within the remit 
and budget of primary health care providers (e.g. G.P). 
 There have been several studies which have evaluated the use, clinical efficacy and 
acceptability of the phenylalanine free amino acid substitutes (Gokmen-Ozel et al. 2009; 
MacDonald et al. 2006; Yi, Singh 2008b), but similar evidence on the use of LPSF is scarce. 
From the earliest described LPSF; a biscuit made from wheat starch, sugar and fat (Woolf, 
Griffiths & Moncrieff 1955), much improvement has been made in the variety, palatability 
and visual appeal of these foods over recent years. 
 However, there is no scientific evidence which has formally assessed the use of LPSF 
in the management of PKU. To date, the use of LPSF (and free availability through national 
health services in some countries), relies on anecdotal evidence and clinical experience that 
they play an important role in the management of PKU, by providing energy, satisfying appe-
tite, increasing food variety and improving overall compliance with the restricted dietary reg-
imen. At present, the use of LPSF is determined by: a) an individual’s preference for the 
products; b) the amount prescribed by their primary health care providers (e.g. G. P). 
 The cost of LPSF adds a substantial amount to health expenditure. The overall annual 
cost of care of patients with PKU in the UK is estimated at a total of £24 million per year 
(<0.1% of the NHS budget) of which 11% is attributed to the use of LPSF (Guest et al. 2013). 
Within Scotland and Wales, the cost of the prescription of LPSF is borne by the state for all 
ages; in England, adults but not children are required to pay for their prescriptions. Outside 
UK there are large differences in the availability, access and cost of the LPSF (Bélanger-
Quintana et al. 2011; Berry et al. 2013; Camp, Lloyd-Puryear & Huntington 2012). 
As public health funds are becoming increasingly limited and health services expendi-
ture even more scrutinised, provision of LPSF through national health services requires both 
scientific and clinical evidence to support their use, efficacy and improvement of patient care. 
This study aimed to explore patients or their parents’ beliefs, acceptability and any associated 
issues with the use of LPSF before we evaluate their clinical efficacy with clinical trials.  
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Study design and methods 
 A semi-anonymous (post code was disclosed) questionnaire survey (Figure 1) was 
designed to ask questions that would reflect issues discussed in the clinical setting by patients 
and their carers. Although the questionnaire was not piloted before being sent out to patients 
and their carers, the content was checked for face validity by the specialist metabolic dieti-
tian’s from the four recruitment centres and for readability by lay people 
The questionnaire was posted to all people with PKU who were actively receiving care by 
one of the four metabolic clinical services in Scotland (Glasgow, Edinburgh, Aberdeen and 
Dundee). A stamped addressed envelope was provided for the return of the questionnaire. A 
reminder was sent out two months later to encourage response.  
Families with children under the age of two years were excluded from the survey as 
children of this age generally have a low intake of LPSF. Patients who did not engage with 
the clinical PKU service were also excluded. Ethical approval was discussed with the West of 
Scotland Research Ethics Service but was not considered necessary for this study. 
 The questionnaire asked 11 questions, both open ended and multiple-choice (Appen-
dix 1). Questions explored: comments received regarding the dispensing and prescription of 
LPSF in primary health care; participants’ (people with PKU or their parents/carers) percep-
tions on the use and usefulness of the LPSF; the acceptability of their sensory properties (e.g. 
smell, taste and texture); and current available support for the supply and use of LPSF. The 
latter included questions about the use of a free (to recipients) LPSF home delivery service 
and the attendance at regular interactive cookery workshops organised by the dietitian’s from 
the four metabolic clinical centres. Participants were also asked about the type and amount of 
LPSF ordered within the previous month. The units of LPSF ordered were compared against 
the NSPKU recommendations for the monthly allowance. 
(http://www.nspku.org/publications/publication/prescription-guidelines). 
 Basic demographic data were also collected. Participants’ comments on the prescrip-
tion and dispensing of the LPSF were given a positive, neutral or negative attribute by the 
investigator, based on any remark made by a member of the primary health care staff to the 
respondent when requesting or collecting a prescription. 
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Figure 1: A questionnaire on the use of LPSF available on prescription 
 
 
 
 
 
 
 
 
 
 
Statistical analysis 
 Statistical analysis was carried out using Minitab version 16. Categorical responses 
were presented with numbers and percentages. Differences between groups (e.g. paediatric 
vs. adult users) were explored with Fisher’s exact test, although small sample size and multi-
ple testing precluded statistical analysis for some responses. 
Results 
 A total of 178 questionnaires were posted to 74 adult and 104 paediatric (age 2-17 
years) patients attending the four departments of inherited metabolic diseases in Scotland. Of 
these, 82 (46% response) questionnaires were returned providing information on 87 patients 
(five questionnaires each provided information on two patients). The majority of respondents 
originated from Glasgow, currently the largest metabolic centre in Scotland. Questionnaire 
return rates were [number returned/number posted, (% of number returned); Glasgow: 60/106 
(57%); Aberdeen: 3/8 (38%); Dundee: 5/18 (28%); Edinburgh: 12/46 (26%); two respondents 
did not disclose their postcode]. The questionnaires were completed by: 47 (59% of respond-
ents; 50% of eligible patients including five questionnaires providing information for two pa-
tients) parents of children [mean (SD) child age: 6.6 (4.1) y] and 33 (41% of respondents; 
45% of eligible including adults looked after by carers) adult [mean (SD) adult age: 26.6 
(9.7) y] patients. Two respondents did not specify. Because the numbers of carers were small, 
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we excluded them from subgroup comparative analysis. Not all questions were completed by 
all respondents. 
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Beliefs and importance attributed by participants on the use of LPSF 
 The large proportion of respondents (n=75/77; 97%) perceived that the LPSF were 
useful for their condition. There was no significant difference between adults with PKU 
(n=27; 100%) and parents of children with PKU (n=43; 98%). Most respondents reported that 
they used LPSF to help control phenylalanine levels (n=78; 96%) and because most of the 
LPSF could be used without restriction in the diet (n=74; 94%). Similarly, more than 80% 
reported that they used the LPSF to aid diet variety and help satisfy their appetite. Although 
not significant, a higher proportion (p=0.07) of parents (93%) than adult patients (78%) 
claimed to use LPSF to provide variety in the diet (Table 6). Of the parents of children with 
PKU, 91%, valued the LPSF for helping satisfy the appetite, compared with 74% of adults 
with PKU (p=0.09) (Table 6).  
 When the respondents were asked about the taste of the LPSF, a higher proportion of 
parents of children with PKU compared with adult patients [Parents of children with PKU vs. 
adults with PKU: 31/41 (76%) vs. 12/26 (46%); p=0.02] believed that the LPSF had an ac-
ceptable taste (Table 6). Both groups placed equal importance on unrestricted use of LPSF in 
the diet (Table 6). Approximately 50% of both adult patients and parents [Parents of children 
with PKU vs. Adults with PKU: 22/41 (54%) vs. 13/25 (52%); p=1.00], used the LPSF be-
cause they were advised to by health professionals (Table 6). 
 Table 6: Reasons and importance attributed to the use of LPSF by a cohort of parents of children and adults with PKU 
 
n (%)* Important or 
very important 
Neither important or  
unimportant 
Unimportant or  
unimportant 
 Parent Adult  
patient 
All Parent Adult  
patient 
All Parent Adult  
patient 
All 
To give variety in the diet 42 (93) 21 (78) 63 (88) 1 (2) 3 (11) 4 (5) 2 (5) 3 (11) 5 (7) 
Because LPSF taste good 31 (76) 12 (46) 43 (64) 7 (17) 10 (39) 17 (25) 3 (7) 4 (15) 7 (11) 
LPSF can be used unrestricted 
in the diet 
44 (98) 
 
25 (93) 69 (96) 0 (0) 2 (7) 2 (3) 1(2) 0(0) 1 (1) 
The respondent has been told to 
use LPSF by health  
professionals 
22 (54) 13 (52) 35 (53) 13 (32) 9 (36) 22 (33) 6 (14) 3 (12) 9 (14) 
The LPSF satisfy the appetite 39 (91) 20 (74) 59 (84) 3 (7) 6 (22) 9 (13) 1 (2) 1 (4) 2 (3) 
LPSF help control  
phenylalanine levels 
45 (98) 27 (96) 72 (98) 0 (0) 1 (4) 1 (1) 1 (2) 0 (0) 1 (1) 
* percentage of group (i.e. parents of PKU children or adults with PKU or all respondents) 
 
 
               46 
  
47 
 
LPSF monthly orders 
 Parents of children with PKU and patients were asked about the amount and type of 
LPSF they had ordered in the previous month before completing the survey (Table 7). Seven-
ty six (93%) of all respondents had ordered some LPSF in the previous month. The three 
most common LPSF ordered were pasta, rice and cous cous; (n=63; 77%), followed by flour 
mix, (n=50; 61%) and biscuits (n=37; 45%) (Table 7). A higher percentage of parents ordered 
biscuits and pizza bases than adult patients with PKU (Table 7). The total number of LPSF 
units ordered was expressed as a percentage of the NSPKU recommended allowance. Fifty 
per cent of the respondents who used LPSF, ordered less than 51% of the recommended unit 
number with wide inter-quartile range (Q1: 30.5% to Q3: 104). 
Acceptability of the sensory properties of LPSF 
 Approximately 40-50% of the respondents reported LPSF sensory properties as good 
or very good, whereas less than a quarter of them perceived these as poor or very poor (Fig-
ure 2). There were no significant differences between parents of children with PKU and 
adults with the condition (Figure 2). 
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Table 7: Type of LPSF ordered by respondents in the month prior to the survey 
N (%) Parents of PKU Adults with PKU Total* 
Pasta/rice/cous cous 36 (72) 25 (83) 63 (77) 
Bread/bread rolls 18 (36) 14 (47) 34 (41) 
Flour 33 (66) 16 (53) 50 (61) 
Breakfast cereals 13 (26) 4 (13) 18 (22) 
Pasta in sauce meal 14 (28) 5 (17) 19 (23) 
Snack pot 13 (26) 4 (13) 18 (22) 
Pizza bases 17 (31)† 3 (10) 21 (26) 
Burger/ sausage mix 15 (30) 8 (27) 24 (29) 
Biscuits 27 (54)† 8 (27) 37 (45) 
Cakes 6 (12) 3 (10) 10 (12) 
Energy bars 6 (12) 4 (13) 10 (12) 
Egg replacer 12 (24) 4 (13) 16 (19) 
Dessert mix/hot breakfast 9 (18) 3 (10) 13 (16) 
Spread 0 (0) 0 (0) 0 (0) 
* Two respondents did not disclose if they were a parent, carer or patient; † p<0.05 between groups 
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Figure 2: Perception of sensory properties of LPSF by adults with PKU and parents of children with PKU 
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Issues with the dispensing and prescription of LPSF in primary health care 
 Thirty nine out of 79 (49%) recalled that they received a comment over the previous 
12 months from a member of staff within a primary health care setting regarding the prescrip-
tion or dispensing of LPSF. Fifteen of these (38%) received comments from more than one 
member. Twelve of these comments were made by a GP, 22 from staff within this area (GP 
manager: n=8; GP receptionist: n=14) and 20 were made within a pharmacy service (pharma-
cist: n=16; counter assistant: n=4) (Table 8). Of the 39 participants who received comments, 
23 (59%) received negative comments; 10 (26%) neutral comments and five (13%) received 
positive comments. One gave no explanation. The majority of the comments on the use of 
LPSF made within a GP surgery were negative [GP: 8/12 (67%); GP manager: 6/8 (75%); GP 
receptionist: 13/14 (93%)] (Table 8). In contrast less than 50% of the comments made within 
a pharmacy practice were perceived as negative [pharmacist: 6/16 (37%); counter assistant: 
2/4 (50%)] (Table 8). Of those who received a negative comment, 81% felt anxious about 
asking for future LPSF prescriptions. Comments quoted by the patients included: “always 
asked why I need these prescriptions and how do I need so much” and “the GP hoped that it 
would not put his prescribing budget up”. 
 
Table 8: Comments received from staff within primary health care regarding the prescription 
and dispensing of LPSF to people with PKU 
 G.P G.P recep-
tionist 
G.P man-
ager 
Pharmacist Pharmacy 
counter 
assistant 
Comments received 
n (%)* 
12 (22) 14 (26) 8 (15) 16 (30) 4 (  7) 
Negative comments 
n (%)† 
8 (67) 13 (93) 6 (75) 6 (37) 2 (50) 
 * Percentage of all comments received (some responders received comments from more than 
one comments); † Percentage of comments given an negative attribute 
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Use of LPSF home delivery and cookery workshops 
 When participants were asked if they had used the LPSF home delivery service, 41/80 
(51%) had used this service on a regular basis. Of these 28 (76%) reported that they found 
this more convenient and it helped with issues regarding supply of LPSF. One patient quoted: 
“it has made my time better managed as the food is delivered straight to my work”; and an-
other said “pharmacist had problems getting things in, so numerous trips to and from phar-
macy”. Fifty four (68%) had attended a cookery workshop session, with 44 (86%) of them 
agreeing that attendance had increased the variety of LPSF they used.  
Discussion 
 This survey looked at beliefs, acceptability and issues associated with the use of the 
LPSF by people and carers of children with PKU. The majority of respondents perceived that 
the LPSF helps them or their children control their phenylalanine levels. Although the LPSF 
do not taste, smell or have the same appearance as the regular products they represent such as 
pasta or bread, this was not a major concern for the majority of the respondents and was in-
dependent of their age. This may indicate that people with PKU or their carers recognize the 
importance of LPSF in the management of their condition. Also sensory properties may not 
be a major concern in a population adhering from birth, to a lifelong, artificial, relatively un-
palatable diet. In contrast, young people with conditions not diagnosed through national new-
born screening programmes but with similar dietary management (e.g. Homocystinuria) 
might find it more difficult to adjust to the less appealing organoleptic characteristics of the 
LPSF, as they have been used to unmodified conventional foods. 
Despite the acceptability and positive attitude to the use of LPSF, carers of children 
and adults with PKU frequently receive negative criticism by their primary health care staff, 
in particular from the staff within GP surgeries with regard to prescription requests and the 
supply of these products. This was in accordance to our original expectations, as the cost of 
these products is borne by the GP budget within the UK. Similar patterns might also be ex-
pected in Europe and the US, where the state may not reimburse such expenses. In a substan-
tial proportion of patients, negative criticism was reported to influence requests for future 
prescriptions. Whether this has a negative impact on the management of PKU remains un-
known, as is also the clinical efficacy of LPSF in the management of PKU. However, it is 
noteworthy that a large majority of parents and adults with PKU rated the LPSF as important 
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in controlling phenylalanine levels. Future studies should address this question with a pro-
spective design. 
As expected the most common LPSF ordered by the respondents were the staple 
foods used by the UK general population. Although there were no major differences in the 
type of products ordered between children and adults with PKU, a higher proportion of chil-
dren ordered biscuits and pizza bases compared with adults. Although this may indicate simi-
larities in eating patterns of children without PKU, health professionals managing children 
with PKU should be aware of this in the light of the obesity epidemic in the general popula-
tion.   
The use of a home delivery service and cookery workshops have been well received  
by parents, carers and people with PKU, and might help them with the use of LPSF. This 
could have implications for dietary compliance and therefore overall management of their 
condition. Cookery workshops are organised on a voluntarily basis and therefore, if use of the 
LPSF increases, there could be an argument that health service policy makers and budget 
holders should support such initiatives. 
This study is not without its limitations. The response rate was modest and it may be 
possible that non-respondents have a different view than participants on aspects around the 
use of LPSF. However, we tried to encourage participation using reminders and a semi-
anonymised questionnaire. The number of participants in this study may be considered small, 
but PKU is a very rare condition and we managed to capture responses from a substantial 
number of participants from an entire geographically defined area within the same health ser-
vice system. Future studies should explore differences between countries or between states 
with different health services within a country. Moreover, the sensory properties of LPSF 
were only self-reported and these need to be explored with proper organoleptic characteristic 
studies.   
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Conclusion 
 People with PKU and their carers have a positive experience, attitude and perception 
on the use of LPSF and their usefulness in the management of their condition. However, they 
seem to confront barriers to both the supply and provision of LPSF in primary health care. 
This may indicate a lack of understanding of the management of PKU in primary care or poor 
communication between specialists and primary care health professionals. Alternatively this 
may simply reflect the lack of scientific evidence demonstrating the usefulness and effective-
ness of LPSF in the management of people with PKU. This aspect should be addressed in fu-
ture studies.   
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Dietary intake and usage of low 
protein staple foods 
in children with 
phenylketonuria. 
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Justification for second study 
The first study in this thesis examined the patients and/or carers perceived benefits 
and issues with the use of LPSF. Yet there is no research evidence to demonstrate their use-
fulness in aspects of the management of PKU and their user’s health and wellbeing.  
Studies on the nutritional management of PKU have concentrated mainly on the use 
of the phenylalanine free amino acid protein substitutes (Bentovim et al. 1970; Smith et al. 
1975), their effect on growth and phenylalanine control (Acosta, Yannicelli 1994, Acosta et 
al. 2003; Gokmen-Ozel et al. 2011).  
In contrast, there are no such studies which have looked at the use of LPSF and the 
role they play in the management of PKU. Anecdotally these products are believed to play a 
substantial part and contribute to the energy requirements, food variety, quality of life and 
phenylalanine control. Although no such studies have evaluated the use of the LPSF, guide-
lines have been developed by the NSPKU society, for the amount of the LPSF needed in the 
diet of children and adults with PKU in the UK and are based on the dietary recommenda-
tions for the amount of energy that carbohydrates should provide in a diet (NSPKU-
http://www.nspku.org/publications/publication/prescription-guidelines). The NSPKU guide-
lines use units of LPSF centred on the age of the patient and aim to provide sufficient LPSF 
to supply 50% of the of the non-protein daily energy requirements (EAR). Yet it remains un-
known how much of the recommended energy the LPSF actually provide in the PKU diet. 
Anecdotally these products are believed to play a substantial part and contribute to the energy 
requirements, food variety, quality of life and phenylalanine control. 
In order to obtain robust scientific evidence of the usefulness of LPSF in aspects of 
the management of PKU, an intervention clinical trial is required whereby patients would be 
randomised, either to the use of or not of LPSF. However, as LPSF have been part of the 
standard management of PKU since the diet was first introduced in 1955 (Woolf, Griffiths & 
Moncrieff 1955) such study design would be inappropriate to perform for ethical reasons. An 
alternative approach would be to assess the current intake of LPSF using a cross-sectional 
study design and explore differences between people with different degrees of use of LPSF.  
The second chapter of this dissertation aimed to: a) look at the dietary intake of the 
LPSF and how this compares with the NSPKU recommendations; b) compare the eating pat-
terns of children with PKU with the diet consumed by the general population using the data 
from the NDNS (National Diet and Nutrition Survey (NDNS- 2008/2009) survey; c)  explore 
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whether or not patient’s use of LPSF is associated with their nutritional status, phenylalanine 
control, diet variety and quality of life.  
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Introduction 
 Phenylketonuria was identified as a disorder that could be managed by a restricted 
diet more than 50 years ago. Since then, there have been many developments in the specialist 
products to aid dietary management. It was recognised that the only way of reducing phenyl-
alanine in the diet was to remove all protein containing foods. This however, meant that pa-
tients were left with very little to eat. There was a need to replace high protein foods and this 
was achieved with a phenylalanine free protein substitute containing amino acids and micro-
nutrients in a form that patients could find palatable. The research into the palatability and 
efficacy of protein substitutes is an area that has been extensively studied over the years 
(Bentovim,A. 1970; Gokmen-Ozel, Hulya 2011;  MacDonald,A. 2006)  
 Protein free “filler” foods (LPSF) were used from the earliest days of dietary re-
striction when patients given wheat-starch biscuits (Woolf,L.I. 1955;  Armstrong,M.D. 1955). 
However, although such foods are used as “fillers”, the value they contribute to diet man-
agement has been overlooked. Although these foods are recommended for clinical use, their 
role and efficacy has always been assumed rather than proven through evidence based stud-
ies.  
 In the first study we explored how people with PKU feel about the use of LPSF. The 
foods were perceived to help with phenylalanine control to satisfy their appetite and provide 
variety in the diet  (Cochrane et al. 2014). However, similar findings have not been evaluated 
in any other studies and are a widely held belief, not just by patients and their carers, but also 
by health professionals who manage these patients.  
 The previous study also highlighted many of the issues patients and their carers face 
when trying to obtain product on prescription mainly with primary health care. As LPSF are 
only available on prescription, and incur a substantial cost to NHS, it is important to collect 
evidence to support their use and benefits in the management of PKU.  
 The variety and palatability of the LPSF has expanded greatly over the years and now 
the range encompasses foods that might also be classed as luxury or convenience foods e.g. 
energy bars, sausage mixes, cakes, crackers, crisps, and recently launched breakfast bars. The 
LPSF give patients the opportunity to produce a diet that can be varied and become similar to 
the rest of the family. Due to the relatively small numbers of patients requiring the LPSF, 
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they, unlike the expansion of gluten free foods for the management of coeliac disease into 
supermarkets, are not generally bought “over the counter”, as are gluten free products and 
must be prescribed through the patient’s G.P. Therefore this cost is added to the prescribing 
budget, and is sometimes seen as an additional burden to the workload of a busy G.P practice.  
  
Aim of the study 
The aim of this study is: 
 
To evaluate the contribution the LPSF make to the diet of children and adults with PKU and 
compare this to the NSPKU guidelines. 
In addition, the study will also 
 Compare the low phenylalanine diet with the diet of the general population. 
 Explore whether the use of LPSF is associated with nutritional status, diet variety, 
quality of life and the metabolic control of PKU 
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Material and Methods 
Eligible participants & study design 
 This was a cross-sectional study where eligible participants were adults and children 
aged between 2 – 18 years, diagnosed with PKU through the newborn screening programme. 
The patients attended the outpatient clinics at: The Royal Hospital for Sick Children in Glas-
gow, the PKU adult clinics at the Southern General Hospital and Glasgow Royal Infirmary 
and were recruited between May 2010 and August 2011. Although this is a wide range of ag-
es of patients, the management is essentially the same for all age groups. The NSPKU rec-
ommendations for the proportion of energy obtained from use of the LPSF is the same for all 
ages. Healthy controls were recruited from the general population. 
Exclusion criteria 
 Children under the age of 2 years were excluded as children below this age are in the 
process of weaning from infant formula onto solid food and are less likely to receive signifi-
cant amounts of LPSF. In addition, their carers are experimenting with the range of special 
medical foods and developing the necessary skills to use the products effectively, therefore 
the range of products used may not be representative of the usual diet for the management of 
PKU. From the age of two years, the majority of children with PKU are weaned from infant 
formula and are established on solid food. Children with hyperphenylalaninaemia who had 
phenylalanine levels monitored, but not on any dietary restriction were also excluded. Alt-
hough we intended to recruit adults with PKU and they were included in the study proposal, 
due to time constraints and an alternative study taking place at the same time in the same 
population, we decided to omit them from recruitment.  
Controls 
 Healthy children over the age of 2 years were recruited as controls. Healthy siblings 
of children with PKU were also invited to participate. Children from the general population 
were recruited by the display of posters in public areas and word of mouth. Siblings were in-
vited to participate at the same time as the affected subjects. Controls were classified into sib-
lings and other controls. 
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Recruitment 
 Eligible candidates were identified from the dietetic records of patients under the care 
of the dietetic department at the Royal Hospital for Sick Children in Glasgow and approached 
to take part. They were sent a letter of invitation to participate in the study during the 3 month 
period before their annual nutritional screen, or if aged between 2 and 4 years, before their 
subsequent clinic review.  
 The letter of invitation was sent to the parent or carer along with: a study information 
leaflet (Appendix 6), a reply slip and stamped addressed envelope. On receipt of a positive 
reply whereby the parent or carer agreed to receive further information before the appoint-
ment at PKU clinic, a copy of the Food Frequency Questionnaire (FFQ) (Appendix 5), a uni-
versal tube for urine collection and a foil bowl was posted out to their home along with in-
structions to return the FFQ and urine sample at the clinic visit.  
 A further explanation and written information on the study (Appendix 2 and 3) was 
given by the researcher at the clinic appointment, written consent (Appendix 4) was then ob-
tained and the FFQ and urine sample returned. Routine blood tests were taken from all partic-
ipants over the age of four years and an additional 4-6 ml blood taken for study purposes. 
Participants were given a copy of the 7 day food diary to take home, food scales if required 
and the PedsQL® questionnaires. A stamped addressed envelope was given to return the dia-
ries and questionnaires on completion. 
Disease Management 
 The clinical management of PKU was based on the results of phenylalanine levels 
from routine bloodspot cards posted by the participant or carer to the biochemistry laboratory 
at Yorkhill hospital. A finger-prick sample of blood is used in routine clinical practice to de-
termine phenylalanine levels once a week. The results are used by the clinical team to deter-
mine the degree of phenylalanine control. Participants were not asked to take more tests than 
those normally requested by the clinical team.  
 Analysis of the bloodspot cards was performed by tandem mass spectrometry accord-
ing to standard NHS laboratory protocols.  Participants were advised that in addition to the 
results from their nutritional screen, the five results prior to and five results post completion 
of food diary would be documented. The median of the 5 blood spots prior to the study and of 
the 5 bloodspots post study was recorded and the percentage abnormality of tests outside the 
target range for each age group were determined as proxies of PKU clinical management con-
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trol. This would give a more reliable reflection of the long-term management of the disease 
and rule out bias of improved compliance prior to the clinical appointment.  
Assessment of eating patterns and dietary intake 
 The frequency of use and type of LPSF was established using a self-administered 
semi-quantitative Food Frequency Questionnaire (FFQ) and 7-day weighed food diary. The 
food diary assessed dietary intake (energy and nutrient intake) and the contribution the LPSF 
make to the diet composition. Participants were asked to weigh and record all food and drink 
taken. The food diary is a record of all food and drinks taken over a 7 day period. Food 
weighing scales were provided by the researchers if required. The food diary was given to the 
participants at the clinic visit and participants and parents were asked to complete the diary 
on the 7 days following the clinic visit. They were given a stamped addressed envelope and 
asked to return the completed diary by post. 
 Although recording intake for 7 days placed a burden on the parent and child, it was 
considered that recording intake for the 7 days would give a more accurate reflection of the 
range of LPSF taken. Recording for less than 7 days, may overlook use of some of the cate-
gories of LPSF used less frequently. 
 Snack type foods can make a significant contribution to the energy intake of the diet 
and this was of interest to the researcher for this study. The researcher made a decision to in-
clude both low protein foods such as biscuits, cake and energy bars, in addition to regular 
foods such as crisps, sweets and sugary beverages. Some of these foods therefore also fea-
tured in the assessment of the daily protein allowance and total energy intake and the results 
would therefore reflect this inclusion. The total energy intake from snack foods was calculat-
ed as a percentage of the Estimated Average Requirements (EAR). 
 In order to determine the role that the LPSF played in the management of PKU, pa-
tients were categorised into three groups: low, medium and high users of LPSF as described 
below. The NSPKU society suggests that 50% of non-protein calories in the diet should come 
from the LPSF. This figure was used when estimating the contribution the LPSF make to the 
energy content of the diet and how close the children with PKU meet these requirements.  
(http://www.nspku.org/sites/default/files/publications/Prescription_Guidelines_Oct_2009).  
The assessment of food variety 
 The FFQ was adapted from a validated Scottish Collaborative Group Food Frequency 
Questionnaire to include the special medical foods and protein supplements regularly used by 
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children with PKU ( Tsiountsioura, M 2014). Foods were grouped into LPSF, protein substi-
tutes and then groups of foods based on the groups used in the National Diet and Nutrition 
Survey (NDNS- 2008/2009: http://www.natcen.ac.uk/media/175123/national-diet-and-
nutrition-survey-years-1-2-and-3.pdf). The NDNS is a rolling programme of surveys de-
signed to assess the diet, nutrient intake and nutritional status of the general population from 
the age of 1.5 years who live in private households in the UK and is jointly funded by the 
Department of Health (DH) in England and the UK Food Standards Agency (FSA). The 
study is carried out by a consortium of three organisations: Nat Cen Social Research (Nat 
Cen), MRC Human Nutrition Research (HNR) and the University College London Medical 
School (UCL).  
 The participant was asked to record the frequency of their intake of the foods over the 
period of a month. This allows an estimation of how often a certain type of food item is taken 
and what foods are omitted from the diet. This gives a depiction of the participant’s dietary 
habits and intake (Tsiountsioura et al. 2014).  The participants were asked to hand back the 
completed FFQ to the researchers on the day of recruitment. For the purpose of analysis, the 
LPSF from the FFQ were also categorised into “staple foods” which consisted of foods such 
as:  flour mix, pasta, bread and rice and milk substitute and also ”convenience” type foods 
which included items such as: burger mix, pasta in sauce and cakes. This was in order to gain 
an insight into the proportion of energy obtained from staple foods and convenience type 
foods in the diet of our subjects. 
Anthropometric data 
 Weight and height measurements (using electronic Seca chair scales, SECA Ham-
burg, Germany and wall mounted stadiometer, Holtain Ltd, Crymych, UK) were taken at the 
beginning of the study from controls and those with PKU and converted to z-scores based on 
the UK 1990 data. These measurements are taken regularly as part of the clinical manage-
ment of the patient during the regular out-patient review. Body composition was measured 
with the foot to foot bioelectrical impedance technique (TBF -300 Tanita, Portable Body 
composition monitor, Japan). This method may not be as sensitive as other methods, but is a 
method that can readily be used in the out-patient clinic and without placing an additional 
burden on the patient and family during the out-patient consultation (Tsiountsioura, et 
al.2014). For the healthy controls measurements took place within the joint premises of the 
Royal Hospital for Sick Children and Human Nutrition Section, University of Glasgow.  
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 BMI class was used to define the participants as: thin, normal, overweight or obese as 
defined by the following criteria (www.who.int/childgrowth/standards/bmi_for_age ): 
 BMI 1st to 4th percentile:   Thin 
 BMI 5th to 84th percentile:   Healthy Weight 
 BMI 85th to 94th percentile:   Overweight 
 BMI >95th  percentile:   Obese 
Quality of life assessment 
 Quality of life was assessed with the validated questionnaire PedsQL
®
 generic core 
scales (Paediatric Quality of life Inventory: version 4.0). On the day of recruitment the partic-
ipants and parents were given the questionnaire to complete and return along with the 7 day 
food diary by post. The PedsQL
®
 report assesses how much a problem carers and subjects 
have with different aspects of their life by scoring from 0-4 on how much of a problem the 
child experiences in four separate domains. The report is available for the following age 
groups: Parent report for toddlers (2-4 years) and Parent and Child reports for ages: 5-7; 8-12; 
13-18. One domain covered physical functioning with 8 categories from which a mean was 
taken from the total score. The psychosocial scale was taken from 3 domains which included: 
emotional functioning, social functioning and school functioning, each with 5 categories. The 
scores from these three domains were added and a mean taken and categorised into the psy-
chosocial scale. The parents or carers and child were provided with separate reports and 
asked to score each scale from: never (0) to almost always (4), with regard as to how much of 
a problem they judge that PKU impacts on themselves or their child. Written permission for 
the use of the Inventory was granted from the MAPI Research Trust. 
Micronutrient status 
 All children reviewed at the PKU clinic at Yorkhill, over the age of 4 years, have 
blood taken annually for a nutrition screen to check macro and micronutrient status. The diet 
of children under the age of 4 years is generally under the control of their carers and therefore 
they are deemed less at risk of developing nutritional deficiencies. Where there is concern 
about the nutritional status due to non-compliance, children would have a nutritional screen 
before the age of 4 years. 
 The micronutrient status of patients with PKU was assessed using objective indices in 
venous blood samples and a spot urine sample. An additional 4-8 mls was collected in addi-
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tion to the routine screening blood of 17 ml approximately. Twenty additional micronutrients 
were measured in the Trace Element and Micronutrient Reference Unit at Glasgow Royal 
Infirmary. The results were compared with in house reference intervals. Participants were 
asked for written permission to use any redundant bloods available following routine bio-
chemical and haematological analysis. This reduced the extra volume of blood required for 
research purposes. The participants were also asked to provide a spot urine sample on the day 
of recruitment.  
 Although urine and redundant bloods were collected, the data collected from them 
were not used in this MSc study due to time constraints and the amount of data already pre-
sented for the purposes of an MSc programme. However, information collected from this and 
also the results from the annual nutritional screen will be used in future studies and publica-
tions.  
Demographic information 
 Information on demographics, gender and age was collected from the patients’ dietet-
ic notes and the case recording form for the controls. Postcodes were given a score from the 
Scottish Index of Multiple Deprivation (SIMD) (2012) and socioeconomic class was ranked 
from the most deprived (score: 1) to least deprived (score 5) and allowed consistency in iden-
tifying areas of multiple deprivations.  
Classification of subject’s disease severity 
 Subjects were classified into mild, moderate and classical PKU depending on their 
tolerance to phenylalanine. This tolerance determines the level of dietary phenylalanine re-
quired to keep the plasma phenylalanine levels within the target range recommended by the 
MRC working party (1993) and are classified as: severe; 250-300mg Phenylalanine/day; 
moderate: 350 – 400mg / day and mild: 400-600mg /day (Guldberg et al. 1998). A system of 
50mg phenylalanine food exchange lists (equivalent to 1g natural protein) allows a consistent 
approach to dietary control. Each subject was then classified according to how many daily 
exchanges (mg phenylalanine) they were prescribed. 
 For the purposes of analysis, the moderate and mild disease patients were grouped 
together due to the small numbers of these patients recruited. 
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Sample size 
 The sample size for the number of subjects required for the study was computed by 
calculating a mean difference of 100 units in phenylalanine with a SD of 90 units between 
low, medium and high free protein users, with a power of 80% and an error of 5%. 17 partic-
ipants will be required for each group giving a total of 51 subjects and it was decided to aim 
to recruit 60 to account for dropouts. 
Data handling and statistical analysis 
 The estimation of Estimated Average Requirements (EAR) for energy intake and 
Recommended Nutrient Intake (RNI) for protein intake was used for determining the total 
energy intake and protein intake (Department of Health 1991). 
 Patients were grouped into low, medium or high users of LPSF by first ranking them 
on the energy from LPSF as a percentage of their EAR and then dividing into three equal 
groups. The Ksruskall Wallis test was used to determine any significance in the variables of 
interest between the groups. 
 The energy being provided by the protein substitute, regular foods and snack foods 
was similarly calculated as a percentage of EAR.  Regular foods were those foods in the diet 
that were either used as exchange food (e.g. potatoes, breakfast cereal ) or freely allowed low 
protein foods (e.g. fruits, fats and oils, preserves). The energy provided by snack foods was 
determined by calculating the energy from individual foods and which was then taken as a 
percentage of the overall energy intake. As described previously, the snack foods included 
foods such as biscuits and cake as well as sugary drinks, crisps and sweets, both regular and 
low protein. 
 Results were collated on Microsoft Excel and analysed by the Minitab 16.0 package 
(Minitab Ltd). Dietary analysis used the WinDiets 2005 dietary analysis program. WinDiets 
includes the complete UK database as published in the food tables and supplements. The 
LPSF, protein substitutes and other regional foods were added to the programme as “local 
foods”. The nutrient values for the local foods were taken from published specialist company 
information and web based manufacturer’s information. For the food diary analysis, data 
were entered into the programme and an average of 7 days intake was recorded and analysed.
 In order to obtain data on the variety of foods taken, the FFQ data was entered into the 
programme as a proportion of food intake taken over a month and expressed as intake per day 
(g). Food portion sizes were based on individual portions as sold or taken as an average por-
 66 
 
tion based on published food portion sizes (Ministry of Agriculture, Fisheries and Food 
1988).  
Ethical Approval 
 The study protocol was approved by the West of Scotland Research Ethics Service.  
REC reference number: 11/AL/0077  R&D reference: GN11DT042 and every partici-
pant and carer (when appropriate) provided written informed consent. 
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Results 
Subject Recruitment 
 Of the children with PKU in the patient cohort at Royal Hospital for Sick Children, 60 
were identified as being eligible to take part in the study. Four declined the invitation, 14 did 
not respond to the invitation and for social reasons were not approached at clinic, 40 (68%) 
patients were recruited and gave written consent to take part in the study. Of these; 23 (56%) 
were male [mean (IQR) age 7.8 (8.0) yr.] and 17 (44%) were female [mean (IQR) age 7.3 
(7.25) yr.]. Six were from three families with more than one child with PKU. Eight (20%) 
were aged between two and four years and therefore did not have blood taken for nutritional 
screen. Of the subjects, the majority 41% (n=17) attended primary school; 29% (n=12) were 
preschool and 27% (n=11) were at secondary school. 
Healthy controls 
 Of the healthy controls recruited 41 adults and children were recruited. Of these, 13 
withdrew from the study and did not complete the food diaries or FFQ. Nine adults complet-
ed the seven day food diary, but as no adults with PKU were able to be recruited, the data 
from the healthy adult controls have not been included in this MSc thesis. 
 Of the 19 healthy children, 10 were male [mean (IQR) age 8.3 (10.25) yr.]; nine fe-
male [mean (IQR) age 8.8 (6.5) yr.). Of these nine (47%) were siblings of children with PKU 
(five male). Of the control children, 32% (n=6) were pre-school; 42% (n=8) attended primary 
school and 26% (n=5) were at secondary school. 
 The information gained from the healthy controls, especially the siblings, can provide 
an insight into the differences between the diet of children with PKU and their peers. Howev-
er, as with the adults, insufficient numbers of healthy child controls, either siblings or other 
controls could be recruited to allow this comparison. Therefore, data from controls has not 
been used in this study. It is the intention to continue to recruit controls, particularly more 
siblings in order to make this comparison possible in a future study.  
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Demographics 
 Eleven (28%) of the children with PKU came from the most deprived area with a 
score of one and 12.8% (n=5) came from the least deprived area with a score of five (Table 
9). One patient had moved to England at the time of the study, therefore did not have an 
SIMD score. 
Disease severity of children with PKU 
 The children with PKU were categorised according to disease severity by the number 
of protein exchanges required to keep their phenylalanine levels within the target range for 
their age. Twenty seven (67.5%) were classed as having severe or classical PKU (2-6-
exchanges / day); 7.5% (n=3) (7-8 exchanges / day) as having moderate PKU and 25% 
(n=10) (9-13 exchanges / day) as having mild PKU (Table 9). For the purpose of analysis, the 
mild and moderate group were combined. 
Anthropometric characteristics of children with PKU  
  Twenty seven (67%) children with PKU had a BMI SDS within the normal range; 
one child (2%) was underweight; 22% (n=9) overweight and 7% (n=3) were obese (Figure 3). 
83% (n=15) of the girls and 52% (n=12) of the boys were classed as within the normal BMI 
range (Table 9).  No girls were obese, however, 18% (n=3) of the boys were obese. One boy 
was categorised as thin and 11% (n=2) girls and 30% (n=7) boys classed as overweight (Fig-
ure 3).  
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Table 9: Patient characteristics associated with gender 
Patient Characteristic      Male 
   N (%)  
 Female 
 N (%) 
   Total 
   N (%) 
SIMD score 1   6  (27.3)   5 (29.4)  11 (28.2) 
 2   7  (31.8)   1 (  5.9)    8 (20.5) 
 3   4  (18.2)   5 (29.4)    9 (23.1) 
 4   3  (13.6)   3 (17.6)    6 (15.4) 
 5   2  (  9.1)   3 (17.6)    5 (12.8) 
 
Stage of schooling Pre-school   7  (30.4)   5 (29.4)  12 (30.0) 
 Primary school 10  (43.5)   7 (41.2)  17 (42.5) 
 Secondary school   6  (26.1)   5 (29.4)  11 (27.5) 
 
Classification Classical 15  (65.2) 12 (70.6)  27 (67.5) 
 Moderate   2  (  8.7)   1 (  5.9)    3 ( 7 .5) 
 Mild   6  (26.1)   4 (23.5)  10 (25.0) 
 
BMI Thin   1  (  4.3)   0 (  0.0)    1 ( 2.5) 
 Normal 12  (52.2) 15 (88.2)  27 (67.5) 
 Overweight   7  (30.4)   2 (11.7)    9 (22.5) 
 Obese   3  (13.0)   0 (  0.0)    3 (  7.5) 
 
Figure 3: BMI distribution between male and female children with PKU 
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Results from the analysis of the 7 day weighed food records 
Patients with PKU: Analysis of 7 day weighed Food diary  
 Of the 40 subjects recruited into the study, 30 (75%) completed the seven day food 
diary which was analysed to determine the energy and protein content of the PKU diet. One 
third took more than 100% (n=10: 5 male and 5 female) and 66% (n=20: 9 female and 11 
male) had an intake less than EAR (Figure 4).   
 
Figure 4: Energy intake of children with PKU 
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As can be seen from Figure 5, there is a tendency for a decrease in energy intake (%EAR) as 
the subjects become older (Figure 5). 
 
Figure 5: Correlation between of energy intake (%EAR) with age  
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 Most of the dietary energy came from regular foods (i.e. phenylalanine exchange 
foods) and LPSF (%EAR) [LPSF vs. protein substitute vs. regular foods: median (IQR): 20 
(14.2); 14 (4.1); 49 (36.7)] (Table 10a).  
 Similarly, the majority of the protein intake was from the protein substitute: [LPSF vs. 
protein substitute vs. regular foods (% RNI): median (IQR): 3 (3.0); 137 (55.3); 41 (37.1)] 
(Table 10b). No subject received a protein intake less than 100% of the RNI for their age. 
36% (n=15) took between 100-200% RNI and 27% (n=11) consumed over 200% RNI and 
10% (n=4) consumed more than 300% RNI. The median protein intake was above the rec-
ommended intake of 12% energy from protein [median (IQR): 14.1 (3.8)] (Table 10b). 
 When the intake of energy from carbohydrate and fat were assessed, the energy from 
fat was lower than the FAO/WHO recommendations of 35% with a median intake of 18% 
[%EAR; median (IQR): 18 (46)] and the carbohydrate slightly higher [%EAR; median (IQR): 
57 (23)] (Table 10a). 
 
p = 0.079  
r = -0.325 
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Table 10a: Energy distribution from 7 day food diary analysis 
 
Dietary characteristics of subjects - % EAR* (% of total energy 
intake**) 
 
N 
 
Median 
 
 
IQR 
 
Minimum 
 
Maximum 
 Energy intake  
 
30    88   41.3     61    141 
Energy intake from LPSF foods 
 
30    20 (27.3)  14.2 (17.1)       0 (0.0)      49 (56.2) 
Energy intake from Regular  Foods  
 
30    49 (55.5)  36.7 (13.5)     15 (22.3)    110 (88.7) 
Total energy from Snack foods  30 
 
   16 (19.9)  22.0 (15.9)       3 (5.0)      52( 48.7) 
Energy intake from Protein Supplement 
  
30    14 (18.0)    4.1   (8.4)     10 (10.0)      30 (37.1) 
Total energy from CHO   30 
 
   57 (64.0)   23.0  (6.5)     34 (56.6)      91 (73.3) 
Total energy from Fat  30 
 
  18  (24.2)   12.0  (7.1)      11(15.5)      46 (33.3) 
* % EAR provided by dietary characteristics;  ** % of the energy intake provided by the dietary component 
Table 10b: Energy distribution from protein intake 
Protein intake - % RNI (% of total energy intake) N Median 
 
IQR Minimum Maximum 
Total protein intake  
 
30 198 (14.1) 104.5 (3.8) 116 (8.9) 345  (18.9) 
Total protein intake from LPSF   
 
30    3  ( 0.2)    3.0  (0.2)    0 (0.0)    8   (  0.6) 
Total protein intake from protein substitute  
 
30 137 (10.5)  55.3 (3.5)   93 (5.3) 276  (15.6) 
Total protein intake from regular foods  30   41  ( 2.7)  37.1 (1.2)   11 (1.0) 153  (  8.1) 
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Comparison of total energy intake between gender  
 No significant difference between genders was seen regarding the total energy from 
regular foods [boys vs. girls: median (IQR): 29 (30); 42 (45) (p=0.589)] and LPSF [boys vs. 
girls: median (IQR): 20 (7); 21 (27) (p=0.662)]. Energy intake from the protein substitute 
tended to differ between the genders [males vs. females: median (IQR): 13 (5); 15 (3); 
(p=0.056)] (Table 11; Figure 6) although the amount of protein substitute prescribed is de-
termined by weight, not age or gender.  
 The amount of energy provided by snack foods (i.e. foods which were both LPSF and 
regular foods such as cakes, biscuits, potato crisps and sweets) did not differ between genders 
(Table 11). When the energy from carbohydrate and fat was compared between the genders, 
no difference was found.  
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Figure 6: Comparison of dietary constituents with gender 
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Table 11: Comparison of total energy intake from macronutrients between genders (% EAR) 
Characteristic N Boys    N Girls     
 
 16 Median 
 
IQR Min Max 14 Median 
 
IQR Min max p 
 Energy intake (% EAR)  16 88 39 60 126 14 84 40 64 141 
 
0.803 
Energy intake from LPSF foods (% EAR) 
 
16 20 7 0 42 14 21 27 0 49 0.662 
Energy intake from Regular 
 Foods  (% EAR) 
 
16 29 30 29 110 14 42 45 15 99 0.589 
Energy intake from Snack 
 Foods (% EAR)  
 
16 17 21  6  45 14 14 22   3   51 0.506 
Energy intake from Protein  
Supplement (% EAR) 
 
16 13 5 10 30 14 15 3 12 25 0.056 
Energy intake from  
CHO (% EAR)  
 
16 57 23 34 85 14 55 22 38 91 0.739 
Energy intake from Fat (% EAR 
 
16 19 11 13 37 14 18 13 11 46 0.589 
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Disease severity and dietary intake 
 The subjects were also classified according to disease severity using the number of 
prescribed phenylalanine exchanges required to keep their phenylalanine levels within the 
target range. This was used to determine if there was any association between disease severi-
ty and dietary intake (Figure 7). A significant difference was found between the severity of 
PKU and the percentage energy intake from regular foods [median (IQR): classical; mild: 37 
(28); 58 (45)] (p=0.011) with the children with mild PKU receiving a greater amount of ener-
gy (% EAR) as would be expected, from the regular foods than the classical or mild subjects 
with PKU. In addition, the energy (% EAR) from the LPSF had a tendency towards, but did 
not achieve significance (p=0.062), with an intake higher from the classical PKU [median 
(IQR): classical; mild: 24 (14); 15 (17)] (Figure 7). 
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Figure 7: Energy distribution vs. disease severity 
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Age and stage of schooling on energy distribution 
 When the energy intake was compared with the stage of schooling  it was noted that, 
although not significant, the pre-schoolers tended to have a higher energy intake (%EAR) 
than either the primary school or secondary school groups [pre-school vs. primary school vs. 
secondary school: median (IQR): 111 (47); 83 (32); 88 (34)] (p=0.098) (Figure 8). 
 From the comparison of the energy intake (% EAR) from the individual constituents 
of the PKU diet, i.e. protein substitute; LPSF and regular foods (Figure 8), as was expected, 
the secondary school age group took significantly less energy than the pre-school and prima-
ry school groups from the protein substitute [pre-school vs. primary school vs. secondary 
school: median (IQR): 20 (8); 14 (3.8); 13 (1.9), p=0.007). The intake of energy (%EAR) 
from the LPSF was not significantly different between the age groups, although was slightly 
higher in the pre-school group: [pre-school vs. primary school vs. secondary school: median 
(IQR): 25.7 (27.2); 22.4 (18.6); 17.6 (6.3) (p=0.103)]. No difference between groups was 
found regarding the intake of energy from regular foods.   
 The energy (%EAR) provided by fat and snack foods was no different when the stage 
of schooling was considered (Figure 9). The intake of carbohydrate was slightly higher in the 
pre-school group [pre-school vs. primary age vs. secondary median (IQR):  71(30); 54(19); 
54 (22) (p=0.090), but did not reach significance.  
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Figure 8: Comparison of age grouping with intake of energy (%EAR) from main dietary constituents.  
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Figure 9: Comparison between age grouping and energy intake (% EAR) from CHO, fat and snack foods 
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Comparison of food intake and eating habits between the patients with PKU and the 
general population 
 The diet for children with PKU and the general population differs in that foods con-
taining phenylalanine are replaced by a protein substitute tailored to the protein requirements 
of the child. In addition there is a need to replace dietary “filler” foods and a reliance on 
foods low in protein such as fruit and vegetables. Therefore, for children with PKU there is 
control of protein intake and an emphasis on the use of LPSF, fruit and vegetables by the 
healthcare professionals managing their diet. In order to explore what difference this makes 
to the diet of children with PKU, a comparison was made to that of the general population 
using data from the NDNS survey.  
 There was a similarity in the pattern of the diet profile, but not in the absolute intake, 
of the PKU diet and the diet from general UK population (Figure 10). However, the use of 
cereals, potato products and beverages was much higher in the general population, even 
though the cereal group included LPSF for children with PKU [mean from PKU diet vs. 
mean from NDNS survey: median (IQR): 14.2 (21.65; 79.5 (221.5)]. 
 
Figure 10: Profile of the diet for PKU and the general population (age 4-18) 
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Association between dietary management and the use of LPSF 
 In order to explore whether there was any relationship between the use of LPSF and 
the management of PKU, the subjects were allocated into low, medium and high user groups 
based on their reported use of the LPSF from the analysis of the 7 day weighed food diaries 
(Table 12). 
Subject demographics and use of LPSF 
 The SIMD score was compared between the three groups LPSF user groups (Figure 
11) and there was no difference noted between the three groups [high vs. medium vs. low; 
median (IQR): 3(3); 1.5 (2.2); 3.5 (2.0)]. 
 
Figure 11: Comparison between use of LPSF and SIMD score 
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Associations between LPSF use, growth and SDS BMI 
 When the association between use of LPSF and anthropometric data was explored 
(Figure 12), a significant difference was found between the low users and high users of LPSF 
[high vs. medium vs. low: median (IQR): -0.3 (1.3); 0.4 (2.6); 0.8 (1.8); (p=0.047)] for SDS 
weight, with the low users having a higher weight SDS (Table 12) and SDS BMI [high vs. 
medium vs. low: median (IQR): 0.1 (1.0); 0.2 (2.2); 0.6 (1.2); (p=0.036)] than the high user 
group. There was no significant difference for height SDS between the three groups 
(p=0.072). 
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Figure 12: Comparison between use of LPSF and anthropometric data 
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Severity of  PKU and use of LPSF  
 Disease severity in our patient group was expressed using the number of prescribed 
phenylalanine exchanges required to keep the plasma phenylalanine levels within the recom-
mended target range (120-360 umol/l – 0-5 years; 120-480 umol/l; 5-10 years; 120-700 
umol/l; >11 years). When the difference in the number of prescribed exchanges was explored 
(Table 12) between the three groups, the high users of the LPSF tended to be prescribed few-
er phenylalanine exchanges than the low users who were prescribed the greatest number of 
exchanges [median (IQR) high vs. medium vs. low: 4 (6); 5 (3.2) 9 (4.7) (p=0.056)]. 
Metabolic control between the LPSF user groups 
 Clinical control of the patient’s phenylalanine levels in our group of subjects was   
determined by comparing the median of 5 phenylalanine prior to and post completion of the 
seven day food diary (Table 12). No significant differences between the three user groups 
were observed. In addition, the percentage of raised phenylalanine results was compared be-
tween the three user groups of LPSF, both before and after the diaries were completed (Table 
12), again no significant differences were found between each of the groups,                     
[prior to food diary completion/post food diary completion (p=0.347/p=0.630)].
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Table 12: Association between anthropometry, disease control and use of LPSF 
Food Diary 
Characteristic 
N High 
users 
   N Medium 
users 
   N Low  
users 
    
Boys/girls 11 
4/7 
Median IQR Min max 10 
8/2 
Median IQR Min max 9 
4/5 
Median IQR Min max p 
Age, years 
 
11 4.9 3.2 2.7 9.2 10 9.3 8.7 1.7 17.6 9 7.7 7.3 2.5 13.8 0.131 
Scottish Deprivation  
score   
11 
 
3.0 3.0 1.0 5.0 10 1.5 2.2 1.0 5.0 8 
 
3.5 2.0 1.0 5.0 0.106 
SDS weight (SD) 
 
11 -0.3† 1.3 -1.8 1.5 10 0.4 2.6 -2.2 2.6 9 0.8 1.8 -0.2 3.0 0.047 
SDS Height (SD) 
 
11 -0.4 0.6 -2.8 0.6 10 1.2 1.7 -1.3 3.7 9 0.4 2.2 -1.1 4.5 0.072 
SDS BMI (SD) 
 
11 0.1† 1.0 -1.2 1.7 10 0.2† 2.2 -3.2 2.3 9 0.6 1.2 0.2 2.3 0.036 
Prescribed no. of pro-
tein exchanges 
(g protein/24 hr.)‡ 
11 4.0† 6.0 2.0 13.0 10 5.0 
 
3.2 3.0 9.0 9 9.0 4.7 5.0 11.0 0.056 
Median plasma Phe, 
umol/l;  pre 7 day food 
diary  
11 234 130 111 481 10 253 212 119 842 9 208 169 146 584 0.909 
Median plasma Phe 
umol/l;  post 7 day food 
diary 
11 257 136 166 750 10 417 350 87 648 8 263 102 190 392 0.546 
% raised  plasma Phe 
umol/l;* pre 7 day food 
diary 
11 0 
 
0 0 80 10 0 25 0 60 9 0 0 0 20 0.347 
% raised plasma Phe* 
 umol/l post 7 day  
food diary 
11 0 40 0 80 10 30 40 0 80 8 0 35 0 60 0.630 
*target range for Phenylalanine levels: 120-360 umol/l – 0-5 years; 120-480 umol/l; 5-10 years; 120-700 umol/l; >11 years:   
‡- based on phenylalanine tolerance: †  Significantly different from low users LPSF:  
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Energy intake and distribution between LPSF user groups 
 There was no difference in energy intake (% of EAR) between the three LPSF user 
groups (Figure 13), although the low users of LPSF tended to have the highest energy intake, 
but this did not reach significance [median (IQR):  high vs. medium vs. low: 88% (44); 80% 
(26); 106% (35) (p=0.076)] (Table 13). 
 There was no difference in the energy intake (% EAR) from protein substitutes be-
tween the groups (p=0.306) (Table 13). However, when the energy intake (% EAR) from 
regular foods was compared, there was a significant difference between the three groups with 
the high and medium users having a lower energy intake (%EAR) than the low users [high 
vs. medium vs. low: median (IQR): (37% (34.6); 40% (24.5); 71% (51.3) (p=0.012)] (Figure 
14). 
 
Figure 13: Total energy intake between users of LPSF 
LowMediumHigh
150
140
130
120
110
100
90
80
70
60
T
o
ta
l 
e
n
e
rg
y
 i
n
ta
k
e
 (
%
 E
A
R
)
 88 
 
Figure 14: LPSF user groups and energy distribution from diet constituents 
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p=0.012 
 89 
 
  
 When the users of the LPSF were compared for intake of energy (%EAR) from car-
bohydrate, a tendency towards the low user group taking more energy from carbohydrate than 
the medium and high users was noted (Table 13) [high vs. medium vs. low: median (IQR): 
59% (33); 52% (17.6); 66% (21.7)] (p=0.064).  No variation was found in the energy 
(%EAR) from fat (p=0.773) between the three groups (Figure 15),  
 The energy (%EAR) from the snack foods which included both LPSF and regular 
foods was then compared between the three user groups (Table 13) and the low users of 
LPSF had a significantly higher intake from these foods compared to high and medium LPSF 
users [high vs. medium vs. low: median (IQR): 12% (11); 14% (13); 36% (26) (p=0.010)] 
(Figure 15). 
 90 
 
Figure 15: Use of LPSF and energy distribution from CHO, fat and snack foods 
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Dietary protein and phenylalanine intake and use of LPSF  
 Low users of LPSF had a significantly higher total protein intake (%RNI) than medi-
um users (p=0.036).  Low users of LPSF also had a significantly higher intake of protein (% 
RNI) from regular foods [high vs. medium vs. low: median (IQR): 41.4 (28.0); 31.6 (17.7); 
62.4 (54.2); (p=0.033)] compared with both the high and medium users of LPSF (Table13). 
 No significant difference was seen in the phenylalanine intake (mg Phe) from regular 
foods between the three groups, although low users of LPSF tended to have a higher median 
intake than the other two user groups [high vs. medium vs. low (mg Phe): median (IQR): 524 
(286); 483(202; 860 (1226)] p=0.081)] (Table 13).  
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Table 13: Dietary intake and association with use of LPSF 
Characteristic N High 
users 
   N Medium 
users 
   N Low 
users 
    
Food diary 
Boys/girls 
11 
4/7 
Median IQR Min max  10 
8/2 
Median IQR Min max  9 
4/5 
Median IQR Min max p 
Energy intake (% EAR)  11 87.9 44.2 64.6 141.
3 
10 79.7 26.0 60.6 111.7 9 105.8 34.6 68.2 125.8 0.076 
 
Energy intake from  LPSF  
foods (%/EAR)  
11 33.3 19.0 24.1 49.3 10 19.1 5.8 17.6 24.0 9 11.4 11.6 0.0 16.8 0.000 
Energy intake from  Regular  
Foods (% EAR) 
11 37.1* 34.6 15.1 80.6 10 39.8* 24.5 29.4 66.5 9 71.4 
*** 
51.3 39.0 110.5 0.012 
Energy intake from Protein  
substitute (% EAR) 
11 14.6 4.3 12.0 20.0 10 12.0 6.2 9.8 30.0 9 14.0 7.5 12.6 25.0 0.306 
Energy intake 
from CHO (% EAR)  
11 59.2 33.1 44.0 90.7 10 52.1 17.6 34.3 68.0 9 66.0 21.7 46.1 84.7 0.064 
Energy intake from 
Fat (% EAR)  
11 19.5 14.4 10.7 45.7 10 17.0 9.2 14.3 30.1 9 25.0 16.4 12.6 37.0 0.773 
Energy intake from snack 
foods (%/EAR)  
11 12.0 11.3 3.5 32.5 10 14.6 13.1 6.0 31.4 9 35.8 26.0 9.4 51.5 0.010 
Protein intake (% RNI) 11 201.5 87.7 133.
6 
273.
8 
10 142.3* 78.5 116.
3 
338.0 9 234.5* 130.
0 
146.
3 
345.0 0.036 
 
Protein intake from LPSF 
 (%RNI) 
11 3.4 1.5 1.6 8.2 10 3.2 4.0 1.1 6.9 9 2.4 3.2 0.0 6.7 0.107 
 
Protein intake from Protein   
Substitute  (% RNI) 
11 145.2 34.3 101.
4 
197.
2 
10 111.1 56.3 93.2 244.6 9 159.6 93.1 115.
8 
276.0 0.108 
Protein intake from Regular 
 Foods (% RNI) 
11 41.4 28.0 10.7 83.8 10 31.6§ 17.7 15.2 98.4 9 62.4** 54.2 19.0 153.4 0.033 
 
Phenylalanine intake  from  
Regular Foods  (mg Phe) 
11 524 286 151 826 10 483 202 322 714 9 860 1226 400 2171 0.081 
 
*Significantly different from low users LPSF:   **significantly different from medium and low users LPSF; ***significantly different from medi-
um and high users LPSF 
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Effect of LPSF use and disease severity on quality of life 
 The association between quality of life and use of LPSF was compared using the Ped-
sQL
®
 questionnaire to determine if there was any relationship between the amount of LPSF 
used and physical or psychosocial functioning (Table 14). Both for the parent and child re-
ports, no association could be found between the LPSF user groups and total quality of life 
score [high vs. medium vs. low users: median (IQR): parents: 80 (26); 92 (9); 87 
(20);(p=0.493)] and children with PKU: [89(25); 91 (4); 89 (17); (p=0.691)] (Table 14). 
When the total score for parent and child response was averaged, again there were no compa-
rable differences between the groups of LPSF users [high vs. medium vs. low: median (IQR): 
8 (15); 7 (9); 7.0 (12): (p=0.987) (Table 14). 
 In addition to the use of LPSF on quality of life, a comparison was also made between 
quality of life and disease severity, no association was found for either parents or subjects for 
the physical or psychosocial functioning between classical, moderate or mild disease. 
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Table 14: Association between quality of life and use of LPSF 
Characteristic 
 
N High 
users 
   N Medium 
users 
   N Low 
users 
    
Food Diary 
Boys/girls 
11 
4/7 
Median IQR Min max 9 
7/2 
Median IQR Min max 9 
5/4 
Median IQR Min max p 
Parent report – physical 
functioning* 
 
11 84 34 50 100 9 97 14 65 100 9 94 9 72 100 0.519 
Parent report – psychoso-
cial functioning** 
 
11 78 22 50 100 9 88 11 35 100 9 83 24 35 96 0.494 
Total parent report** 11 80 
 
26 52 100 9 92 9 45 100 9 87 20 53 98 0.493 
Boys / girls 5 
2/3 
    6/2     3/4      
Child report – physical 
functioning* 
 
5 90 21 66 96 8 96 8 79 100 7 94 13 78 100 0.351 
Child report – psychoso-
cial functioning** 
 
5 70 28 62 98 8 89 10 59 100 7 83 20 50 95 0.590 
Total child report*** 5 
 
89 25 68 97 8 91 4 66 99 7 89 17 63 95 0.691 
‡: Peds QL® – Paediatric quality of Life Inventory – version 4.0 
*mean of score for all items in problems with physical health summary score; ** mean of score for all items in the domains:  problems with 
emotional functioning, social functioning, and school functioning; ***total score for mean of all items for physical and psychosocial domains. 
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Diet variety and use of LPSF 
 The information obtained from the FFQ was mainly used as a means to explore differ-
ences in the number of items of LPSF and regular foods used by the subjects (Table 15) which 
provides an indication of the variety of food use between the three groups. A significantly 
greater proportion of LPSF items were taken by the high than low users of LPSF [(% of total 
LPSF items) high vs. medium vs. low: median (IQR): 44% (14.4); 40% (8.6); 27% (38.4) 
(p=0.048)].  However, when the number of regular foods was assessed, the percentage num-
ber of regular food items selected by the three groups was very similar and not significant 
(p=0.839) (Table 15).  
  
Comparison of use of LPSF and the general population 
 When the patients with PKU were split into LPSF user groups and compared with the 
children from the NDNS survey (Figure 16). All users of LPSF showed a similar trend with the 
eating habits of the NDNS group. Although the low users followed a similar trend to the high 
and medium users, their intake (g/day) had a greater discrepancy for cereals and potato prod-
ucts by being lower than the other two groups [high vs. medium vs. low; median (IQR): 16.5 
(19.9); 18.3 (25.3); 7.8 (19.9); p=0.000]. 
 The LPSF were then allocated into the daily weight (g/day) of intake of the “staple 
foods” e.g. bread, pasta and milk and “convenience” type foods e.g. pasta in sauce, burger mix 
and ready-made cakes and reassessed. The low users of the LPSF were shown to have a signif-
icantly lower intake of the staple LPSF (g / day) [high vs. medium vs. low: median (IQR): 
49.5(32.9); 40.9 (17.9); 11.2 (36.3)] (p=0.015) and also had a significantly lower intake (g/day) 
of the “convenience” type LPSF than the high or medium user groups [high vs. medium vs. 
low: median (IQR): 3.7 (5.6); 3.4(4.4); 1.8 (2.4) (p=0.074)] (Table 16). 
 Similarly, when the LPSF cereal foods and regular cereal foods were combined and re-
allocated into the same groups as defined in the NDNS (Table 16), along with the remainder of 
the LPSF which were allocated into the appropriate food groups; such as low protein milk into 
the dairy group and then re-analysed, the high user group consumed significantly more grams 
of cereals products, both LPSF and regular foods, than the low user group, with the medium 
users being comparable to the high user group [high vs. medium vs. low: median (IQR): 10.2 
(18.7); 8.9 (12.2); 4.5 (5.) (p=0.030)]. 
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Figure 16: Comparison of users of LPSF and the general population (age 4-18) 
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Table 15: FFQ analysis and users of LPSF  
Characteristic N High 
users 
   N Medium 
users 
   N Low 
users 
    
FFQ 
Boys / Girls 
12 
6/6 
Median IQR Min max 10 
6/4 
Median IQR Min max  9 
6/3 
Median IQR Min Max P 
Energy intake (%EAR)  12 130 45 107 184 10   98 20 62 136 9 71 19 40 108 0.000 
Energy intake from  LPSF 
(%EAR) 
12   47 15 39 87 10   28      6 24 34 9 18 18 0 22 0.000 
Energy intake from RF 
(% EAR) 
12  68 38 36 96 10   54 26 26 90 9 37 33 26 69 0.039 
Energy intake from P/S 
(%EAR) 
12  15 6 11 25 10   15 6 4 25 9 14 6 12 20 0.915 
Energy intake from CHO 
(%EAR) 
12  95 22 71 148 10  64 18 43 100 9 49 12 21 71 0.000 
Energy intake from Fat  
(%EAR) 
12  26 9 17 42 10  18 6 7 25 9 12     7 6 22 0.000 
 Total Protein intake 
 (% RNI) 
12 233 64 164 411 10 181 121 74 337 9 201 103 123 293 0.274 
 
 Protein from LP (%RNI) 12  10 4    5 15 10    3 4 2 12 9 3 5 0 7 
 
0.001 
 Protein intake from P/S 
(% RNI) 
12 152 11 106 276 10 142 84 36 276 9 141 46 109 203 0.573 
 Protein from RF (% RNI) 12  69 47 26 123 10   40 27 24 97 9 47 92 13 139 
 
0.123 
Total food items from 
LPSF foods (%)* 
12  44 14 31 61 10   40 8 31 50 9 27 38 0 55 0.048 
Total food items from RF 
(%)** 
12  42 15 7 57 10   38 12 8 49 9 44 22 26 62 0.839 
Total food items (%)*** 12  42 11 14 55 10   38 12 14 48 9 38 14 25 54 0.890 
 
* %Total number of Low protein food items(n = 23); ** %total number of regular foods(n = 109); ***%LPSF + regular foods (n=132) 
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Table 16: Daily intake of foods (g) from food groups between LPSF users  
Characteristic*  High 
users 
    Medium 
users 
    Low 
users 
    
FFQ N =  Median 
Mean 
IQR Min max N =  Median 
Mean 
IQR Min max N =  Median 
Mean 
IQR Min Max P 
LPSF – staple foods -  12 49 
55 
33 32 85 9 41 
47 
18 10 126 8 11 
22 
36 0 81 0.015 
LPSF – “convenience 
foods”  
12 4 
6 
5 1 24 9 3 
4 
4 1 12 8 2 
1 
2 0 3 0.074 
FFQ -  Daily combined food groups (g of food) 
Cereals (Combined 
natural cereals and 
LPSF cereal food) 
12 10 
15 
19 6 38 9 9 
13 
12 5 42 8 4 
6 
6 2 10 0.030 
Dairy 12 24 
25 
13 13 36 9 18 
20 
17 3 50 8 6 
14 
19 1 54 0.079 
Fat spreads 12 5 
6 
8 0 15 9 5 
4 
3 0 10 8 4 
3 
5 0 10 0.708 
Potato products 12 8 
24 
7 1 204 9 8 
28 
7 1 205 8 6 
8 
6 3 16 0.669 
Miscellaneous 12 23 
23 
32 6 47 9 17 
19 
24 6 43 8 18 
15 
17 0 35 0.353 
Vegetables  12 10 
8 
8 2 14 9 5 
8 
8 1 19 8 6 
7 
12 0 14 0.373 
Fruit 12 25 
29 
21 0 91 9 40 
40 
30 0 101 8 15 
35 
57 1 141 0.995 
Beverages 12 65 
69 
38 37 152 9 38 
50 
43 15 122 8 45 
54 
64 19 103 0.249 
Sugar/preserves 12 7 
7 
7 0 20 9 3 
4 
5 0 13 8 4 
5 
4 3 9 0.116 
Savoury snacks / 
crisps 
12 4 
6 
9 0 12 9 4 
5 
10 0 12 8 3 
6 
11 0 14 0.949 
Meat / fish 12 0 
0 
0 0 0 9 0 
0 
0 0 0 8 1 
1 
1 0 1 0.122 
* food groups as defined by National Diet and Nutrition Survey (NDNS) 
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Discussion 
 Within the dietary management of PKU, the area least studied is the use of LPSF. 
These foods have been anecdotally associated with providing diet variety, being used as “fill-
er” foods to satisfy the appetite and also deemed necessary for providing sufficient energy. 
This second study attempted to evaluate the intake of children following a low phenylalanine 
diet to characterise the diet of people with PKU and explore associations with the use of 
LPSF.  
Patient characteristics 
Association between gender, SIMD and BMI 
 Of the children with PKU in the study, 68% were of normal weight whereas 28.7% 
were overweight or obese. This was only slightly less than the Scottish figure of 29.9% 
(Gray, Leyland 2011), but as the size of our sample population was small, it would suggest 
that children with PKU have a similar risk in becoming overweight as the general population.  
In the 2011 report by Gray and colleagues, boys from the households with lower income were 
more likely to be classed as obese, whereas with our study boys who were overweight or 
obese came from households with a higher income (groups 3-5).  
 It might be argued that children with PKU should be more likely to have a normal 
BMI than their peers without PKU, due to the scrutiny their diet comes under and the regular 
anthropometric monitoring at PKU clinic. They and their families also have the opportunity 
for a consistent healthy eating message from a specialised group of health care professionals. 
It may be that health professionals who manage children with PKU give priority to the man-
agement of the disease during the short time allowed during clinic consultations rather than 
other aspects of overall health and well-being which may be given a lower priority in the day 
to day support given to families. Health professionals may also be reluctant to broach the sub-
ject of yet more restrictions on dietary intake, given that the children are already following a 
restrictive and potentially socially isolating diet.   
In addition, no data was collected on activity levels or sedentary behaviours as part of 
this study and would be a useful area to study. In turn, this may well give more information 
on why children with PKU follow similar trends to the general population with rates of over-
weight and obesity and is a question which warrants further investigation. 
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Overall energy and protein intake of the subjects 
Energy intake 
 From the diary analysis, it was noted that only one quarter of the subjects took more 
than 100% of their EAR for energy. A higher proportion of children having less than 100% 
EAR came from the primary and secondary age groups. These results may be a consequence 
of under-reporting by the subjects. It is known that food diaries are not an accurate way to 
record intake as subjects will either alter what they eat or omit to record all they ingest   
(Rennie, Coward & Jebb 2007, Trabulsi, Schoeller 2001, Klesges, Eck & Ray 1995).  
 The diaries of the pre-school children in our study were more likely to be completed 
by a parent or carer e.g. nursery teacher and therefore may be a more accurate recording of 
intake. In order to obtain greater accuracy of results in future studies, a checklist of foods tak-
en over the week, such as the list in the FFQ, could be compared with the foods recorded in 
the diary for the same recording period.  
Our subjects were asked to record their intake for 7 days and this may have increased 
the daily burden on both subject and carer and perhaps account for the difference between the 
age groups. Older children with PKU may not wish to acknowledge when they are deviating 
from their dietary prescription. In addition, anecdotal reports suggest that parents and carers 
of older children are less likely to weigh all their exchange foods as they learn to judge por-
tion size and may affect the accuracy of the food diaries (MacDonald, A 2008). Gokmen-
Ozel (Gokmen-Ozel et al. 2012) demonstrated that even when weighing exchanges, inaccura-
cies were noted, therefore leading to an under or overestimate of intake, particularly the calo-
ries consumed. However, it appears that the calculated daily energy intake of our participants 
was within their age recommendations.  
 The energy obtained from the use of the protein substitute was higher in the females 
in the study group and also the pre-school age group. The greater amount of energy provided 
by the protein substitute for the younger children would be expected as the amount of protein 
substitute (g/kg) is calculated based on age, with the younger children both males and female 
patients, being given a greater amount of protein per kg than older children to account for a 
more rapid growth rate (Anonymous1993).  
 In a regular diet, the percentage energy intake from protein, fat and carbohydrate is 
based on the FAO/WHO recommendations, with fat providing an average of 35% of the en-
ergy; protein 15% and carbohydrate 50% http://www.sacn.gov.uk/pdfs/sacn_02_26.pdf. Rec-
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ommendations for the Scottish population are similar with a maximum of 35% energy from 
fat (http:// www.scotland.gov.uk/Publications/ 2005/01/20577/50672).  
 The findings from the analysis of the 7 day weighed food diaries, indicated that alt-
hough the diet for PKU had similar energy intake from protein to that recommended for the 
general population, of 12-14.6% of EAR (88.5% of the recommended energy intake from 
protein) with the majority of energy from protein coming, as expected, from the protein sub-
stitute, however, the fat intake was much lower at 17-25% of EAR (60% of recommended 
energy intake from fat). This may be because many of the foods having a higher fat content 
are restricted in the diet or avoided completely e.g. cheese, meats, although there is no re-
striction on spreading fats and oils. Those foods commonly providing a lot of fat in the diet of 
many children are either severely restricted e.g. chips, potato shapes and crisps, or avoided 
completely such as chocolate and replaced by lower fat alternatives such as chewy sweets. 
When Thiele and colleagues (Thiele, AG 2012) studied the dietary intake of children before a 
trial of the co-factor tetrahydrobiopterin (BH4), they noted similar results with the fat intake 
(81 ± 25% below the recommendations), found that the carbohydrate intake was lower than 
the recommendations at 93 ± 22% with 11% of the total food consumption being provided by 
sweets and snacks. 
In addition, it is not as easy to eat out or consume takeaways with a high fat content 
such as fish and chips or burgers and chips or curries, as these meals also contain high 
amounts of protein, this may also affect the fat intake as there are no suitable low phenylala-
nine alternatives. There was no difference noted in energy intake from fat between genders, 
which is also reflected in the fat intake in the general population (NDNS survey) where girls 
had a median energy intake from fat of 34% and boys 33%.   
 The intake of carbohydrate was greater than the recommendations at 52-66% of EAR 
(118% of recommended energy intake from carbohydrate). This can be explained by the en-
ergy coming from fat contributing less to the total energy intake and the energy from protein 
being the same as that recommended.  
Based on the results of the FFQ (Table 16), it is likely that the majority of the carbo-
hydrate intake was from the LPSF staple foods and fruit. However, as it was not possible to 
get a complete breakdown of the sugar and starch content of the diet of the subjects, it is dif-
ficult to say how much the carbohydrate content of any sugary beverages e.g. fizzy drinks or 
foods in the miscellaneous section, which would include sweets, contributed to the daily in-
take of carbohydrate. In addition, from the analysis of the FFQ, no particular food group was 
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taken more by low users of the LPSF than the other two groups. This might indicate that us-
ing the FFQ is not a good reflection of intake, or that the completion requires more guidance 
from the metabolic dietitian to the parent or carer in how to record daily intake. 
LPSF such as bread, pasta and rice have comparable calorie content to their regular 
equivalents (Table 5), therefore energy intake from carbohydrate between the subject group 
and general population should be comparable. When the age groups were compared, the 
highest intake of carbohydrate was from the pre-school group with this group a higher intake 
of LPSF (%EAR) (Figure 8).  With this age group, the parents or carers may be more likely to 
use the LPSF as they are still in the early stages of learning about the diet and may be more 
experimental with the LPSF. When the children get older and are more conscious of the dif-
ferences between their diet and that of their peers, children with PKU are less likely to adhere 
to their dietary restrictions which include use of the LPSF (MacDonald et al. 2012; MacDon-
ald et al. 2010, Walter, White 2004) . 
As expected, the patients who had a milder form of PKU had a higher intake of ener-
gy from regular foods (including the phenylalanine exchange foods), than in the classical and 
moderately affected groups in part because low users were prescribed a greater number of 
phenylalanine exchanges.  Also this increased energy intake from carbohydrate containing 
foods, but particularly not LPSF, or fat and protein in this group, may help to explain the in-
crease in overweight and obesity in the PKU population.  
If the study is repeated in the adult PKU population assessing the intake of LPSF and 
rate of obesity and overweight, it would be interesting to see if it is a low intake of LPSF ra-
ther than disease severity that was more prevalent in the overweight group. Adherence to diet 
starts to deteriorate during adolescence (Sharman, Mulgrew & Katsikitis 2013) and therefore 
adults are less likely to be on strict diet and adhere to prescribed exchanges than the paediat-
ric population, therefore an association between use of LPSF and obesity would be relevant. 
 These results illustrate that the overall distribution of energy from macronutrients in 
the patient population studied are noticeably different from that recommended for the general 
population, due to restrictions placed on the patient’s dietary intake. In the PKU diet, the pro-
tein intake especially, is carefully tailored to the requirements of the child and carefully 
monitored and calculated providing between 3g / kg for very young children up to 1g / kg for 
the older children. This is less than that normally consumed by the general population 
(NDNS survey). 
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 When the subjects were allocated into a group dependant on their use of the 
LPSF, the patients with severe or classical PKU consumed a greater amount of energy from 
the LPSF than either of the other two groups. Patients with classical PKU have a lower toler-
ance to phenylalanine and therefore are unable to cope with natural dietary protein i.e. have 
fewer prescribed exchanges. Therefore in order to satisfy the appetite they would be encour-
aged fill up with low protein foods which include the LPSF. However, in the milder forms of 
PKU, patients are given more freedom of choice as where to obtain their daily phenylalanine 
intake and it is seen that use of the LPSF decreases. 
Furthermore, when the energy intake from units of LPSF as recommended by the 
NSPKU was compared with the energy intake supplied by the LPSF from analysis of the 
food diaries, the low users of LPSF barely achieved one third of the non-protein energy ad-
vised. Even among the high users of the LPSF, the maximum intake of 49% was the highest 
achieved. The NSPKU recommendations do not distinguish between or give alternative sug-
gestions for patients with different disease severity, merely give broad recommendations for 
all patients following the PKU diet. This generic approach may not be appropriate and war-
rants further consideration. 
 Sufficient energy is needed to allow adequate growth, weight gain and prevent ca-
tabolism and a deficit will cause phenylalanine levels to rise, weight gain to falter and growth 
to be poor. There was no significant difference between the groups for height which would 
indicate that all subjects did achieve an adequate overall energy intake. However those who 
were low users of the LPSF had a greater SDS BMI and SDS weight therefore consuming 
calories in excess of their requirements. 
 While the phenylalanine levels in all groups, both before and after the 7 day food dia-
ry records, were not significantly different and within the target levels required by the meta-
bolic team, this would suggest that low users of LPSF did not take excessive amounts of ex-
change foods which contributed towards their energy intake, i.e. they were not choosing high 
protein foods to satisfy the appetite; rather they were relying on low protein, high carbohy-
drate foods., In addition, although the low users of LPSF had a slightly higher energy intake 
from carbohydrate than both the medium and high user groups, this did not come from LPSF, 
but from snack type foods. The snack foods included some use of LPSF snack foods such as 
low protein cakes, biscuits and energy bars and also included regular cakes, biscuits, crisps, 
fizzy drinks and sweets. Therefore, the low user LPSF group tended to use more foods which 
had a low nutrient value, commonly referred to as “junk foods”.   
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The range of mutations that result in raised phenylalanine levels requiring phenylala-
nine intake to be restricted and monitored are considerable and some patients will not have 
any need for the LPSF at all. In order to clarify the level of restriction most benefitting from 
use of LPSF, and control of BMI, future repeat studies should perhaps band patients into a 
broader range of groups using degrees of prescribed phenylalanine restriction. This would 
help to determine the severity of hyperphenylalaninaemia most likely to lead to obesity and 
overweight. 
It was not possible in this study to differentiate between carbohydrate from starch or 
sugar because of lack of information for the LPSF from specialist food companies, but in fu-
ture studies, if this information was available, it would help to demonstrate if the increase in 
overweight and obesity in the low user groups was due to excessive intake of sugary foods 
such as sweets and fizzy drinks. 
 The high users of LPSF were shown to have a lower energy intake from regular foods 
(Table 11) which also included foods used as phenylalanine exchanges such as potatoes and 
breakfast cereals. The high users of LPSF also took fewer portions of fruit, but similar 
amounts of vegetables than the other two groups (Table 16). Although foods allowed without 
restriction in the diet for PKU include fruit and vegetables and Rohde et al (2012) demon-
strated that unrestricted intake of fruit and vegetables with phenylalanine content less than 
75mg/100g did not affect blood phenylalanine levels, it would be expected that the higher 
users of LPSF would take more of these unrestricted foods. However, there was no signifi-
cant difference in number of portions of these foods between the LPSF user groups, suggest-
ing that the low users did not use more fruit and vegetables instead of the LPSF to help satis-
fy the appetite.  
When compared to the general population (Figures 10 and 16), although the children 
with PKU had a similar trend in their food consumption, they took fewer portions of unre-
stricted foods. It was not clear why patients with PKU do not consume a greater amount of 
these foods along with the LPSF to provide diet variety or to satisfy the appetite. It may be 
that the family do not use a wide variety of fruit and vegetables or that there is difficulty in 
access to a supply of fresh fruit and vegetables. One of the aims of the study was to compare 
the diet of children with PKU to the diet of their siblings and the healthy unrelated controls. If 
this had been achieved, it might have given some insight into the eating habits of a family 
where there is a child with PKU and allowed comparison with the general population.  
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Protein intake 
 Effective dietary management of PKU also relies on an adequate intake of protein 
from phenylalanine free amino acids and an appropriate intake of phenylalanine from regular 
foods according to tolerance. Insufficient protein and energy will result in the breakdown of 
body tissue releasing phenylalanine and consequently raising the blood phenylalanine levels 
also leading to growth impairment (Rocha et al. 2013). Early recommendations (Cockburn 
and Clark 1993) for protein suggested that children should receive the RNI for protein with 
an additional 50% added, due to the diet’s artificial nature, which would take bioavailability 
into account. MacDonald et al in 2011, however, suggested a figure of the RNI with an addi-
tional 20% protein added would be adequate and this is similar to the recommendations from 
the USA and Holland. 
 The protein substitute is the main source of protein in the form of amino acids in the 
low phenylalanine diet and the results from the study (Table 13) show that all subjects 
achieved an adequate intake of protein when compared to the RNI with a median protein in-
take of 142-234%. When the intake of protein was considered, around 10% of the subjects 
took greater than 300% of the RNI and no subject took less than 100% RNI.  Our results also 
show that the younger patients are more likely to consume more protein / kg than older chil-
dren as the recommendation for total protein intake is greater for younger patients (Anony-
mous1993). This would suggest that the guidelines from these early studies are still providing 
our patients with an adequate protein intake which can also be confirmed by all patients 
growing satisfactorily.  
The MRC guidelines have not been updated since 1993, however the evidence has 
been reviewed from studies published over the past decades and new guidelines for patients 
in the UK will be published in late 2014. This is in addition to the findings of the scientific 
review published in 2012 which looked at evidence for management of PKU and gave rec-
ommendations for future research (Camp et al. 2012). 
 The impact that phenylalanine from regular foods have in the overall protein intake 
obtained from the food diaries, show that although the intake of regular foods was greater in 
the low users, there was no effect on overall phenylalanine control  as this was also the group 
that had milder type of PKU. Therefore as the low users had a greater number of exchanges 
and no significant difference in maintaining their target phenylalanine levels, because they 
had mild PKU, this increased intake of protein from regular foods would suggest that low 
LPSF users made food choices within their dietary recommendations by selecting foods of a 
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lower phenylalanine content to use as “filler foods”. As the low users did not use the LPSF as 
dietary “fillers”, it may be suggested that as they were prescribed more exchanges, they did 
not perceive the same requirement for using the LPSF. 
Influence of food choice and PKU diet 
 Parents or carers exert most influence over food choices in children before they reach 
teenage years and can therefore restrict a particular food group such as snacks, if wanted. 
However, as children gain more independence and start to make their own food choices, es-
pecially as they reach secondary school, parental influence is less effective. It is also at this 
age that phenylalanine control starts to deteriorate and adherence to diet becomes an issue 
(MacDonald et al. 2010, Walter, White 2004). From the results of the study, it was noted that 
although gender did not affect the intake of energy from snacks, the age of the child had most 
effect, with the secondary school age obtaining more energy from snack foods than those of 
primary or pre-school age (Figure 9). However, it was notable that it was not LPSF snack 
type foods which these children gained most energy, but from regular low phenylalanine 
foods (Figure 8).  
Adherence to diet is a problem not unique to PKU (Borus, J.S. 2010; Bregnballe,V. 
2011;  Fredericks,E.M. 2010). Young people with diabetes and cystic fibrosis also have diffi-
culty adhering to their treatment regime. So it is not unusual for young people with PKU to 
want to avoid taking the LPSF which look and taste different to their regular counterparts. 
Although the survey of adults and carers in Scotland  (Cochrane et al. 2014) showed that taste 
and appearance of the LPSF was acceptable, teenagers have a need to fit in with their peers 
and using the LPSF out-with the home can make them feel different and therefore they will 
tend to use low phenylalanine foods to fill them up rather than using the LPSF.  
The analysis of the food diaries showed that it was not use of high protein foods such 
as cheese, meat, ordinary bread or pasta by the teenagers (the pre and post blood spot results 
bear this out), that they were using to satisfy their appetite rather it was low phenylalanine 
snack foods.  However the number of teenagers completing the food diaries was low, which 
means drawing any conclusion is difficult. When requested, the teenagers willingly consented 
to take part in the study, however when given the food diaries and FFQ to fill in and return, it 
was within this group that the greatest numbers did not return the information for analysis. 
Therefore there is a need to find a way of engaging teenagers to understand their thoughts and 
perception on the use of the LPSF. Engaging children with PKU as young as possible in the 
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preparation of their diet and learning how to cook with the LPSF may encourage use of the 
products for a longer time than at present. It was shown from the survey results in the first 
study (Cochrane. et al 2014) that the use of cookery classes benefitted the adults in the prepa-
ration and use of the LPSF, if the classes were tailored towards the child or teenager, this 
might help to raise awareness of the benefits and use of the LPSF. 
Association between physical and mental wellbeing and use of LPSF 
In this study, no difference between the parent reports and child reports of the LPSF 
user groups in terms of physical or psychosocial functioning was discovered, suggesting that 
the use of LPSF does not seem to be associated with how people with PKU or their carers 
feel about their quality of life and do not view that the use of these products as something that 
has a negative impact on their life. In 2011, ten Hoedt and colleagues (ten Hoedt, et. al 2011) 
survey of parents of children with PKU and Galactosaemia found that parents of children 
with conditions such as PKU, have a poorer quality of life than parents of children without a 
chronic condition. This may indicate that the overall restrictions placed on the parents and 
families of the children with PKU negatively affect their day to day wellbeing. However, it 
was not stated which aspect of the condition contributed most to the poorer quality of life. It 
may be that a larger sample size in our patient group could demonstrate that greater use of 
regular foods, for children with milder disease, may place fewer restrictions on the family and 
therefore result in a better quality of life. 
In the 2011 report on Scottish health (Gray, Leyland 2011), it was stated that chil-
dren’s mental wellbeing was shown to be negatively affected by being overweight or obese. 
This was not shown to be the case in our cohort studied as the results from the Peds QL
®
 bear 
out. Given that our patient group had the same incidence of overweight and obesity as the 
general population, measures should be taken to reduce this additional risk factor to mental 
wellbeing (Rocha, MacDonald & Trefz 2013). 
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Conclusion 
 No association between the use of LPSF and socioeconomic status, age or gender or 
metabolic control was identified. In addition use of LPSF did not have a negative impact on 
physical or psychosocial well-being.  Children with classical PKU consumed more LPSF 
than those with milder disease.  However,  low use of LPSF was associated with increasing 
BMI with food choices being inclined towards snacks of regular foods and using a greater 
amount of  ” junk” foods to satisfy the appetite and provide energy especially in the older 
children. When the number of portions of foods, both regular and LPSF were compared there 
was no difference between the groups. No subject met the recommendations for non-protein 
energy from LPSF suggested by the NSPKU society.  
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Practical implications and suggestions for future research 
  The use of LPSF in the diet for PKU has been the mainstay of treatment now 
for around fifty years, making it unethical to conduct a randomised controlled trial to provide 
evidence for the role they play in the control of phenylalanine levels and the contribution they 
make towards nutritional status and other aspects of health and wellbeing.  
 The first study provided information on the patient’s perception of the need for these 
foods and the results show that patients use them to aid control of phenylalanine levels, help 
to satisfy the appetite and provide variety. However, this survey did not take into account dis-
ease severity and use of the LPSF. Therefore, we do not know if people with milder disease 
severity have a different perception of their value than people with classical or moderate dis-
ease severity. Results also identified many families had a problem with regard to access of 
these products, but again it is not known if this is associated with other factors such as disease 
severity which was not explored. In addition, it may be that a lack of awareness and under-
standing by the primary care staff on the use of the LPSF in management of PKU results in 
patients and carers receiving repeated problems accessing product. A survey targeting prima-
ry care staff in both the patient’s G.P practice and local pharmacy might help to identify what 
level of support and education the metabolic team should provide.  
 Those with milder disease severity are generally thought of as having greater freedom 
of choice in use of regular foods to provide phenylalanine requirements and therefore a less 
restricted diet. However, the results from the second study suggest that this group chose less 
LPSF and also used more of the snack type foods. This trend is reflected in a higher BMI and 
incidence of overweight and obesity in the low LPSF user group. It may be that patients who 
are prescribed a greater number of phenylalanine exchanges do not perceive the LPSF as a 
valuable contribution to dietary management and prefer to consume energy dense snacks. 
 It was not possible in this study to obtain a breakdown of the components of the 
source of carbohydrate in the LPSF and regular foods to determine the proportion of sugar, 
starch, fibre or non-milk extrinsic sugars using the manufacturer’s product information and 
therefore only total carbohydrate was assessed. It would be useful in a future study to try to 
obtain more information about these components, especially the sugar content, to determine 
the role sugary foods play in the energy content of the diet of people with PKU and therefore 
whether low users consume more sugar than starch in their diet.  
 This information would give an insight into some of the various factors that play a 
part in the growing incidence of obesity in patients with PKU (Burrage et al. 2012). As our 
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results have shown, it is not the energy from fat of the subject’s diet that contributes to excess 
energy intake, but carbohydrate.  
 The results from Study1 show the value patients and their carers place on practical 
support from the metabolic dietitian in helping them use the LPSF effectively by the provi-
sion of cookery classes. Again, it is not known if it is the patients with the more severe dis-
ease who attend these classes or indeed are supported by having foods delivered by the home 
delivery company to help them overcome difficulties with their primary care practitioner. 
 Patients with a milder form of PKU may be helped to lower their overall calorie in-
take by being advised to use foods of a higher protein content to provide their phenylalanine 
prescription, such as yoghurt, spreading cheese and pulses, therefore requiring the use of a 
greater amount of LPSF to provide bulk and variety and satisfy the appetite rather than snack 
foods. This may help to reduce the risk of becoming overweight or obese. Over time, the 
LPSF have greatly improved in taste, texture and variety and these improvements should ap-
peal to most groups of disease severity. In addition dietitians should encourage patients to use 
more LPSF to free exchanges, thereby encouraging the use of more nutritious regular foods  
 The exchange list produced by the NSPKU avoids foods which are slightly higher in 
natural protein e.g. yoghurt, spreading cheese or nut based products such as peanut butter, 
therefore patients tend to steer away from these foods and choose foods with a lower phenyl-
alanine content to make up their phenylalanine allowance. The results from study 2 show that 
patients therefore tend to use snack foods for this purpose.  
The NSPKU list could be adapted and expanded to take into account more protein 
dense foods thereby aiding patients to make suitable choices and necessitating greater use of 
LPSF. This would make the diet for PKU more liberal and consistent with all patients having 
the same emphasis being put on using the wide range of LPSF available. However, it would 
also then necessitate guidance being given on what percentage of the staple LPSF compared 
to “convenience” LPSF should make up the diet.  In the increasing scrutiny of primary care 
budgets, this guidance by metabolic specialists would give more confidence to the G.P’s in 
that the prescriptions they are issuing are suitable for their patients and perhaps lead to fewer 
problems in access to the LPSF by families. 
 As food labels become more informative, we should use this information to give pa-
tients greater freedom in use of more protein dense foods, be less wary of them using previ-
ously “forbidden foods”, but trust that with good dietary education, patients and their carers 
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will still control their diet effectively. In this way, a wide range of LPSF could be encour-
aged, therefore steering patients away from using high energy snack foods. 
 The advice that there should be “diet for life” (Levy, Waisbren 1994, Smith, Beasley 
& Ades 1991) has brought with it many challenges for adults to face as they grow older. 
There is an increasing tendency towards obesity, heart disease and diabetes in the general 
population and tackling this in the general population is difficult (Ortner Hadžiabdic, 2014) 
and the adult with PKU may not be at any lower risk of developing these conditions. This is 
an area not yet studied in PKU, as early treated adults are only now reaching their 50’s and 
are just at an age at which these conditions are widespread in the general population.  
 Another area for study should be the attitude of health professionals managing these 
patients towards discussing yet further restrictions on an already constrained diet, if we are to 
tackle the increase in obesity amongst our patient population. We owe it to our early treated 
adults to ensure that they are not at increased risk of obesity related disorders because they 
have made unsuitable food choices. 
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Overall Conclusion 
 
 Although, patients with PKU and their carers perceived that the LPSF were important 
in helping control phenylalanine levels and they did not have any concern with the sensory 
properties, not all subjects used these foods up to the level recommended by NSPKU. Pa-
tients and carers often felt anxious about asking for the LPSF because of the attitude of pri-
mary care staff and it was not clear from the survey if disease severity was associated with 
access to LPSF. A programme of education by the metabolic dietitian for primary care staff 
in both the G.P practice and pharmacy upon the diagnosis of PKU will ensure new parents 
receive adequate support at all health care levels. 
 Health professionals should be aware of the link with low use of the LPSF and the 
trend towards obesity and overweight amongst their patients. Advice should be given to re-
duce the use of foods commonly considered to be “junk foods with patients and their carers 
given directed information on which suitable foods could be used for phenylalanine exchang-
es, especially for those with milder disease, to ensure staple LPSF are used to satisfy appetite. 
rather than the “convenience” LPSF or snack foods. Health professionals should not be reti-
cent when advising their patients and patient’s carers about the risks of obesity and over-
weight and assist them in making suitable food choices. 
 Future studies should be undertaken to explore any link between disease severity and 
access to LPSF along with attitude of those with less severe disease on the value of the LPSF 
in the management of their disease. 
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Issues, limitations and reflection on the study  
Recruitment 
 The PKU clinic at the Royal Hospital for Sick Children in Glasgow, Glasgow Royal 
Infirmary and Southern Genera Hospital, have the largest cohort of patients on a restricted 
phenylalanine diet in Scotland. There are around 70 children and 160 adult patients in total. It 
was therefore envisaged that recruitment to the study would enable the designated number of 
60 therefore easy to obtain. Subjects were to be contacted by letter 3 months prior to their an-
nual review appointment. The decision to contact the families three months before the clinic 
visit was thought to enable patients to be aware of the study in a timely fashion and not have 
to wait up to a year before they would consent to take part. It also allowed a constant recruit-
ment of subjects.  
 However, not all patients or carers replied to the letter and were therefore approached 
to take part in the study at their clinic appointment.  The majority of patients and parents 
when approached in this way agreed to take part and gave consent for extra blood tests and 
anthropometric measurements to be taken. However, although they were given the FFQ and 
the 7 day food diary along with instructions on how to complete it and a stamped addressed 
envelope for return of documents, many patients did not return the study documents. Patients 
and parents were contacted by phone and email, but some documents did not arrive and con-
tributed to the missing data and small numbers in the study. In any future studies, it is envis-
aged that letters would be sent out to all families at the start of the study and a reminder sent 
in the week before the clinic visit to aid recruitment. 
Recruitment of adults 
 In the study proposal, adults were to be recruited into the study from the adult clinics 
at Glasgow Royal Infirmary and the Southern General Hospital. A decision was taken to con-
centrate recruitment on children first and then recruit adults. However, at the time that adults 
were to start recruitment, a separate study into the psychosocial effects of PKU in the adult 
commenced and it was not deemed suitable to ask these patients to take part in the LPSF 
study. This meant that no adults were recruited and also had an impact on the overall num-
bers of subjects able to be recruited. Future studies investigating issues distinct to adults than 
paediatric subjects would enable the investigator to concentrate on one group at a time and 
perhaps give information valuable for management of the adult PKU population. 
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Recruitment of healthy controls 
 The low numbers of healthy controls recruited was due in part to the lack of available 
time and an unexpected increase in workload experienced by the investigator. Although post-
ers were displayed around the hospital and the invitation extended to family members of the 
children attending clinic, insufficient numbers were able to be recruited. This led to the deci-
sion not to include the data obtained from completed diaries and FFQ. However, information 
obtained will be used in the future if the study time can be extended. It was disappointing not 
to be able to compare the diets of siblings with other controls to examine the impact of hav-
ing a family member on special diet on the eating habits of the family, but this will be ex-
plored in future studies. In addition, the majority of the healthy child controls were recruited 
from groups 4 and 5 of the SIMD and would lead to bias with the results, so in any future 
studies, greater effort would be made to increase numbers from the groups 1-3.  
Difficulties with the postal service 
 Patients and carers were asked to return the 7 day food diary and PedsQL
®
 question-
naire by post after completing it within two weeks of their annual review appointment. This 
proved to be optimistic on the part of the investigator. Some documents were completed only 
after several contacts with the family. Some participants claimed to have completed the ques-
tionnaires and posted them which did not then arrive. During the study, there was some diffi-
culty with the postal service and at least one document had to be collected from the main 
postal sorting office when not delivered.  In the future, it would be better to arrange collection 
of the documents personally or return at the next clinic appointment so that fewer documents 
would be lost with a reminder just before the visit. 
Investigator’s relationship to subjects 
 As the principal investigator was also the clinical supervisor of their dietary manage-
ment, it was thought that this would aid recruitment as the subjects might feel more at ease 
and able to ask questions or decline to take part if they felt unable to complete all the study 
requirements. However, the opposite seemed to be true. Many participants agreed to take 
part, have the necessary anthropometric assessments, blood tests but did not complete the 
food diaries or FFQ, which was the main requirement of the study. It was felt that perhaps 
they felt unable to refuse, or did want to take part, but were unable to complete the necessary 
tasks involved and then felt uncomfortable when questioned regarding returning the docu-
ments. 
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Bias from food recording 
Using the results from foods diary analysis, the overall contribution that the LPSF, 
protein substitute and phenylalanine exchanges play in the management of PKU was evaluat-
ed. The results from the week to week monitoring of the phenylalanine levels pre and post 
diary completion were compared to determine any bias on phenylalanine levels leading to 
patients being more careful in what they consumed. No difference was found in the percent-
age of results outside the target range which might indicate that dietary habits did not change 
significantly during the week because of the length of time the subjects were asked to record 
their intake.  
Many of the teenage subjects who gave consent to take part in the study did not return 
the questionnaires and some of the questionnaires were not as accurately completed as would 
be desired. This may then have led to a distortion in the overall results of the study. The 7 day 
weighed food diary is one of the most accurate methods of recording intake, but has its draw-
backs as participants are known to alter intake when completing diaries. It is also time con-
suming and laborious to the subjects and prone to inaccurate recording because foods were 
not weighed. Using one method only, may have improved the number of complete food dia-
ries or FFQ and thereby increased the study numbers. The weighed, daily food diary and FFQ 
are often used in the management of any dietary treated disorder. A useful study would be to 
compare results from both methods of recording and thereby accuracy of recording, which 
would give a useful tool in the day to day clinical management of PKU.  
Investigator’s clinical duties 
 The amount of time needed to complete the necessary investigations at the time of 
recruitment was underestimated by the investigator. No additional clinical time was allocated 
for recruitment at the annual review or follow-up. This did not impact on the clinical man-
agement of the patient, but did impact on the time available to chase up subjects and carers to 
enable the return of documents. This in turn led to a lower than expected number of patients 
completing the study. As mentioned earlier, the investigator’s workload increased with an 
additional clinical area and led to the reduction in time available to chase up missing docu-
mentation. 
Subject’s clinic attendance 
 Patients with PKU under the care of the metabolic service are given 3 monthly clinic 
appointments and each year has blood taken for a nutritional screen. This meant that at each 
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PKU clinic it was variable the number of patients who might be eligible to take part in the 
study. Some weeks there might be 4 or 5 patients suitable and the next week there would be 
none. The greatest impact of this was the time available for follow-up of patients and getting 
the necessary documentation out and then returned to the patient before the review.  
The number of subjects estimated which would give a suitable sample size was based 
on the recruitment of subjects prior to their annual review clinic visit. Due to the poor re-
sponse to the invitation letter and subsequent enrolment at clinic, a letter to the whole popula-
tion group at the start of the study period, followed up by a second letter, just prior to the 
clinic appointment would perhaps have improved recruitment of subjects and sibling controls. 
 
Micronutrients 
The design of the study included evaluating micronutrient status associated with nutrient in-
take as assessed from a 7 day food diary and FFQ. The aim was to compare accuracy of re-
cording using the two recording methods with micronutrient status.    
 Ethical approval was given to evaluate all features of the management of PKU, but 
this then led to too many aspects being considered. Sufficient data was collected so that it 
would be useful for a future study to consider the intake of micronutrients compared with re-
sults from the annual nutritional screening. 
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Evidence table 1: Micronutrient status in PKU 
Author Aim 
 
Subjects Micronutrient 
studied 
Intervention Outcome 
measures 
Results  Comments 
Barretto et al 
2008 
 
Brazil 
To investigate 
erythrocyte 
Zinc, serum se-
lenium and cop-
per levels in 
children with 
PKU 
32 
1/12 – 19 yrs. 
Zinc 
Copper 
Selenium 
3 day dietary food record 
 
Same protein substitute – 
age appropriate – Se free 
 
Venous blood: 
7-10mls 
Cu – all normal 
Zn – N – 62% 
Se – n – 9.4% 
 
 
Lowest Se in oldest 
pts.,  
Highest Zn in 
youngest 
a. Diet def. in Se,  
b. Bioavailability of Zn 
may be affected by excess 
fibre and other minerals.  
c.P/S source needs to 
contain micronutrients. 
d.P/S needed to supply 
nut demands of children 
in Brazil 
No mention of Phe 
levels – compliance 
with diet 
No separation of diet 
and P/S intake 
 
Sievers, E et 
al 
2000 
 3 PKU, 
10 controls breast-
fed 
Iron 
Copper 
Manganese 
2-5ml milk, 
Faeces 
Usual diet 
Retention of Fe, Cu, 
Mn exceeded con-
trols 
 No mention of how 
many infants breast 
or formula fed 
Sievers E; 
Arpe T; 
Schleryerbach 
U; 
Schaub J 
 
2000 
Germany 
To determine if 
retention of Mo-
lybdenum and 
plasma conc in 
infants with 
PKU is equiva-
lent to healthy 
breastfed infants 
4 PKU – Low Phe  
formula + breast 
or normal formula 
milk 
17 healthy con-
trols 
Mb Collection of pooled breast 
milk, test weighing of breast 
fed infants, bottles weighed 
Urine collection 
Faeces, plasma samples 
Intake and retention 
of Mb 
Intake and retention of 
Mb 18 times greater in 
infants with PKU than 
Intake and retention of 
Mb 18 times greater in 
infants with PKU than 
healthy breast fed infants 
No comparison with 
bottle fed infants,  
Fisberg RA 
et al 
1998 
Brazil 
To study the 
effects of the 
Phe restricted 
diet. 
42 children 
1-12 years 
31 controls 
Zinc 
Copper 
3 day dietary record 
 
P/S given according to man-
ufacturer’s instructions 
Weight 
Height 
5ml venous blood 
Children with PKU 
< 7, Height / age 
lower than controls 
Plasma Zn higher in 
controls Plasma cop-
per similar in con-
trols 
 Low protein foods 
not readily available 
therefore  affecting 
calorie intake 
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Author Aim 
 
Subjects Micronutrient 
studied 
Intervention Outcome 
measures 
Results  Comments 
Sievers, E; 
Oldigs, H-D; 
Dorner, K; 
Schaub, J 
1990 
Germany 
Evaluation of 
balance data for 
Fe, Cu, Mn 
3 infants with 
PKU 
10 healthy controls 
– previously stud-
ied- breastfed 
 
 
Fe, Cu, Mn Wt. before feeding 
2-5ml sample of prepared 
diet.   
Faeces 
 
Fe, Cu, Mn concen-
trations in breast milk 
and PKU diet 
Median concentra-
tions and retention of 
Fe, Cu, Mn of PKU 
diet  exceeded mean 
concentrations in 
breast milk 
Not clear what type of 
normal feeds infant 
received to provide Phe 
allowance – Ordinary 
formula or breast milk. 
Small sample size 
No indication of 
amount of “normal” 
feed infant received. 
Acosta PB 
Et al 
2004 
USA 
To determine the 
incidence of iron 
def. 
37 children with 
classical PKU  
2-13 years  
For 1 year 
Children grouped 
according to P/S 
prescribed 
Iron  
Hb, haematocrit, ferritin, 
TFR concentrations 
3 monthly diet diaries 
 a.Fe within reference 
ranges  no child had 
Hb concentrations 
suggesting anaemia 
b.7 elevated 
TFR/ferritin ratio 
c.4 elevated transfer-
rin receptors 
No mention of Phe 
levels although com-
pliance with P/S men-
tioned as a cause of 
low ferritin in 1 pt. 
Tondo et al 
2009 
Spain 
Study a range of 
elements in pts. 
with IEM with 
and without die-
tary treatment 
 
Co, Mg, Mn, Se, 
Zn 
Mo, Cu assessed 
72 pts. 
2 months – 44 
years 
92 controls 
2 groups  
On dietary re-
striction and group 
2 not on diet 
Copper 
Selenium 
Zinc 
Data from manufacturers 
for P/S + 3 day question-
naire 
 
P/S contained vitamins and 
minerals 
 25 Pts. on dietary 
treatment had de-
creased Se levels 
14 pts. had decreased 
Co levels 
All other elements 
normal 
Se and Co dietary 
intake higher than 
RDI 
 
Jochum F et 
al 
1999 
Germany 
Monitor effects 
of low selenium 
intake 
87 children with 
PKU 
5-15 years 
 
34 controls 
Selenium Wt., Hot, neurological, 
dermal examination. 
Hair, urine and blood taken 
to measure Se 
 a.Se in plasma, whole 
blood and hair lower 
than in controls 
b.Urinary Se excre-
tion lower 
No mention of dietary 
intake, Phe level apart 
from stating that chil-
dren well controlled. 
No mention of P/S  
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Author Aim 
 
Subjects Micronutrient 
studied 
Intervention Outcome 
measures 
Results  Comments 
Robinson, M;  
et al 
1999 
To determine if relaxed 
or discontinued diet 
predisposes to B12 
deficiency 
N=83 
(11-38 years) 
Patients divided into 3 
groups: 
Strict: diet + aa sup-
plement 
Relaxed: diet + aa sup-
plement – 1g Protein 
/kg 
Unrestricted: no pro-
tein restriction and no 
aa supplement 
B12 Neurological examina-
tion 
Vitamin B12 assay 
Red cell folate 
Dietetic Assessment 
Blood Phe levels 
Vitamin B12 lev-
els 
 
Erythrocyte folate 
 levels 
Vitamin B12 < normal 
range: 
6 in unrestricted group 
3 relaxed group 
1 in strict diet 
1 patient in strict 
diet group with low 
B12 had not been 
taking vita-
min/mineral sup-
plements 
Hvas,A.M; 
Nexo, E; 
Nielson J.B 
Denmark 
2005 
To examine vitamin B 
status in adult PKU 
patients. 
Query need for sup-
plementation 
Patients with PKU > 
17yrs  
Unrestricted diet  
n=31 
(18-43yrs) 
B12 FFQ 
7 day food diary 
Serum cobalamins 
Erythrocyte folate 
Information on neuro-
logical symptoms 
Neurological 
symptom score 
Serum total trans-
cobalamin 
Cobalamin satu-
rated transcobal-
amin 
 
75% had biochemical 
B12 deficiency 
↓B12 intake 
↓B6 intake 
<RDA intake of  
Protein 
Normal folate status  
Small numbers of 
participants 
11/31 took vitamin 
preparation 
7/31 took no sup-
plement 
24/31 took LNAA 
No distinction be-
tween B12 defi-
ciency and severity 
of PKU 
Taylor et al 
1984 
Liverpool 
Effect of diet on calci-
um and trace element 
status of children with 
PKU 
25 children 
6 mths. – 17.5 yrs. 
Sibling controls 
 
Calcium 
Trace elements 
Pts. received P/S with-
out added vits and 
minerals, 
Given mineral, multi-
vitamins and additional 
Vit D 
Whole blood and hair 
samples analysed 
 
 
 
 a.Hair Zn and Ca lower 
than controls 
b.Hair cu higher than 
controls 
c.Blood Zn and Cu 
within normal ranges 
d.1 Pt. blood Cu above 
normal range 
No mention of Phe 
levels, dietary in-
take not measured, 
no mention of com-
pliance with P/S 
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Author Aim 
 
Subjects Micronutrient 
studied 
Intervention Outcome 
measures 
Results  Comments 
Bohles 
1991 
To investigate carnitine 
conc in patients with 
PKU in relation to iron 
availability 
3 groups 
N=169 
- <2 yr.(n=32) 
- >2 yr.(n=75) 
- Off diet(n=62) 
Control N=57 
Serum ferritin 
Serum carnitine 
Daily iron intake 
Blood test 
 Some patients may 
have low carnitine 
even on strict diet. 
Low Hb 
Correlation be-
tween Fe and 
carnitine (Fe co-
factor for car-
nitine synthesis) 
Acosta PB 
1996 
Review of studies of 
intakes of Fe, Zn, Vit-
amin A of children 
treated for PKU 
Studies with 
between 8-21 
children 
 
Zinc 
Iron 
Vit A 
3 day food intake records, 
plasma analysis of ferritin, 
Zn and retinol analysed 
 
 
 
Differences seen in 
the plasma concentra-
tions between casein 
hydrolysate and L 
amino acid mixes 
 
Arnold, G et 
all 
2001 
Mean Hb low < control 
group for all ages 
41 Iron Parent /patient report – 3 
day recall 
prescriptions reviewed 
145% USA RDA for Fe in 
P/S for ages 1-4 
175% Fe for ages 7-11 
111-114% Fe for ages >12 
years 
 No significant diff in 
mean Hb, 
haematocrit 
Mean red cell count ↓ 
Mean Hb low < con-
trol for all ages 
Compliance 
with p/s not 
known 
Vugteveen, I; 
et al 
2011 
 
Netherlands 
 
Retrospective 
study 
Functional B12 defi-
ciency should be con-
sidered rather than se-
rum B12 concentra-
tions  
Diet treated 
Patients with 
PKU  
N=91 investi-
gated 
n=16 – insuffi-
cient data or 
pregnancy 
M=36; F=39 
(1-37 years) 
B12 
MMa 
Hcy 
Data on Serum B12, serum 
MMA and plasma Hcy 
collected at the same time. 
From laboratory database.  
Functional B12 deficien-
cy defined as MMA con-
centration above P 97.5 
Metabolic  control – av-
erage Phe conc in year 
preceding measurements 
of B12, MMA and Hcy   
18 patients with ab-
normal concentra-
tions of B12, MMA 
and / or Hcy 
No correlation with 
blood Phe concentra-
tion 
Folate and B6 
not measured. 
No measure-
ment of compli-
ance with pro-
tein substitute or 
vitamin/mineral 
supplementation 
Population 
treated as one 
group 
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Author Aim 
 
Subjects Micronutrient 
 studied 
Intervention Outcome 
measures 
Results  Comments 
Acosta PB, 
Yannicelli S  
 
1998 
 
Company 
supported 
study 
Evaluation of Phenex – 
1 amino acid mix for 
selected micronutrients, 
biochemical indices of 
trace mineral status 
while on treatment for 
PKU 
27 infants with 
PKU 
Iron Indices of iron status, plasma 
trace and ultra trace minerals reti-
nol and α-tocopherol concentra-
tions assessed at 3 and 6 months. 
Monthly 3 day diet diaries. Data 
compared with similar formula 
from another company in two 
studies 
 Mean intakes met / 
exceeded RDA’s. 
Individually 2 low for 
Ca, 4 for Fe, 2 for Mg 
and Mn, 1 for Zn and 
1 for Vit A 
Data not complete. 
Study concluded 
that the formula 
supported normal 
iron status and trace 
minerals when fed 
in recommended 
amounts. 
Acosta PB 
1996 
Review of studies of 
intakes of Fe, Zn, Vit-
amin A of children 
treated for PKU 
Studies with 
between 8-21 
children 
 
Zinc 
Iron 
Vit A 
3 day food intake records, plasma 
analysis of ferritin, Zn and retinol 
analysed 
 Differences seen in 
the plasma concentra-
tions between casein 
hydrolysate and L 
amino acid mixes 
 
Bodley 
1993 
Investigate serum Fe 
conc and dietary intake 
in infants and children 
with PKU 
N=53 
< 1 yr. (n=6) 
1-3 yr. (n=22) 
4-12 yr.(n=25) 
Serum ferritin 
Hb conc 
 
Review of dietetic information + 
blood results 
Serum ferritin 
Dietary iron 
intake 
All patients had nor-
mal Hb  
17% (<1 yr.);  
73%(1-3yr) and 
44%(4-12yr) had 
subnormal serum 
ferritin 
 
May need greater 
than RNI iron due 
to low bioavailabil-
ity 
Age 1-3yr most at 
risk 
Darling 
1992 
Investigate Se status in 
PKU patients 
N=73 
10-27 yrs. 
66 on diet from 
diagnosis 
7 on diet >9yrs 
Controls n=25 
(13 were family 
members)  
Se 1. Supplemented protein 
substitute 
2. Unsupplemented Protein 
substitute 
 
Blood test 
Serum Se 
Se content of 
soil 
Serum Se in subjects 
and controls signifi-
cantly different 
Se in supplemented 
group significantly 
↑than unsupplement-
ed group 
No clinical signs of 
Se deficiency seen 
in subjects 
Reilly C; 
Barrett J et 
al 
 
1990 
Assessment of treated 
children with PKU 
20 children <1-
14 years. 
20 siblings as 
controls 
Selenium 3 day weighed dietary record, 
food samples taken for analysis. 
3. Blood and urine samples 
collected 2-4 hours prior 
to clinic visit 
 No difference be-
tween the groups for 
plasma or urine Zn, 
Cu, Fe or Mn 
Plasma Se signifi-
cantly lower 
Mineral mixture 
given to children 
with PKU did not 
contain Se 
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Author Aim 
 
Subjects Micronutrient 
studied 
Intervention Outcome 
measures 
Results  Comments 
Longhi 
1987 
To study TE status and 
serum ferritin levels 
N=19 
n-=8 treatment 
started at diag-
nosis after birth 
(gp A) 
n=11 treatment 
started late alt-
hough diag-
nosed at birth 
(gp B) 
Divided into 3 
groups: 
1-5months 
6-12 months 
13-24 months 
 
Fe, Zn, Cu, Se, Mn 3 day dietary recall 
Blood test 
Trace element intake 
as a proportion of 
RDA for the 3 age 
groups 
Se, Fe intake ↓RDA 
in the group A of all 
ages. 
 
In Gp B – Zn, Mn, & 
Se intake ↓ RDA 
 
Mn intake ↑ in age 
gp 6-12 months 
Patients with 
PKU are at risk 
of Fe, Cu, Zn, 
Se due to insuf-
ficient intake 
Require Se sup-
plementation 
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Evidence Table 2:  Management of PKU and reimbursement of medical foods in Europe and USA 
Date Author Title Aim Findings Comments 
 
2012 Giovannini 
et al 
Italy 
Phenylketonuria: 
nutritional advanc-
es and challenges 
Review of treatment advances 
and challenges in PKU man-
agement 
 
- goals of dietary treatment 
 
 
- nutritional characteristics 
 
-LCPUFA supplementation 
 
 
 
-Protein substitutes 
 
 
 
 
-Glycomacropeptide 
 
 
 
 
-New strategies 
 LNAA 
 
 BH4 
 
 PAL 
-compliance in infancy and childhood ade-
quate, but difficult in adolescence and adult-
hood.  
 
-dietary regime provides higher CHO and low-
er saturated fat intake.  
 
-restricted diet contributes to low DHA intake. 
Subtle neurological deficits seem with early 
treated children  
 
-progress has been made with palatability, 
composition, compliance, formulation, age 
related formula 
 
-GMP natural protein in purified form is free 
from phe. May provide acceptable, alternative 
protein source. 
 
-alternative to conventional PKU treatment, 
many treatment rationales 
-BH4 responsive patients have lower plasma 
phe >30% reduction. PAH mutation dependant 
-mouse models show promising lowering of 
plasma phe 
 
 
 
 
 
 
- Other factors than degree of  
control of Phe influence  
cognitive outcome 
 
 -Children with PKU have 
 lower plasma cholesterol  
than healthy children 
 
-DHA is essential and  
should be supplied beyond  
infancy. Studies are needed  
to evaluate optimal dosage 
 of DHA supplementation. 
 
-protein substitutes should  
be continued to be  
monitored for efficacy 
 
 
-GMP may help compliance 
 
 
-studies needed into role,  
dose and composition of  
LNAA 
-BH4 will be in conjunction  
with dietary treatment 
 -may be useful in 
 conjunction with dietary  
therapy, independent from  
PAH mutation 
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Date Author Title Aim Findings Comments 
2013 Fidika et al 
Germany 
Quality of life 
among parents of 
children with PKU 
Evaluate parental QOL 
Identify predictors of PQOL 
Cross-sectional study in Germany.  
Inclusion: 
-parents with one or more children with PKU 
-children and adolescents <20 years, living with parents 
-children diagnosed through NS. 
Method: 
-self reported questionnaire 
Subjects: 
-13 fathers(14.6%); 76 mothers(85.6%) n=89 
Low numbers of fathers meant no  
comparison between them drawn. 
Parents of Pre-school children had  
lowest total PQoL scores (m=61.3;  
SD=12.9), significant difference 
 with school age children (p=0.011) 
Parents perceive QoL positively,  
but need child age appropriate  
support. 
2012 Belanger-
Quintana et 
al 
Multi-centre 
study 
Diet in Phenylke-
tonuria:  A snap-
shot of special 
dietary costs and 
reimbursement 
systems in 10 in-
ternational centres 
Exploratory data gathered from 
10 international specialist PKU 
centres 
All centres members of European nutrition Expert panel 
on PKU, 1 centre from each country, not representative 
of other centres in each country. 
-retail price per package of 3 commonly used protein 
substitutes representing 4 phases of patient ages 
-retail price for 3 commonly used types of low protein 
foods 
- state benefits available to alleviate cost of dietary 
management 
- costs varied widely between  
countries 
- all counties reimbursed to a  
degree through subsidy or insurance. 
- Protein substitute most expensive  
component of dietary management  
and funded in full 
- low protein food reimbursement 
 and availability  varied widely  
- cost of low protein foods influenced  
by local reimbursement system  
– lower cost for patients  
self-financing 
-Study highlights inequality in  
healthcare policies and access to  
products in Europe 
2012 Camp K et 
al 
USA 
Nutritional treat-
ment for inborn 
errors of metabo-
lism: Indications, 
regulations, and 
availability of 
medical foods and 
dietary supple-
ments using phe-
nylketonuria as an 
example 
Review of the indications for 
use, regulation, availability and 
categorisation of specific nutri-
tional products for the treat-
ment of IEM. 
Nutritional products divided into 2 categories by pur-
pose: 
-medical foods containing protein without the affected 
amino acid. Provided 85-90& protein needs of patient, 
may contain vitamins and minerals 
- foods modified to be low in protein which are an alter-
native to foods which are excluded or limited in diet. 
- IEM infant formulas regulated by FDA as infant for-
mulas 
- medical foods for >1 yr. exempt from nutritional  
labelling and health claims Act(1990) 
 
- Newborn screening programme  
identifies individuals with IEM  
where nutritional treatment is 
 standard of care, but lack of 
 evidence –based research  
documenting effectiveness of  
treatment means inconsistent  
access to treatment. 
- Inconsistencies remain in  
medical food health insurance 
 cover by states. 
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Date Author Title Aim Findings Comments 
2012 Macdonald 
et al 
UK 
Adherence issues 
in Inherited Meta-
bolic Disorders 
treated by low 
natural protein 
diets.  
-study highlights issues in gain-
ing dietary adherence in ami-
no acid disorders 
-adherence issues similar to other chronic disorders such 
as CF, DM 
-burden on family of day to day management 
-some children identified as having behavioural prob-
lems 
-family with poor parenting strategies associated with 
less adherent children 
-lack of available information for parents 
-cultural barriers affect adherence 
-limited availability of special medical foods 
-study needed to evaluate effects of 
 diet and adherence leading to  
standardised educational tools in  
order to support patients and carers  
2011 Macdonald 
et al 
UK 
Retrospective, 
observational data 
collection of the 
treatment of phe-
nylketonuria in the 
UK, and associat-
ed clinical and 
health outcomes 
-retrospective, observational 
chart review at 3 specialist 
centres. 
- 125 subjects included: 20 
adults and 105 children  
-study explored number and 
consistency of returned blood 
samples 
- study explored how often 
subjects out of recommended 
range 
- phe concentrations in range if 
>70% within target 
Inclusion criteria: 
-diagnosis of PKU 
->4 phenylalanine measurements for adults and >6 phe-
nylalanine measurements/year 
-data collected on 141 subjects 
 
 
-discrepancy in classification of  
“adult” – aged 16 or 18 
-small sample size 
-only 3 centres contributed 
-self- selected population 
- 16 subjects did not meet inclusion 
 criteria 
- clinical contacts analysed but no  
mention of this in primary aim of study 
2010 MacLeod E , 
Ney D 
USA 
Nutritional man-
agement of Phe-
nylketonuria 
Review of development of die-
tary prescription, outcomes of 
nutritional management, 
compliance with the diet 
across age ranges and new op-
tions for management  
-recommendations for protein exceed RNI for protein 
by 30% (UK) -  evidence suggests no increased re-
quirements 
-phe requirements for adults-9.1mg/day 
-phe requirements for children – 14mg/day, but must be 
assessed individually 
-natural protein <25% in diet 
- monitoring – needed to adjust phe prescription 
-new therapies such as BH4, LNAA may be effective 
for some with PKU 
-GMP – may result in reduction of phe conc as taste 
better than conventional protein substitutes 
-unclear if those with PKU have a lower 
 risk for cardiovascular disease 
-mouse models suggest increased plasma 
 phe adversely affects bone development 
-compliance decreases with age – 50% 10-14 
 and 79% 15-19 year olds have blood  
phe conc >target range 
-only 19% adults able to achieve  
compliance after 9 months back on diet 
-Generally used in conjunction with  
diet restriction may improve control 
- only very small studies evaluating GMP 
-more studies needed regarding optimising 
 health of patients as they age. 
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Date Author Title Aim Findings Comments 
2011 Macdonald 
et al 
UK 
Nutrition in Phe-
nylketonuria 
Review present knowledge 
concerning protein, AA, vit-
amins and trace element sta-
tus, in addition to growth and 
body composition 
-no data to support higher doses of phe  free aa, but 
20% extra given in line with guidelines to compen-
sate for losses / reduced digestibility as per vegetari-
an diets 
-few reports documenting phe intake of adolescents 
or difference between prescribed and actual intake. 
No recent reports of phe deficiency  
-growth data from Germany, Netherlands and France 
reported poor growth, only protein intake not energy 
intake recorded 
- studies reporting tendency to overweight from late 
1970’s 
-restricted diet requires supplementation of micronu-
trients, many factors affect micronutrient status 
 
 
-if phe levels within target ranges,  
dietary phe not measured 
-phe allocation varies from country  
to country-but no method shown to  
be better than other and comparison  
of phe control shown to be similar. 
 
 
- data from UK, with higher protein 
 intakes did not show any growth  
retardation 
-no mention of general population  
changes 
-Selenium deficiency most commonly 
 reported problem 
2009 Ahring K et 
al 
Multi-centre 
Dietary manage-
ment practices in 
phenylketonuria 
across European 
centres 
Summary of dietary practices 
in individual treatment centres 
within 10 European countries. 
Questionnaire obtaining infor-
mation on: numbers of pa-
tients; management guide-
lines; training of dietitian’s; 
roles and responsibilities; 
monitoring; reimbursement of 
dietary products; challenges 
for management 
2
nd
 Questionnaire on: 
Policy on protein substitution; 
allocation of phe; phe ex-
change system; infant feeding 
practices; tyr supplementation 
and monitoring 
 
-Newborn screening varied between centres (4-10 
days) and threshold conc triggering intervention var-
ied (300 – 600 umol/l) 
-Routine anthropometric assessments similar 
- Biochemical and Haematological measurements 
varied 
-IQ not routinely assessed 
-Dietitian’s training and status varied between centres 
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Date Author Title Aim Findings Comments 
 
2013 Guest J.F et 
al 
UK 
Costs and out-
comes over 36 
years of patients 
with phenylke-
tonuria who do 
and do not remain 
on a phenylalanine 
restricted diet. 
Retrospective study to quantify 
the costs and consequences of 
managing PKU in the UK. 
Estimating the cost of diet for 
life. 
 
Patient data used from 390 G.P 
practices in UK 
THIN database (The Health 
Improvement Network) – in-
formation entered by G.P’s – 
Study population: 
 – all patients in the database 
who had at least one PKU read 
code n=94 
->15 years 
Mean age 36; 68% female; 
85% (n=80)on diet from <1 yr. 
of age 
Pts. divided into 4 groups: 
Group1-patients who had re-
mained on diet 45% (n=36) 
Group 2-Patients who had dis-
continued diet and remained off 
(n=32) 
Group 3-discontinued diet and 
restarted (n=12) 
Group 4-untreated PKU – nev-
er on diet (n=14) 
Data included information on 
prescriptions, tests, G.P con-
sultations, demographics 
 
 
 
-Incidence of neurological symptoms for Gp 2 double 
that of Gp 1. 
-11% patients on diet (Gp 1)received >74% of pre-
scribed amount of aa supplement; 55%recieved 
<25% 9 (based on expected amount used) 
-number of prescriptions ↑60% between ages 5-10 in 
Gp1 
-neurological/psychiatric symptoms accounted for 
22/29% visits to GP for Gp4 compared to ≤14% in 
other groups 
-prescriptions for AED –n=290 per pt. for Gp4 com-
pared to n=30 in other groups 
-mean cost of managing pt. for first 36yrs - £149.374 
– Gp1: £21.367 for Gp4 
-mean cost - £89,000 
-aa supps- main cost-57-63% 
-LPSF-9-11% 
-diet estimated to cost £9,500 per year 
 
 
 
Estimated 2500 with PKU in the UK 
 – cost to treat with optimum diet  
- £24m – <0.1% total NHS budget 
 (2008/2009) 
-small sample size -reflects low  
incidence of disease 
-gaps in patient records 
-hospital costs not considered,  
costs incurred by patients/families/time  
off work 
-well- being/behaviour/QoL not  
considered  
-burden PKU imposes on society  
not estimated 
- GP role in patient management  
demonstrated by study 
-as number of patients received less 
 than opt aa supplements, a need for 
 clear management guidelines for PC 
-need for a comparative study between  
the groups to quantify consequences of 
 stopping diet 
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Date Author Title Aim Findings Comments 
 
2013 Eijgelshoven 
I et al 
Netherlands 
The time consum-
ing nature of phe-
nylketonuria: a 
cross-sectional 
study investigating 
time burden and 
costs of phenylke-
tonuria in the 
Netherlands 
Cross sectional study via ques-
tionnaire 
Systematic literature review 
identified aspects of PKU 
management that imposed a 
burden on patients and carers 
69 participants invited 
-22 adult patients(median age 
28yrs) 15 mild /6 severe PKU 
-24 caregivers of paed pts.  
(median age 11 yrs.)-9 
mild/12 severe PKU 
completed questionnaire (67%) 
Recruited from 7 metabolic 
centres 
Pts. aged 0-4 excluded – study 
joined to existing registry 
Median time burden for managing PKU – 265hrs/yr.: 
527 hrs.-caregivers/175 hrs. –adults 
-46% total time burden – dietary management  
-11%-monitoring protein/phe intake 
-severe PKU associated with greater time burden 
p<0.05 
-pts. / caregivers of   with severe PKU had greater 
OOPC than pts. / caregivers of children with mild 
PKU p<0.05/p<0.05 
-aa supps –reimbursed 
-LPSF – 99% OOPC 
 
Outcome of study demonstrates time  
burden and costs resulting on having  
PKU or caring for child with PKU 
-time 1hr 24mins/day –caregivers / 30 
mins adult 
-higher for severe disease 
-main OOPC – LP foods 
Time burden higher for caregivers  
than adults with PKU reflects relaxing 
 diet in adulthood. 
Severe PKU more time consuming  
than mild due to increased monitoring 
 and stricter control. 
Costs of dietary products reimbursed  
by govt or health insurance in Europe. 
Limitations: 
Small sample size 
Pts. unwilling to disclose income 
Age limit 
 
2013 Berry S.A. et 
al 
 
USA 
Insurance cover-
age of medical 
foods for the 
treatment of inher-
ited metabolic 
disorders 
To define limitations of insur-
ance coverage of medical 
foods and feeding equipment  
 
-survey of 350 parents of chil-
dren with IMD  
Majority-99%- of families had some sort of insurance 
cover 
41% had out of pocket expenses: 
-11% families purchasing medical foods 
-26% purchasing supplements 
-33% needing medical supplies 
-59% using modified LP foods 
 
Adults had worse coverage than children with IMD 
Internet used for purchase of medical foods and in-
curred greater expense 
 
 
 
Conditions are identified through national 
 newborn screening programmes and  
there is improved outcomes in prompt  
treatment and effective dietary therapy,  
but medical foods not consistently covered  
by states leading to inequalities in health  
care provision and a burden on families 
Greater awareness needed by health care  
providers and policy makers to overcome  
burden on families. 
 130 
 
 
Date Author Title Aim Findings Comments 
2010 Alaei M 
Et al 
 
Iran 
Family Social Sta-
tus and Dietary 
Adherence of Pa-
tients with Phenyl-
ketonuria 
Evaluation of family social 
status and dietary adherence 
in Iran. 
 
Cross-sectional study 
105 patients – 46 male/59 fe-
male diagnosed by Newborn 
screening  
Social status defined by: 
-number of children in family 
- number with PKU 
-parents education (4 groups), 
employment and marital status 
Also recorded: age at diagnosis 
and duration of treatment 
 
44.8% mean plasma phe >above ref range. 
No association between parents education and mean 
phe levels 
Increase in mean rank phe of patients whose parents 
divorced 
Increase in phe in patients whose parents unemployed 
Positive correlation between age of diagnosis and 
mean phe, treatment duration and number of affected 
children in family 
Younger pts. (<12yr) had better dietary  
control 
No relation between parent’s education  
and control 
Adherence poorer in divorced parents 
Control not affected by employment status 
 
Social status affects adherence  
Level of dietary knowledge in carers  
needing investigating. 
 
2004 Walter J et 
al 
UK 
Blood phenylala-
nine control in 
adolescents with 
phenylketonuria 
Multicentre study of control in 
PKU to determine compliance 
of adolescent patients with 
current recommendations 
Phe levels in children 10-12 
yrs. between 1994-02 ana-
lysed 
Pts. diagnosed via NBS 
-frequency of blood sampling 
-% phe conc > recommended 
-mean phe for pts. 
-difference between males and 
females  
75 patients data collected (42 
male) 
 
phe levels increased with age  
– at 10 years 20% > recommended 
-at 19 years -75% >recommended 
Blood sampling fell from 83% to 51% at age 20 yrs. 
Mean phe greater in males from age 18 yrs. –not sig 
 
During adolescence phe control declines  
with age 
Females did not have better control 
As females need good control during 
 pregnancy, strategies for improving  
compliance needed. 
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Date Author Title Aim Findings Comments 
 
2006 MacDonald 
et al 
UK 
Home delivery of 
dietary products in 
inherited metabol-
ic disorders reduc-
es prescription and 
dispensing errors 
Aim: to investigate efficacy of 
a commercial home delivery 
of special products used in the 
management of IMD. To in-
vestigate if errors in dispens-
ing are reduced. 
-62 patients with IMD -4 non-
English speaking; 7 on com-
plex feeding regimes 
-study over 12/12 
-50 with PKU 
-12 with other IMD  
-aged 6/12 – 30 yrs. (2>18yrs) 
-50% not randomly allocated to 
subject group (2 older pts. allo-
cated to this group): 50% to 
control group (pts. with >2 diff 
company products in control 
gp) 
 
Control group: 9 pts. had 12 dispensing errors  
– inappropriate P/S for age: 1 error in subject group 
-wrong flavour: 11 errors in control group: 1 in sub-
ject group 
-prescription delays -39 incidents with 16 subjects: 1 
in subject group 
Control group: P/S 
-55% prescribed >90% P/S in 12/12 
-24% had <50% P/S 
-31%-obtaining prescriptions   
Subject group: 
-86% prescribed >90% 
 
No difference in biochemical control 
 
-no information on division of non-PKU pa-
tients between groups 
-No information on division of non-English 
speaking pts. between groups 
-delivery of products does not imply consump-
tion of products-many factors affecting bio-
chemical control-not just receiving product on 
time 
-subjects/controls called monthly by phone 
which may affect compliance with disease con-
trol/prescription request. 
 
Better education /communication of primary 
care may have similar benefits to home deliv-
ery of products.   
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Date Author Title Aim Findings Comments 
 
2010 Weaver M et 
al 
 
USA 
Medical foods: 
Inborn errors of 
metabolism and 
the reimbursement 
dilemma 
Highlights inequalities in pay-
ment and reimbursement with 
the special products needed f 
or management of IMD 
-survey of states’ newborn screening representatives 
-state policies on reimbursement 
Definition of Medical foods given  from Orphan 
Drug Act 
-3 scenarios given highlighting burden placed on 
families and inequalities between states for reim-
bursement of same condition/treatment 
-highlights problems faced by adults with IMD in 
obtaining medical foods 
- 4 options proposed: 
-require legislation to ensure equal reimburse-
ment of medical foods 
-state model policy 
-legislation to require third party payers to offer 
coverage 
-work with health insurance companies to im-
prove reimbursement policies 
1993 Millner B 
 
USA 
Insurance cover-
age of special 
foods needed in 
the Treatment of 
Phenylketonuria 
Highlights failure / inequalities 
of private health insurance 
companies in the payment of 
essential dietary products for 
patients identified through na-
tional NBS programmes 
3 treatment centres in New York surveyed 
Information obtained on patients with PKU and other 
IMD 
-special foods prescribed 
-assistance provided by specialist centres to help pa-
tients find suppliers 
-how the foods were paid for 
- 236 patients identified – 213<21 yrs./23 >21yrs 
-117 had private health insurance 
-62 Medicaid 
 
Coverage varied between Medicaid and private 
insurance at the 3 centres and coverage varied 
between what was paid for by these between 
centres 
-cost of special products a major burden to 
families 
-staff at centres were required to negotiate be-
tween companies and patients 
-suppliers of products not an issue 
-varied schemes developed by the centres to 
help support patients 
Need for a uniform policy for reimbursement 
of essential products required in the treatment 
of conditions identified through national NBS 
programmes 
2010 Macdonald 
A. et al 
UK 
The reality of die-
tary compliance in 
the management of 
phenylketonuria 
Literature review of the chal-
lenges in dietary compliance 
in PKU 
-assessment of compliance 
measures 
-factors associated with com-
pliance – age, health profes-
sionals attitude,  
-strategies to improve compli-
ance  
-Education – pts. understanding of condition  
-Improved communication between patients and HP 
-simplifying dietary regimen 
-involvement of family members 
-promoting self-management 
-increased access to HP 
-behavioural approaches 
 
Some patients will not adhere to treatment re-
gardless of input 
Need to collect data to monitor trends in treat-
ment 
Need for agreed standards of care and assess-
ment measures between centres  
Need for evidence for achieving dietary com-
pliance 
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Appendix 1: Questionnaire on the use of the low protein foods available on pre-
scription 
 
The use of the low protein foods that are available on prescription is part of the treatment of 
Phenylketonuria. 
 
We would like to investigate the use of these foods and any on-going issues related to their use. 
 
We are particularly interested in getting some information from you on this. 
 
I would be very grateful if you could take time to answer the following questions. In order to 
get reliable results, it is important to answer all the questions, however if there is a question 
you do not want to answer, please miss it out and move onto the next question. 
 
We would be grateful for some information on where you live and who you are: 
 
Your postcode: ……………………………………….. 
 
 
Are you:         a)  A parent of a child on a low protein diet       
                         If so, what is the age of your child with PKU: ………………… 
 
 
      b)  Following a low protein diet  
                           If so, what is your age: ……………………. 
 
 
     c)  A carer of a person on a low protein diet  
  
             d)  Male / Female (please circle) 
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1.  In the past month could you tell us how much and what type of low protein foods you 
ordered: 
 
Low protein food Amount 
ordered 
over past 
month 
Did you 
receive 
your full 
order 
Yes / No 
If not- 
how 
much 
did you 
receive 
If you did 
not re-
ceive the 
full order, 
why was 
this 
Was this a typi-
cal month for 
this product 
Yes / no 
 
Comments 
Prescription bread – 
unsliced loaf 
 
 
     
Prescription bread – 
sliced loaf 
      
Prescription rolls   
 
    
Pizza bases   
 
    
Prescription cake 
mix 
      
Prescription cakes       
Flour mix 
 
      
Low protein food Amount 
ordered 
over past 
month 
Did you 
receive 
your  full 
order 
 
Yes / no 
If not- 
how 
much 
did you 
receive 
If you did 
not re-
ceive the 
full order, 
why was 
this 
 
Was this a typi-
cal month for 
this product 
Yes / no 
 
Comments 
Pasta – spaghetti / 
noodles 
 
 
      
Pasta shapes 
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Pasta Lasagne 
 
      
Cous cous  
 
      
Rice 
 
      
Pasta in sauce 
 
      
Snack pot 
 
      
Breakfast cereal – 
flakes / loops 
 
 
 
     
Hot breakfast 
 
      
Low protein food Amount 
ordered 
over past 
month 
Did you 
receive 
full order 
Yes / no 
If not- 
how 
much 
did you 
receive 
If you did 
not re-
ceive the 
full order, 
why was 
this 
Was this a typi-
cal month for 
this product 
Yes / no 
 
Comments 
Biscuits / crackers 
 
      
Burger mix 
 
      
Sausage mix 
 
      
Dessert mix 
 
      
Energy bars 
E.g. Duobar / Vita-
bite 
      
Milk replacement 
 
      
Egg / egg white re-
placer 
      
Other products  
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2.  We would also like to find out about any other issues you may have experienced over 
the past 12 months. 
 
Have you received any comments from any of the following health professionals regarding 
your prescription?  
 
What member of staff made the comment   (please tick all that apply) 
G.P 
 
Receptionist 
 
Practice Manager 
 
 
Pharmacist 
 
 
Counter assistant 
 
Other (please state who): ………………………………………………………………. 
 
If possible could you let us know what was said? 
 
How did this make you feel?  
(please circle) 
 
More confident       confident           No different      anxious      
very anxious 
How do you feel about asking for new foods to be added to your prescription list, or trying oth-
er foods on the prescription list? 
 
More confident       confident           No different      anxious      
very anxious 
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3. Over the previous month, Could you tell us what condition the low protein food was in 
when you received it? 
 
Please rate the following: 
 
 Very 
rarely 
rarely occasionally often always 
Good condition      
Well within date      
Very close to the use by date      
The food was past its use by date       
The food was damaged       
The packaging was damaged       
The food was unfit for use for other 
reasons (e.g.  mouldy)      
     
4.  Do you use the Home Delivery service for low protein foods:      yes  /  no 
 
If not, can you say why: 
If yes, has this helped any problems you have had in the past:        yes  /  no 
 
What problem has it helped with? 
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5.  Do you use the low protein flour mix to make your own foods: yes  / no 
 
If yes, could you say what you use in a month:  
 
 
 
Number of 
packets used 
/ month 
Was this a 
typical 
month 
Yes / no 
 
Comments 
Homemade bread    
Homemade rolls    
Homemade shaped 
bread e.g. pitta 
bread/wraps 
   
Homemade pastry     
Homemade cakes    
 
5.  Thinking about trying out new recipes, please rate the following: 
 
 Strongly 
agree      
agree neither 
agree or 
disagree 
disagree strongly 
disagree 
I don’t like trying new foods in case I 
don’t like them 
     
I don’t like trying new recipes in case 
they don’t work out 
     
When I make something new, it is not 
eaten 
     
I have difficulty getting the foods on pre-
scription when I want to try anything 
new. 
     
I lack time to try new recipes      
I don’t feel confident using food labels to 
help me decide what foods are suitable 
     
I never adapt recipes from magazines 
and websites  
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6.    In general how would you rate the following prescription foods: 
 
 Very poor poor Neither poor 
or good 
Good Very good 
Smell      
Taste      
Texture      
Appearance      
Ease of use      
 
7.  How useful do you find the low protein foods: 
 
Please circle:   Useful          Neither useful or not useful       Not useful  
 
8. We would like to know why you use the low protein foods. 
 
 most im-
portant 
important neither im-
portant or 
unimportant   
unimportant very unim-
portant  
 
To give 
variety in 
the diet 
     
They taste 
good 
 
     
They can 
generally 
be used 
freely 
     
I have been 
told to use 
them 
     
Because 
they help 
satisfy my 
appetite  
     
Because 
they help 
me to con-
trol my 
PKU 
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9.  Have you attended any cookery workshop organised by your dietetic department    
Yes / No 
 
 
If yes, has this helped you increase the variety of the low protein foods you use:           
 Yes  /  No 
Comments: 
 
10. Any other comments about the low protein foods you would like to make: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you very much for taking the time to answer the questions. We hope that the infor-
mation you have given us will help us to address many of the issues that occur with the pre-
scription of the low protein foods. 
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Appendix 2: Parent / Guardian Information Sheet (PKU Child) 
 
 
13032011 Version 2 
Parent / Guardian Information Sheet (PKU Child) 
Low protein staple foods, nutritional status and disease manage-
ment in children and adults with phenylketonuria (PKU). 
 
You and your child are invited to take part in a study which evaluates the current die-
tary management options of children and adults with PKU. We are happy to answer 
any questions you may have. 
 
What is the purpose of this research study? 
The purpose of the study is to find out how the current dietary management options 
(e.g. low protein staple foods, protein exchanges and protein substitute) can contribute 
to the management of PKU and other nutritional aspects of people with PKU   
 
Why has my child been chosen to take part in this study? 
Your child has been chosen because they have PKU and is under care of the 
metabolic specialists at Yorkhill Children’s Hospital. 
 
Does my child have to take part? 
No.  If you agree to participate and then change your mind this is absolutely fine.  You 
do not have to give a reason.  Your decisions about this will not affect the standard of 
care you or your child will receive. If you are happy to take part, please sign the 
enclosed consent form and send it back to us in the pre-addressed post-paid 
envelope.  You will be given a copy of the signed information sheet and consent form 
to keep for your records. 
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What does my child have to do if we agree to take part? 
If you are happy to participate and you have returned the signed consent form please 
fill in the enclosed questionnaire which asks you about the foods which your child take 
regularly in the diet and how often these foods are taken. Please bring this 
questionnaire with you at your regular clinical appointment. During this 
appointment, we will also measure your child’s body composition using special 
weighing scales and grip strength with a special instrument. None of these tests cause 
any discomfort. We will also collect extra blood (around ½ tablespoon) to use to check 
for some other vitamins and minerals not usually checked by your doctor, but don’t 
worry it will not involve any more needles or jags. We will also ask your permission to 
use any left-over blood collected during your visit to use for these extra tests. In the 
week following this appointment, we will also ask you to record accurately how much 
food is eaten and what drinks are taken over a 7 day period by your child. Scales will 
be provided for this if you do not already have suitable scales. It is very important that 
your child does not to change their eating habits during their participation in this study. 
We will ask your permission to collect some information about your child’s 
condition from your child’s medical records and you will be asked to complete a simple 
questionnaire which will tell us about how the management of the PKU diet can affect 
your quality of life. You and your child may be seen 2 times by the researcher during 
the study. The first will be at the hospital during the annual review and the second 
when you have completed the dietary records. If this requires additional visits to the 
hospital any of your travel and other expenses will be reimbursed. 
 
Are there any other disadvantages and risks of taking part? 
There are no risks and none of the methods in this study causes pain. There may be 
some inconvenience due to diet record keeping as they may take some time to fill in.  
 
What are the possible benefits of taking part? 
Although there are no direct benefits to you or your child from participating in this 
study, its findings may allow us to evaluate the role and importance of the current 
dietary management options of PKU. 
What if there is a problem? 
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It is quite unlikely that you will come across a problem by participating in this study. 
Any complaint about the way you have been dealt with during the study will be 
addressed.  If you have any complaints please contact either the research team 
directly (0141 201 0163) or contact the Comments/complaints Officer at 0141 201 
0000. 
 
Will my or my child’s taking part in this research be kept confidential? 
Yes, all data collected will be treated in confidence. Only the researcher of this study 
will be aware of your participation. When we present the findings of this study, we will 
remove your name and any personal details. 
 
What will happen to the results of the research study? 
The results of this study will be published in scientific journals and presented at 
scientific conferences. If you wish we can send you a report of your results. 
 
Who is organising and funding the research. 
The organiser of the research project is Barbara Cochrane (0141 201 0163), 
Specialist Dietitian as part of her MSc project. If you have any questions you should 
contact her by telephone. It is funded from a grant obtained from:  The PKU research 
fund at Yorkhill. 
 
Who has reviewed the study?  
Before any research goes ahead it has to be checked by an Ethics Committee. This 
project has been checked by the West of Scotland Ethics Committee.  
 
Thank you for reading this – please ask any questions if you need to 
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 What you eat or drink every day for a week 
and which are your favourite foods. 
  Finding out how much muscle you have in 
your body and how strong you are by asking 
you to stand on our special scales and by 
holding a special instrument. None of these 
measurements hurt and most of the children 
find them fun.  
 To measure some vitamins in your blood. We 
will NOT want you to have any extra jags. We 
just ask you for a little extra blood when the 
doctor needs the blood from the yearly blood 
test. 
 To have a look at your medical notes. 
 To ask you a few question about the way you 
cope with PKU 
 
 
Appendix 3: Information Sheet for young people (Child with PKU) 
 
 
Information Sheet for young people (Child with PKU) 
Low protein staple foods, nutritional status and disease manage-
ment in children and adults with phenylketonuria. 
What is it all about? 
Hello! We would like you to take part in a research study that will try and find out if the 
low protein foods that you get from your G.P. help you with your PKU management 
and diet.  
 
If you and your carer are happy to participate, we would like to look at the following: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13032011 Version 2 
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But first, before the study starts, we will ask you if you want to take part 
and ask you to sign a form with your carer to let us know you are happy to 
take part. 
 
What if I do not want to take part or change my mind? 
You are able to choose not to take part in this study. If you decide not to, 
we will not change anything about how we look after you at the hospital. 
This is also the case if you decide to take part, but then change your mind 
during the study and wish to stop the study.  
What happens at the end of the study? 
The results of this study may help us to look after children with PKU 
better. We will also present these findings to others. We will remove your 
name and any of your personal details first. 
 
Will we tell anyone about you taking part in the study? 
No, only the researchers and your family doctors will know about your 
taking part in this study. It will not be possible for anyone to find out your 
name.  
If you have any questions, or if there is anything you do not understand 
about the study, you can contact Barbara Cochrane, Dietitian, 0141-201-
0163. 
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Appendix 4:  Consent form 
 
                                                                                 
Study Number: 
CONSENT FORM 
Low protein staple foods, nutritional status and disease manage-
ment in children and adults with Phenylketonuria. 
 
Name of Researcher:          Please initial box 
 
1. I confirm that I have read and understand the information sheet for the above 
study.  I have had the opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
 
3. I understand that anonymous data which is collected only as part of this evaluation will be 
looked at and securely stored by responsible individuals. I give permission for these individuals 
to have access to my records. 
 
 
4. I agree to my GP being informed of my participation in the study. 
 
 
5. I agree to take part in the above study. 
 
 
 
________________________ ________________ ____________________ 
Name of Patient Date Signature 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
_________________________ ________________ ____________________ 
Researcher Date  Signature 
 
When completed,  1 for carer;  1 for researcher site file;  1 (original) to be kept with case records 
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Appendix 5: Food Frequency Questionnaire 
 
 
 
 
 
Food Frequency Questionnaire for People with PKU 
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We would like to find out how often you are using foods that make up your diet over a typical week. This should include all main meals, 
snacks and drinks. You should also include any meals such as take – always, in cafes and at relatives’ houses. For each food and drink 
listed there is a portion size offered, if you have more than one of the portions, put extra ticks in the box. 
 
How to complete the questionnaire 
 
For every line on the questionnaire, you should tick one box to say how many times per week you use the food. 
 
 If you do not usually have any of this food, please tick the first box (rarely or never) 
 If you have the food or drink more than once a month, but less than once per week, please tick the next box (one or two per 
month) 
 If you have the food or drink every week but not every day, please tick one of the weekly boxes to tell us how many measures of 
this food or drink you have in a normal week (1 per week, 2-3 times / week, 4-6 times per week) 
 If you have the food or drink every day, please tick one of the daily choices (1 per day, 2-3 per day, 4-6 per day) 
 
For dishes that are made up of more than one food you may have to split it up into its separate parts e.g. salad sandwich (2 slices low 
protein bread, butter, tomatoes, lettuce, mayonnaise)or Lasagne (lasagne sheets, tomatoes, onion, peppers, white sauce) 
 
For a few foods, you may have more than one measure at a time e.g. you may use 2 exchanges of breakfast cereal – use the daily choice to 
account for this. i.e. 2 exchanges of cereal would be 2-3 per day. 
 
If you have any food or drink that is not listed e.g. Takeaways, or if you are not sure where to put any food or drink, please use the sec-
tion for “other foods”. 
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Example: 
If you have a small bowl of cereal most days, with a carton of milk replacer and the Protein substitute each day – 3 times a day and never 
eat apples, your form should look like this: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Portion size Rarely or 
never 
1-2 per 
month 
1 day / 
week 
2-3 days /  
week 
4-6 days / 
week 
Every 
day 
… times / 
day 
Loprofin loops flakes 1 small bowl     X   
Low protein milk replacer 1 carton      X  
Apple 1 X       
PKU Cooler 20 1 pouch      X 3 
 
It is very important that you put a tick on every line. 
If you rarely or never have the food, it is very important that you tick the 
box for rarely or never 
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Low Protein Foods and Protein Substitutes 
         
Loprofin loops flakes 1 small bowl        
First Play hot breakfast  1 sachet        
Bread         
Low protein sliced loaf / roll 1 slice / 1 roll        
Juvela Pizza base 1 base        
Crackers 1 cracker        
Cookies 1 biscuit        
Wafers 1 wafer        
Rusks 1 rusk        
Pasta         
Shapes – penne, spirals etc. 2 tablespoons 
-cooked 
       
Cous cous 2 tablespoons 
-cooked 
       
Pasta in sauce 1 sachet        
Biscuits         
Crackers 1 cracker        
Cookies 1 biscuit        
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Wafers 1 wafer        
Rusks 1 rusk        
Low protein flour mix 1 x 500g pkt        
Low protein cake mix 1 x 250g pkt        
Low protein rice pudding 
mix 
1 sachet        
Low protein dessert mix 1 sachet        
PK Foods jelly mix 
 
1 sachet        
Low protein milk replace-
ment 
1 carton        
Low protein burger / sausage 
mix 
1 sachet        
         
First Play LP Snax 1 pkt        
First Play Chocolate spread 1 teaspoon        
Low protein energy bar 1 bar        
Egg replacer 1 teaspoon        
Protein Substitutes         
PKU Gel 1 sachet        
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PKU Anamix Junior 1 sachet        
PKU Cooler 10 1 pouch        
PKU Cooler 15 1 pouch        
PKU Cooler 20 1 pouch        
PKU Lophlex LQ 10 1 pouch        
PKU Lophlex LQ 20 1 pouch        
XP Maxamum G        
Lophlex Powder 1 sachet        
PKU Express 1 sachet        
Ordinary Foods 
Weetabix 
 
½ biscuit 
 
 
       
Sweetened cereals e.g. 
Coco pops, Frosties 
6 dessert spoons        
Ordinary white or brown 
bread or rolls 
 
1 slice or 1 roll        
Croissants, garlic bread  1 roll or 2 slices        
Other breads – e.g. Wraps, 1 piece        
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tortillas, pitta, Naan 
Low calorie bread e.g. Nim-
ble 
1 slice        
Full fat cow’s milk 1 small glass or ¼ 
pint 
       
Semi-skimmed cow’s milk 1 small glass or ¼ 
pint 
       
Soya milk 1 small glass or ¼ 
pint 
       
Flavoured milk 1 small glass or ¼ 
pint 
       
Yoghurt-flavoured 125g pot        
Cheese spread 1 tablespoon        
Cheesley 1 small slice        
Yoghurt drinks 1 small glass or ¼ 
pint 
       
Full Fat cream cheese 1 tablespoon        
Cheddar-type cheese 1 small slice or 
stick 
       
Cream 1 tablespoon        
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Eggs-boiled, fried scrambled 
or omelette 
1 egg        
Yoghurt-plain 1 small pot        
Edam, Brie  1 small slice or 
stick 
       
Cheese strings 1 string        
Boiled potatoes ½ medium sized        
Chips 6        
Roast potatoes 1 small        
Baked potato 1 small – size of 
kiwi 
       
Potato shapes e.g. smiles 1 shape        
Potato croquette 1        
Chip shop chips 1 small bag        
Fast food chips, e.g. McDon-
ald’s, Burger King 
1 small portion        
Ordinary boiled rice 3 dessert spoons        
Ordinary pasta 2 tablespoons        
Baked beans 1 dessert spoon        
Tinned spaghetti 1 ½ dessert spoons        
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Peas 1 ½ dessert spoons        
Sweetcorn 2 dessert spoons        
Crisps 1 small pkt        
Tinned soup 
 
1 small bowl        
Homemade soup- low pro-
tein 
1 small bowl        
Mayonnaise 
 
1 teaspoon        
Ketchup / bottled sauces 
 
1 teaspoon        
Jar sauce e.g. for pasta / 
sweet and sour 
½ jar        
Gravy 1 tablespoon        
Carrots – cooked 1 tablespoon        
Onions 1 tablespoon        
Broccoli 2 florets        
Cauliflower  2 florets        
Mushrooms 1 tablespoon        
Sweet potato 1 tablespoon        
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Butternut squash 1 tablespoon        
Tomatoes 1 small        
Cucumber 2 slices        
Lettuce 1 leaf        
Swede or turnip 1 tablespoon        
Cabbage 1 tablespoon        
Green beans 1 tablespoon        
Peppers ¼ pepper        
Coleslaw 1 tablespoon        
Apple 1        
Orange 1        
Banana 1        
Grapes, melon, pear 1 small serving        
Strawberries 6        
Dried fruit 1 tablespoon        
Tinned fruit 1 tablespoon        
Pure fruit juice  1 small glass        
Diluting juice – sugar free 1 glass – made up        
Diluting juice – ordinary  1 small glass – 
made up 
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Children’s juice – Capri sun/ 
fruit shoots 
1 bottle / pouch        
Fizzy drinks 
-sugar free 
1 can / small bottle        
Fizzy drinks 
-with sugar 
1 can / small bottle        
Sports drinks / Lucozade 1 bottle        
Tea 1 cup        
Coffee 1 cup        
Wine 1 glass        
Spirits 1 measure        
Beer / larger 1 can / bottle        
Alcopops 1 bottle        
Cider 1 glass        
Water 1 glass        
Jam / marmalade 1 teaspoon        
Honey 1 teaspoon        
Chocolate spread 1 teaspoon        
Butter / margarine 1 teaspoon        
Sugar 1 teaspoon        
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Popcorn 1 small mug        
Breadsticks 1        
Ready to eat jelly 1 tub        
Chocolate e.g. fudge 1 bar        
Jelly sweets e.g. Haribo 1 bag        
Chewy sweets e.g. chewits / 
skittles 
1 bag        
Ice cream / sorbet 1 scoop        
Ice lolly 1        
Meat burgers 1 small burger        
Mince 1 tablespoon        
Sausages 1 sausage        
Bacon 1 rasher        
Cold meat 1 slice        
Stewed, fried, grilled or roast 
beef, pork or lamb 
1 tablespoon        
Chicken nuggets 1 serving        
Meat or chicken pies, or sau-
sage rolls 
1 individual pie or 
1 roll 
       
Casseroled fried or grilled 1 tablespoon or 1        
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turkey or chicken slice 
Fish 1 small fillet or 1 
serving 
       
Fish cakes or fish pie 1 fish cake or 1 
serving 
       
Grilled or poached white fish 1 fillet        
White fish cooked in batter 
or breadcrumbs 
1 serving        
Smoked oily fish – kipper, 
mackerel or salmon 
1 small fillet        
Grilled oily fish (fresh tuna, 
salmon, mackerel or herring) 
1 small fillet        
Tinned tuna 1 tablespoon        
Prawns 1 tablespoon        
Other foods not included, 
e.g. take-aways –  
Please specify 
        
         
Thank you so much for completing this questionnaire. Please bring it with you at you next clinical appointment and hand it 
in to Barbara or your metabolic dietitian 
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Appendix 6: Information leaflet            
                              Information leaflet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How important are low 
protein foods to you? 
Participation in the study is entirely volun-
tary. If you do not wish to take part or want 
to withdraw at a later stage, the standard of 
care you receive will not be affected. 
This study is taking place along with re-
searchers from the University of Glasgow.  
 
 
 
 
The importance of low 
protein specialist foods 
in the diet for PKU 
  
161 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phenylketonuria (PKU) is one of the more 
common inherited disorders diagnosed 
through the newborn screening 
programme. 
Around 6-8 babies are diagnosed with the 
disorder in Scotland each year. 
The use of the low protein diet in the 
treatment of Phenylketonuria (PKU) is well 
recognized as being successful in 
preventing the harm to the developing 
brain that may be caused by high 
phenylalanine levels. 
Part of that treatment for both adults and 
children, with PKU, is the use of specially 
manufactured low protein foods such as 
bread, pasta and milk. However, although 
these foods look different and taste 
differently from the ordinary products, 
they are needed to provide energy and 
help fill people up. 
Because the foods have to be provided on 
prescription from your General 
Practitioner, sometimes there is difficulty 
with getting what you need at the time you 
need them. 
Some of the foods also are difficult to use 
and this can be off putting as they do not 
always turn out as planned. 
 
 
 
 
This study is to find out how the foods are used, what 
problems and concerns people have about using them 
and also try to find out how much of the foods are 
needed to provide sufficient energy for growth and to 
prevent excess use of the foods that have to be 
restricted (exchange ) foods. 
At present, there have been few, if any studies looking 
at the contribution the low protein foods make to the 
diet. 
What is involved in the study? 
What we would like to find out is what type of foods 
are eaten, how much and how often they are taken by 
the use of a weighed food diary, a questionnaire to ask 
about what type of low protein foods are eaten and 
the difficulties you may experience and also a food 
frequency questionnaire which tells us what are the 
most common foods eaten. 
All of these will help us find out the contribution the 
foods make to the overall nutritional dietary intake.  
This will help to tell us the type of foods you like using 
and what difficulties you may come across when 
trying to obtain sufficient supplies of the foods or in 
trying new foods. This in turn will help us to help you 
manage the diet well. 
In addition to the questionnaires and food diary, 
we would like to compare the results to the reg-
ular blood tests you do and the annual blood 
test taken when you come to the clinic. We will 
not ask for any extra blood tests.  
 
We are also interested in comparing the diet for 
PKU with the dietary intake of people without 
PKU to give us an idea of how the PKU diet com-
pares in energy to the diet of the general popu-
lation. We might ask if other members of your 
family would be interested in filling in a food 
diary at the same time. 
 
During your visit to the out-patient clinic you will 
be asked if you would like to take part in the 
study. One of the benefits might enable us to 
help you and your G.P decide how much of the 
special foods you need to keep you healthy. 
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